var title_f29_57_30608="Implant breast reconstruction";
var content_f29_57_30608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Implant breast reconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The placement of a reconstructive implant is preceded by tissue expansion (\"secondary\" or two-stage implant/expander reconstruction), in order to grow additional soft tissue covering (mainly skin) for the new breast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30608=[""].join("\n");
var outline_f29_57_30608=null;
var title_f29_57_30609="Calculator: Creatinine clearance estimate by Cockcroft-Gault equation";
var content_f29_57_30609=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CreatinineCl_CG_form\" name=\"CreatinineCl_CG_form\" onkeydown=\"clrResults();\" onkeyup=\"CreatinineCl_CG_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          CreatClear = Sex * ((140 - Age) / (SerumCreat)) * (Weight / 72)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"CreatinineCl_CG_fx();\" type=\"radio\" value=\"Male|1\"/>",
"              Male (1)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Sex_radio\" onclick=\"CreatinineCl_CG_fx();\" type=\"radio\" value=\"Female|0.85\"/>",
"              Female (0.85)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"CreatinineCl_CG_fx(); minMaxCheck();\" onchange=\"CreatinineCl_CG_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"CreatinineCl_CG_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Creat_param\" onblur=\"CreatinineCl_CG_fx(); minMaxCheck();\" onchange=\"CreatinineCl_CG_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Creat_unit\" onchange=\"CreatinineCl_CG_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"CreatinineCl_CG_fx(); minMaxCheck();\" onchange=\"CreatinineCl_CG_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"CreatinineCl_CG_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creat Clear",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Creat_Clear_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Creat_Clear_unit\" onchange=\"CreatinineCl_CG_fx();\" style=\"width:105px;\">",
"               <option value=\"16.666666667|0|L/hr\">",
"                L/hr",
"               </option>",
"               <option value=\"0.01666666667|0|mL/hr\">",
"                mL/hr",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mL/min\">",
"                mL/min",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CreatinineCl_CG_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      You can estimate the creatinine clearance (",
"      <b>",
"       Creat Clear",
"      </b>",
"      ) from the formula if the serum",
"creatinine concentration is stable. The",
"      <b>",
"       Weight",
"      </b>",
"      is the estimated lean body weight.",
"(See UpToDate topic reviews that discuss calculation of the creatinine clearance, for a review of the accuracy of the",
"creatinine clearance as an estimate of the true glomerular filtration rate).",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      Sex",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g.  (1), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.",
"        <i>",
"         Nephron",
"        </i>",
"        . 1976;16(1):31-41.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30609=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CreatinineCl_CG_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.CreatinineCl_CG_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 0.85; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Creat_param.value.indexOf(',') >= 0){ Serum_Creat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Creat_unit.options[Serum_Creat_unit.selectedIndex].value.split('|');",
"Serum_Creat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Creat_Clear =  Sex * ((140 - Age) / (Serum_Creat)) * (Weight / 72);",
"",
"unit_parts = Creat_Clear_unit.options[Creat_Clear_unit.selectedIndex].value.split('|');",
"if (doCalc) Creat_Clear_param.value = fixDP((Creat_Clear - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CreatinineCl_CG_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CreatinineCl_CG_form){",
"",
"Creat_Clear_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f29_57_30609=null;
var title_f29_57_30610="Ultrasound equivocal appendicitis";
var content_f29_57_30610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Ultrasound equivocal appendicitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The gray scale ultrasound of the appendix is projected in the longitudinal (A) and transverse planes (B). The appearance of the appendix is near normal except for a diameter that measures 7.6 mm in the long axis, and a diameter that measures between 7 and 9 mm in the transverse plane. Since this diameter should be 6 mm or less, the diagnosis of appendicitis is entertained. There is no loculated fluid around the appendix and no free fluid present in the peritoneal cavity. The echogenic line of the mucosa and submucosa is intact and the lumen is distended with complex material (arrow). The findings of the enlarged diameter with no other specific pathognomonic features make the diagnosis of acute appendicitis equivocal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30610=[""].join("\n");
var outline_f29_57_30610=null;
var title_f29_57_30611="Docosanol: Patient drug information";
var content_f29_57_30611=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Docosanol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/57/6034?source=see_link\">",
"     see \"Docosanol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abreva&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691885",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat herpes infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701970",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to docosanol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a rubber glove to put on the ointment. This stops the spread of infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12206 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30611=[""].join("\n");
var outline_f29_57_30611=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162125\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020393\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020392\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020397\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020398\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020400\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020395\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020396\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020401\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020402\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/57/6034?source=related_link\">",
"      Docosanol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_57_30612="Endoclip bleeding DU endosc";
var content_f29_57_30612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Bleeding duodenal ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 511px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH/AgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtvj98Xtd+HXiHTbDRrLTbiK5tfPc3aOzBt7LgbXXjivLx+0/4xP8AzCfD/wD35m/+O1b/AGyxnxpofr/Z/wD7UevBLaLcd3TFDdkVGN2e8xftL+MGxu0rQM+0M3/xyrsP7Rvi1+ul6H/36l/+OV4XDDnr1rStI+RXPOo0dlOjF9D3mz+PXiabG7TtG/COX/45Wmnxr8QsM/YNJ/79yf8AxdeK6eNoxit+zQMAcZryq+LqR2Zt9Wj2PVB8YvEJUEWOl/8AfuT/AOLp0Xxg8RM2GsNL/COT/wCLrjLK1V1GQBV4WCKQetefLMK6u1I0hQp7NHVt8XdeUc2Wmf8AfEn/AMXTo/i9rTfestNH/AH/APiq4bUbP92WGRisqMScHHNZPMq/851wwFKavY9YHxV1kjIs9P8A++X/APiqT/haeuEjFnp3P+w//wAVXn9gjSfL3rWgsioBap/tHEXtzsbwNGGjR14+KGt4/wCPLT8/7j//ABVNb4o63jiy0/8AFH/+Krmni24wAPWkESscYFVHH4n+dkLC0v5Tqx8TNaKZ+x6fn02P/wDFVCfijrgPNnp3/fD/APxVYUcEYX5gMVUvY4x91cV0rHVmviZCwtL+U2dS+LviC1XMdjpZ+scn/wAXWBcfHbxTEuRpuj475jl/+OVi6uMxHFcXqbqqFWxmnRx1eUrc1zroYKjJawR6Qvx88TkZOnaNj/rnL/8AHKmT48+JGH/IO0j/AL9yf/F146TweOKaJCveu76xVf2iqmX0ekUeyn48eJAuRp+j/wDfuT/4uoX+PviVRxpujn/tnL/8XXk1k8M02y4nEQHcjNbNjo9pqF28FteqzKMjIxmsp46dLWbdvRnDWoUKSblH8Gd8Pj/4m5zp2jAD/pnL/wDHKrP+0N4oVsf2bouP+uUv/wAcrzDVLV7G8ltZxh1NZr4YnByK66dec4qSejEsNSaukewt+0L4pEYYabov/fqX/wCOVE/7RXipemmaJ/36l/8AjleQM0XlFWJD9veoCCynjitVVn3J+rU+x7LB+0b4nMw8/TNFEWfmKxS5x/38qS//AGivEccxFnYaLJFjIZoZQf8A0ZXh0ilTmm7vlxV88m73Ilhqd9j2U/tJeLBn/iV6F/36l/8AjlNb9pTxcD/yC9B/79Tf/HK8WfBJ4qI4PtVqcjJ0Idj2iT9pjxgoyNK0D/vzN/8AHKteFv2kPFmreJ9J0250vQkhu7uKB2SKUMFZwCRmQjPNeEyDI4rT8CRbfHnhx+v/ABMrf/0Ytaxn0ZjUoq3Mj3v4y/H3xN4I+I+q+H9L07RprO1EJR7mOUyHfEjnJWQDqx7Vx0f7UvjNz/yCPD3/AH5m/wDjtcn+1EM/HHxFgZ+W2/8ASeOvN4BiNRirk7IwpQ5nqe9p+0/4xJwdJ8P/APfmb/47Vhf2mPGB66VoH/fmb/47Xg8ajPHJq5CuQO9c8qjR1xox7HuS/tKeLTnOlaF/36m/+OVYj/aN8WOMnS9D/wC/Uv8A8crxWGL5Djv1q7bx5AAGMVzTxEl1NFQh2PaIP2g/Fcv/ADDdEz/1yl/+OVej+Ovio48zTtGXjn91L/8AHK8asVI37ThuxrWlnuLpla5cOQMLhQOK4qmMqq9pDeHjfRHq0nx61hbLiz0v7bu/1ZikwR/33Udv8d/EbzRrLYaOis2GbypeB/38rytYcMjj746ZFSheWOOpzWEsfVtpIFhodj1fUvjlrsN28dlbaPPGoBD+VKMnH+/VSL47+KJHC/2dowJ/6ZS//HK8tVEbeQ+HH8OK04by3XR2s/simdm3efnkD0q442q27ysP6vCKso3PTr74z+KLRY2NlorhxkYil/8AjlUn+O3icDI07R/xil/+OV5lbxEL3/Gn3EQCgGslj61/iH9XprRo76b4/wDipCcabouPeKX/AOOVUP7RXiwNj+zND/79S/8AxyvObuMFenWqBt8HOK7IY2bWrNY4Wm/snrcf7Qniphzpuif9+pf/AI5Ug/aB8UY503Rs47RS/wDxyvKIocDpT/IBqZY2fc2WEo/ynqrftA+KQoI03Rc/9cpf/jlQt+0N4pXI/szRc4/55S//AByvL3jGMYqlNFz704Yyo+ppDB0W/hR6q/7Rni1T/wAgzQ8f9cpf/jlH/DRvivj/AIlmh8/9Mpf/AI5Xk5twzUz7Id2R0HWtfrcu5v8AUcN/Kj13/hovxXj/AJBmh/8AfqX/AOOU9P2iPFTctpuiD/tjL/8AHK8hFtkkZx71NFbYIA5NJ4yS6ieBw/8AKetf8ND+KS2BpuikevlS/wDxymn9ojxV20zRP+/Uv/xyvLjbs+MgUn2Y8nHNQsdPuZvBUP5T08/tFeLB/wAwzQ/+/Uv/AMcpj/tHeKwpxpeiZH/TKX/45XmE0GI1G3Ddz61Rniweeh5rSOLk+pm8FR/lPVX/AGlPFy9NL0I/9sZv/jlQt+0z4vA40rQf+/M3/wAcryGSPt3qCSHiuiOIl1ZhPCU1tE9dl/af8YqDjSfD+feGb/47Xon7Pvxo8QfEfxhfaTrVjpVvbwWLXStaRyK5YSRrg7nYYw57V8oTxdeK9p/Y6j2fFHVj66PJ/wCjoa6qdTmODE4dRjzRL37ZIz410PH/AED/AP2o9eG2kfy9K94/bBGfG2hn00//ANqPXilrH7VVSVkZUIXJYE55rUsocuOKqwp0xWzpq/MM+tcNadkenThoaVpbnAOO1dFptozFQgNU7CEECux0WzAQH1rwMRNydjS6SJbOzICDHXrWzFZ5TJHSrFvaEkECtBYtkWD1rk3bJTTtY5u6tzJmPYTnvioTo6KAEX5jXRGPHUdKsW8AkwxFZVYKTuzsVb2aOdtNM+zfe5rQ8nOK1Z7bIPGahjtiCc8VMNEP2yn7zKE0G4DAqE2jIcitsQZ4xmmyxYHIpq97iVRPQw3jdlwKzdRf7OuZPSty7kWEEucCvNvFerG6uWij3Ki/rX0GEwSr4R1b6pnoYTBuu3bYl1G/E8T+Qu8jtXG3ru8rBxg10elwvbMksgGyQYBqfUtAaebz42BDda4a1SGEq8j2avc2qunhJ8ktn1MbTNDm1OLFuuW6daxtXsZdNneKYYZTivV/DFjFZRB3fAHpXn/xBnSXVJDHkDPenhZYmdTna/dvZnFhsQq9SUUzlmRHiDbgWPb0rX8M6Pe6lcsNObZJCN5bdjFYKcfNXWeA4prjWY7eCZohLwxBxxXrTbt7jsa4iNqbadvXYtaro+salp7ahcKsyQfKZF6n61z0NvAbSUyOwm/hAr17xrqVp4c8OHTbY5aQFQPXPU15b4e1GysL43Gp25ni/ujmuem5TUlT26bLXqux8/gq88RTlNxsr6W6o56aIqcN9a3fC2gX2uGaOxjWQIPmBNUNevLe+vp57KIxQs2VU9qqWepXlg5exuZIGIwSjYrqtOpTtflf32OqcZSjeOj8zZ1fw1fafbSzTQNsj4c4+7XNCJiMqOKtz6vqE0UiTXs0iSffVmJBo0iaCW+hgu38uJztL/3a1pxnCPvO79DFKcV79jNdWB6VAy+tb/ibTJNKvWiYho25jcHhl7GsJyea0hLmV0QmpK6IT+lbngNc+OPD2P8AoI25/wDIi1hNnFdB8PSf+E48Pn/qIQf+jFrRbikrxZq/tPIX+OviEA/w22f/AAHjrzyFfl6V6d+0sn/F7vEJxyRbf+k8debxA9vzrScjloQsrjkBzmrlvwRxmokXOKsxggiuacjp5dC9BkkBfyrUggOAw71StQEZS3ritoSY2iP5s159eb6DuTWsShTnAJrTt4d5UHoKrpFuiIKqSehPatGy3RNh0ZumOK8qrNNaDUmSQae893HBApeR+ijvVe5t3hkkiIIdTgg9q0LkSpJHJE7wyryGU4Iqu6u5Ls+5ieSTkmseZKPmXBvd7GcbY7iR96p7eFBGd3Ln9KsSDHNRKpLYHep520asdHH83Ham3Cbjk+lWUTauT1prj5e1EJEpXZkXEe7HHFQ/Z/l5B61oOCaAuRW6qtKxvaxSWAjGRxQYQo461pCPCc81XaMnpQqly4lEx9u9V5YDkfWtQw9KjMWTVRqWNYOzKcVkrc5IqWOyAPORWjBFjBIqz5BrOddrqaObMOa1EZO3JqKNdrHIrelti2cCqb25UnIq4V09yk7ojSIHH0pxtucgZqaKM8cVchhJHIrOVVxejM3FpGNPb7zwNvrVC6s8Y6nFdRLbHPAqlcQkDoKuniWTqctNaBYy3c9qpyw4UZFdFcQFug4qo8A2kFc13wr9zKSZzNxDjPWvZP2RI9vxJ1Rv+oTIP/I0VeXXFvweK9d/ZQi2fEPU2B/5hbgjH/TWKvTw1TmkjhxS/dsf+1ym/wAaaIf+nD/2o9eNWkeF5Fe1/tZLnxnov/Xh/wC1GryG0UY5xXTXlZnJho6CogyMA+9alku2RfeqgdFOAetaGnr5syKvc159Z+6z1qUdNTsdMgUxDjmu40SAGIccYrmNHh2ooNdhpTiMYPSvnMTVszFxbub1ogAHFXniVowSPaqUDZUEGrQkAXk1zuqrW6nHOEubQoy2w3fj0q3DEFGKq3M/lnPbvWe3iO2jnEWfm6ZxShPnbO2NCtVVoq5uSoCMYqvKqovtT4LqOaMMrZBom2MmGOK3hG5nGEou0iuJlUn0HesnUdTK/KmMk8VPqbpBCxDfrXKSXQkuEHbcP512U4QceaS0R7GEwsZ++0a3iqEp4eeaVj5hHVe1eTR20k1yY13N/FmvWvG0/keG3TbvDDb9K5DwLokmprdzBseWmOfpXVwpmjjSryqW5dXr5HqZTjI0sLOpUdldlLBGgAlSfLc81FZ6rJlEjyy9MGt86RPHp1zBKvytnbzXNtaJoaG4u5AzDlUHevHrYmli5u2vZHFialOu5U202np8zb1DUXsdPeRSo4yAa8q1W6e7maWU/MxzWhrGq3GpzFpCVjH3UBrFmOT/APXr2cvhVo0vZzlpvbsVg8D9WTb+JkG45xmrNtczW7B4ZGRx0IOKrEckmkZsdK9JLmIxCe1i7PPNdOHuZnlb/aOarSP1z0pnmHPFRs5JOaIxtojlS8hJG+U4qJWJ605846cUxcg9Oa0RDiOdcpxVRwefSr4YgfWq7pyf5VSlYxlC5CZZXADuzgDAyc4FRFs54qZ0GBjio2G3NaqVzllC2iIs5Peuh+H/AB448PY/6CEH/oxa57q3t710XgAH/hOPD3/YQg/9GLTW5Ek+U6X9pUf8Xq18+1v/AOk8dedQJ616Z+0jHu+M2un/AGbf/wBER159DFuVQB7VFWdmzKivdQRoOvFXYIgVDUkVuQSGHPardtFyF9a46kzo5SSNdxxgVo2Iw/zdKrNEc4HBq1CrDGQa4qsrofJc3oEzBhmAHWrcdw5gXG1mU9e9Z9rJiLlS2O1aUDK8W3Zj0ryqraWpk6etyR7kTOqtnee56VBghscGiVNpDjtToc5OR0rFvQ1jG2wxwT8nY1LbwbiNvUU5lG4YHWpEOzBzjNRcp7DZk2jmqQJZjxxWlIyuOKLW3QyZK/L6U4StoOLS3MyRM9qRE9a1rmGMyDYhCelQrAMcitVLUtTuiqy4UVGI8k1dIAbGKWJQSeKTnoaxVioYvl7VEkBOeK1PKBPTIqRLbjIFRCrZ2E5WKEEOSM1dEIxUqRBWwBzVmOHOMDgdaVbW1ja1yiYcVWmtsnpWyYhtYkfSmGIEYArnVRxZrCBkpbcirkUAx7Vejtx1xUqwDsKUqtzRxvsZskWc8VnXcQziuka3O08c1n3VsMZxzWkJW1ZjyWOakhAFVJ4cfSt2SDbnIqpLb8dK7KdUxkjm7uDjIHNepfstpt8f6lx/zDH/APRsVcBPBkHA4r0z9mmHy/HeonHXTnH/AJFjr2cBVvUijixa/dSKn7Vw/wCKx0bn/lx/9qNXjUOccGvZv2rRnxho3/Xj/wC1Grxy3U4/GvWrv3jDBxvFDliLEZNdJ4ctws4YnJqhYWheQZTcK6Kyh8iUHbivJxVRtcqPUSVrHWWPylffiunsIiyL6Vyuk3KykKByK7rS4iYl4rwK9NyfvESjyLUtQRsijk092YJmrtrGT1XIqV4k7jiuKrBxV4nE6yUrM5bVZytu5xzXGYMk5POc16Vf2yOpO0fSsIabEpLhAGHtSiprbU93A4qEIPQis7020CqSPxqG+1eQkhTjAyPes3Vgcn2rJur1Etm3uMgYxXfhZTbUUd9LCRm+e2rINb8Qzb9nBPfmovD8txf3yA8ncCAPrXK3txudue9ehfDKGJlkm6yqo/Ctc0qOhQaPSx0Y4PCSmkbXjRTLpiW6As7sAFAyar+D7V9Js5Y5mCF+SrcVP4l8RWOkFsgS3WOFHavKPEHiXUdTuGZp2ij6BE44rxMDhK2Jo+zXuxfVny2DweIxOH9ivdg9bv8ARHofizxRbafbskTJI/YA968n1LUbjULky3D59F7CqMrlhuZ2Zj3JqvvIbrX0mBy6nhY+7q+57OEy2nhI+7q+5bbk81VlFTByQOc5pdma70+U2kUWWopBirzx8Hiqsy5IHSt4zOaULkBIPc00ZAJB+lTiMgD0pGTGc1opmTpJqxX3HHJpW6/WnFR2HNNK/NmrUjGdGwck4z70EcZ700H5vQClJ9Kq5g4XEK5qCQdqmHXNG3J4q1KxzOldlML82a6LwCo/4Tjw/wAf8xCD/wBGLWQsfBrovAMR/wCE10A46X8H/owU1U1M50HytnT/ALQ8Zb4ya6eMFbf/ANER1wUcWACOtej/ALQSZ+MGtnH8MH/oiOuHiiygOOTWGInaTOLDr3FcbbRluMZ+varcVo5OTjOeKdBFtNXYVJbHrzXnVKr6HUojltgGXPXvVgxKFye1TJH1yOaSbCofWuPncnqIS3PzDjrWhA2GFZkH+sFaUEZdwq9TWNZK5LROzbsKRwe9JFgkDvV+OwkdI0XYXY4wDzVq70S4sSDPGVbqBXPunYzU4rQrJD8oJFMmgHGK0YmVkIZegqueoBrFdwUmU1iNXIAAeadgDjFNLcHAqkurDViSFSeBSKoI6UnbJFIz4bjvSc3c0iiCb5nJUYA4psJAOKfMwAyOKhtm3SHPrTcubU6ktDQjQNjAq0E2xHjtTrOME9KtiMbsY4Nc923dE2RRSH5ulTxoM1cMOB05qBl2tyK6kk1eR00lcbIoOdoqMRjPAqaE85I7VLGgJ4FcFWVnc7oQ01GRxcAEc1YMA2jtVhYwrDinAYqIuWzE0mVTHxjrVG8hBBAFbDrgdKgliDL0rpUrqzM3BbnMywgk8VUniytb8tvhiKp3EPHSrjLqc1SBzk8XBGOK9G/Z2j2+Nr84/wCYe/8A6MjriruLKHA5rv8A9n9NvjG+4/5cG/8ARkdezlsv38F5nm4xfupGH+1Mm7xlowx/y4/+1GrzfSdMjkUM4Oa9Q/abUN4z0YkdLL/2o1cXpSAQg4r18dNqdkYYTSmi/pWmJ5qqB1rr7nwXJFp7XgdCoGSKyNMwrKe9egWuv27aWbSWNjIRjGODXHS9m0+dmtWVePK6Svrqef2Ft9nl3DHWutbVk0+zWRlyOnFZN5CiudgwTVN0nunVGH7oHJzXm1Iu9z2IU41bc+x6L4b1GLUYC6Age9alxGBHwM1y3huUQPtXAQDrmukkvIxEdxHPSuSdO6dlqeDi8O4V/wB2tCjcDCHisK5uVhzlc1rX1wqxkhhXC+JNXSBCm8BzWVODuevl+GlVdrGT4g1MGRxFgGuH1C8cFtxBBNW7q6372LZJNYV8yl/lORXp4WPI7o+6weGjTshks2T6+9aOi+IrzR5jLaEcjBU9DWO2MdajJwK6qtONbSaujsr0oVIOE1dGje6nPfXLz3LZdzk1myyZYk00daifrVU6ajojjlSUFpsIzc1HkbqD1oTLMK32OSaLcUZxmrAUhQBg+tLaqWGMcVIy7WOa5pTu9TncbsrsvykkVUmTJJI5zVxxgc81XlPetISZHsyuVNNk6dKkZsCombOea3i2yZU7IjI4zio2XODUp+714pjnjAraLOOqiEn5jTenan9SeKQrwPettTiktQQEnHGKnjiDE02Ne+Kv2cWQSQetYVanKb0qSerIFg6Yrf8AAkYHjPQj/wBP0H/oYqksGeg6VteC0A8YaJx/y/Q/+hisIVW5I1rUkqcvQ6P49xbvizrJH92D/wBEpXExJtjHrXffHNc/FjWT/swf+iUrjI0KANjnp0qcXP8AeSXmfM4dXpx9AtEVi28H2AqxDEFJpbWPBJ6VZVTyRXmznqdIpBVcjrVZwXyD1q2VLcConjIPA70ovXUh6CQx4xx0FX4sxsrYwD3qvCMMMirx+fYG6KOOKwqSbYnvYvaVfHTr+K7eMzqnJTPWul1PxhFeWItrW1YyOMNLcEHaPYetckq7tqr1NSm22NknkVEKzpttbswqU4Sd5bltXByaiJG/rxTIyQMHrUTbt4wOKwSbKLTDINGMLSRZOcmlkPGBVLe4IOCh4qBqmUEr7VVYnOKT11NYLURwD1qS0UeZ0zUIBLc1dsY8t61L0R0XNe0TI6c1oRRDblqbaQ5wBV9LbnrkURTSsjSC5ldjY4wwwBVSe3yx/nWvHDtHFMMQfrWiV0rm9P3WYflYU46U2HcsmCODWnJbgHCg4pRbrkcc1z1aTa0OxVFYIk3AY61OUC444qa3gC9OasNCCBkVpSXKtUck6quUiqleRULRbsgDpWkIAegNBt8A4q76EqqkYb2/BZl5NZ91bgKeK6Z7cEHNUrq2U5Cjio5Ui3JSOSuIvQV3XwMg8rxbeMe9i3/oxK5+5tlU9K6/4PJt8V3RHayYf+PpXo5an9Zhd9TzMcv3Ujlf2lgD4x0fP/Pl/wC1Grj9Fh3RLnpXZftJHPjXR1PT7F/7Uauc0ZAIBgV7OO/jM48K/wB2jasLfDKQK3lt9qhl+8KztMRioOOa34ELLXBJndB2MYRs9yQwBP8AKpntSVYZIrbjtUIB2DNSNaJyWrGbbOhYhR0MjSLYwHnnnitKYkj5jTGPljIA46VVlZmGSazcW1qVrVlzFXU7gxQtt5NeceKpWkZd31rvtQJ8pg/IrkdZtleFsqCcda51Nwnc93LOWnJNnn8xO88nNV5c76sXCFZWz2NVn+9XpwPrIjW6VCTUzjFQHrWoqg01GxqRjUbVaOOohh571JbplximY5q3ZoTMoxTlKyOVwbZp28exQcfWmTYD89DVsxjyyD2qpcDca4Yu7uZuFilM/YdarSHGPepZlIJqCTOK64ByDGOTUL+9StkVE4JNbRMJwFQDPtTZh6UoBGaY5yKtPUwnBNajAPmNPC59KYBnPPSpIkJYYrbnsjhlC7sSxoc1q2ScHFVYYSSK0rVDGpB9a4a1RM6oU7Ik24Na3g9f+Ku0Q4/5fYf/AEMVl/e5rV8InHi7RAev22H/ANDFc9J++icRG1OXozqfjYmfiprB9of/AESlckI8qBiu3+MsYb4oasT3EP8A6JSuXWMbBgVGNnavP1f5nyeGX7uPoimqAN0NTheOAaftGTxzU0a7lxXE5HSNiRVzkc0kbmOfeg5HTIzVhUwp9ah6Z3D6VCd2ZtEanfMzHGScnHrT3bAzmkRduTUF2/IqleTFbXQnS4jBQSEgZ61qO4EzJGwIH4iueiUP97mtWLZBbYUY4/KlVitluY1dy2kiZ4PNKWUDJOKyROAThqn87fEOaUY20ZNi8rdx3p5Hyc5yaoW7l3wDxWlCm5CTk4qeWzY9bkYOxSSar5Dng96uTRM64AJpsdo6r8ykc+lRKy2OqmiBV+YAc1radD8w4qgkTLMAfSt3SkJIA6Vg3rY6VC5tWcByM9TWjHakAntUVijeYMjithEwoFbrV2JqT5NEZJiYScdKbCmGbIwta7W+XBxwarSQbHINactwjWT0KLxDccCohEd2ccVeZOMZogjwOemahtmqqWQsEeAPWpfKJGatRoAvepEiJXkUKL0OSVUoiIheBQy/LzV7Zx0pjpwQBT5CVUuZzLwcdarSxZU+taXlH5uKikTjkUra6HRGpYwLiAk5wa6X4TRGPxTdEjH+iN/6GlU3h+Vsj3rc+G648R3Jx/y6sP8Ax9a7Muv9ah6mONlzUJHm37TUuzxzoo9bH/2o1YegvmJfSrv7Vtwlv440RnJH+gf+1GrG8I3cc1tGQ2civazNOM+boeZhJXhY9C0cY6DjFb0KZNYujkMBtroLcA15d77HapWRJgKKZINzHFWdgYcimeQxyRVy2JjNdSpLBkdKqvAXXOOlarJg4PSrVvY+bbl06DnFLkc1ojRYlU1ds5G9swQVYFvQCsmXQJ7lCFUgV2ZtS1105zgVrw2RVeBgAZrysZOpFxhQi3Js6pZo8Olbc+YPENm1pfSxv1BrEbIPNdz48gCavc/Lj5ulcVcgb+BXq4dtxXNufoeDre1hF90QseKhPWpmqI9a6bnTMjY0w9akfFMxVo5JrUdGu5uKvRxNFtYgiqttxIDWywDxAcE1hVnZ2JXuvUa0hI4qtIzZGRxinSNsyCarSuWPXiojEJQRBM2GOAahbkVK555PApCPlroWhk0V2HNNxgmpnqMDrWiZhJEbAlaifPTmrI6YqGTG7pWkWclUhUEtitSyti3PNUrdA0o4robSMLEPWssRU5VoYRjeRLFbbQDipfKIGccVajG5BUmzK4ry3Udzo5LIzypC5q/4UJ/4TDQx/wBPsP8A6GKr3LAIAKm8Jc+MNDz1+3Q/+hiunDXlJMwxC/dy9GehfGBM/EnVT7Q/+ikrlmGF4xXZ/Fld3xG1T/di/wDRS1x90pCcdawxumIn6v8AM+Qw38OPoVUQs3HY1ajXAxxUVsp5HerRIA4rhbOkYy9qaU+XJAxSufm4qYKWjqb2JaM85U44rNvn+YVqXBwSMdO9Y92p80V00VqJ6E1tJjGMZqe5nYWzE9AOarW0bBlxzmtrT9LOoX0Ni/yCY7SfSqlZSuzlnJR95mZHGslurJjpmoizFQme9ad9aDSLuSzPWIkEE1SjHm3OFAxVNODakhRqX1NLS4MoAetdNplmZMLjOazdHtv3oHr2ruNJscbSOtcjk3c0WpVg0tEJLKOf0qabT0IwRkVvm2wvvUTQE9uKmS5WdNOSWpyUml5cnHHY1f0yw8o9sVvfY/UVJDaYPHArNQT1tqdDxEUtBltDh/YVfjQEHNNRNmPrVuMKe3WuqEbHn1al9RrJgjgVSukHPStOftx9Ky7sMzDjtV3SJoNtmSXLSY9Kv26b8Y7Gs50eN/nBGTwav203lryCTWMrOWh31V7vumlGg3DNTbR9aqLMCAcEVaTOwEmnHezPOmmtWKyfL0FNEQK/MBViEq4OacycA961cTHna0KTRjBxVa4gIFaSxfNRLHnIaocTSNWzMZo/3ZB64rY+HyFdcuCR/wAu5/8AQlqnNHg4HStXwQu3WZ8f88D/AOhLXTl6tiYepdapejI8E/bCOPHGhf8AYP8A/aj1xfw+vgY/KJO4Gu2/bCXPjXQz3/s//wBqPXkGgTSW8qlHZee1fTY6mqkGjzcM7M+jtBk+Uc11lp0+teW+C9WaZVDtkivSrC5Dgc182rrRnqWdrGuBlcZpUkH3ahE3AxTDJt5ArT1MlBvcnlx171JZTmIjYecdPWsma9bOF/HNVTdyKxcMRgVtSqODTRusK5xszfViupxvjjvWpfXCAbC4XdwRms7SL2zurH98VjmHU55+tYmuahDChNoTMR1djXfShUU1Uha277HKsK8RVUGmnHQ8r+KEQi1+baAAQDXnNw2WNeh/EWcy3McjABmXFebSN8xrkcUpOx+lZY+WjFPsKSelMagtTC/ag9RyGnrSUZ5pueao52yWJsMDWkkwArKU4OamSUg9aznC4OzWpcuGUqcDmqLHBNPaYkVCxyaIRsJaaCEjNKT8tMzQT8taWM5A/NM7GlJ70o701oZSVxgprAsaf24q3Yw+cxHWm5cquctWOlyK0gIkUk1uxgKvPSqUkIgZc08XIJ2A1y1G6mqFRpN6mmsyqg9TTg/HXis2eTYUIan/AGghevPWuf2V9jt5VyC3coDY5zV3wcd3jHRP+v6H/wBDFYskheT3rb8FKf8AhL9EP/T7D/6GK9HC0tUeZi0lTl6M9U+KgH/CxdUJ9Iv/AEUlclcAMDXX/FRC3xC1Q+0X/opa5JlyDx3ry8crYid+7/M+Ow1vZR9EV4E+c1IykZxSKSrEAVM0eY8iuCbtodSREFyelWFG1eKYkZ4NTOoCDis7pszkZN2cyHjiqjIdwyBirc4/enNQnJJGM4rpi7GNRkMeY3yKn0/UPsOoQ3ZkbdE2496q3KsoOOlVICW37hmt4x5lcwnbl1L2vaqmo6lcXwBLy4yenT2qxpGySFGA+fPP0rnrvEZIxjNb3hdcwH61vidYc76kQSS0O28PwBphx0rurCPGK4/w2MS5xzXZ2ecjHSvNTOtL3bl90yvApY4dyge9SIpyM1cihyR6VcrM5Z1OVEJtl2ggcio3jwMEYrSfATFUrlWcYA60QSMadRyepQZwX2rzVqCJiCGGKlgtlVgxUVBd3jRSbUT5QeeetYVMVa9tkbuTm+WBdcKFVXIHpmqN0EViDjFVjM9xJul4A5ABqpPKWmIBIArirY6MFpqaUsO09WTDy5MgYNPWxDjcrAelQ28RJq7HGwHXivMlmk101NJycfhZXurSRbcgcn2qsZZI1RZDge9b8MW/G7niqurWaSIRtwR0I7V7mCxbqxRnTxCbUJEdrICODV6M7uO9YNlvBKnpnArdtgwAyOa9NPTUjEQUWW0iG3BqK4iJBxVgD5ck0OMg56Vnc85SadzImiOM46CtLwemzVZj3MJ/9CWq9wpA9qv+FlxqUv8A1yP8xXXl+uJh6nROd6bPnj9sJseNND/68P8A2o9eQaTE2FJ6GvXP2xD/AMVtoYH/AED/AP2o9eU6Lwi19Li3ZGFDodr4fuXtGDLnAHQd69J8O69FKQpfDeleaWKkrwe1XbSV7W5WRTyDXzFWV5No9OhK+jPb4pw6jDYqQOG4zzXGaXrIeNcuM4rW/tSMdXANQq8bXbOmNNtmldNsORWdd3Ajiz1+lV7jVEYgKwJrLutRQAqG564qJYiN7I76MLbl1tRUoPkbg461I8ksuMALF3z0Arl21CMty4znpUOta+YrQxxMBkdPWvp8qg54SpKo7RZ12i3yxWpgePNQS61Z1gYNHGoAI9e9cTI3zGrd9cM8jMx681mlsk81w8qT0Pdw3uJQXQkJpKYW5ozSsd3OBNJmlzTc0yGx2TmnA80wE4z2pA3NKwKRIWpM8ZprGm7utFgcxw5p2eKjDU7NFhJ3FpFbr0opoPagmWgvJrW0VgrnIrIBPrVm2laFsqRmpqR5o2MJx5tDV1ORQTiskyAtxRPMZNxY81WB6HrShS5VYpT5NEazMJIVbOSODTI5Cj5H5VVhkYHAqwnXPFCjrYJSfLYkQbpdw6eldH4JXPivRj3+2w/+hisaCPAHHJrpPBaY8UaQT1+2Q/8AoYr18JRT1PNxMv3cvQ9D+Kxx8QNTH+zF/wCi1rlI+c5rqvisN3xC1Me0X/opa5lEJJAr5THv9/P1f5nyWH/hR9EN8sM3AqQphQO1OWMq5qRug9q85y7nXHYSNYxH3LH8qq3rlVAqfcM8Aj61Q1GXcQoopRvLUykrEDfMd2KaiZY8daGcbCOhxS27YG5uwrd6I5pMz9YbyoPlHJ71gSNKUOx2UmtbV7gTOEAwM96pNHldqd69XCrkgmzCbstTHd5kl/eOWz3zXYeFpCIhkdTXNS27+YDgY9a6Hw+NoAPY1pjGp01Ymj2PTPDx+Ycda7OwI79K4jw42/aR6V2mn53AGvGSszva9w24UDYq2dy9OtQW5A4OMetWHkwRtGa1tc8mo25WGgNIcsMAU6XaqmnM4VMkVmalqUVuAWYYJxXLVk2m0OnCVSVoofLOUBA61i3l4G3DGWq5LMGUOOVNZLRh5jx3rwJVfdfc9TD0orWRJbySMvzDFTGHcMnrUsNqcDGKtRxNwCBgd682dTXQudVJ3iMs0Izn0q4iHIGKbChDjutaEcWTkVVDDSxMtDz61XW4sKkYpLhA45HarKoQelJImQa+rw9H2UbHEp+9cwIowJ2+Xoa04ju49KjkQRsTipLNdwyep5FehHa511Z8y5i3GOxHFKRweKkQYHSnMOKahdHnuRTmQFTkVa8NJtv5MjH7s/zFRyLV3Q1xev6+Wf5iujL01ioepTn7rR8zftig/wDCb6Ee39n4/wDIj15foKBgM4r1D9sXH/CcaFn/AKB//tR68n0WcoVHpX0uNV1obUFdHf6Yqk4wK0LiFfLJwKw9LusnpWrcXeYivevmJwalqdlNNPQjt7nynwTg9Aa1bWR5ZAC2QecmuYLkv2zmtOS8NvDuUfMR2rCvRvZR3Z69KVtDsoWs4RH5kilyeRmjV4LWWCRrba3ynkGua0vSLvUdHl1X7REERiuxmweKTSJZBIRK6hO+K5p4SVP3os6o1Izfuy2MrWEa1iUqCme9YU90STliR23V2XiS0NzAMTR7ewzXBapbvbyldwP0Nexgq7qQUJPU6YVOZJplW4cs1Vu5qRjgcmoy2RXoJdD0qc+VXYpyDS5NX7GGBoGeVvm6YqvciPP7s1lz3drGtPEpuxXJpufajPWm5q7G3OPpO9Jmgc0FJ3FJNIaMUc5oAAaeKbkYGBhu/vShiKTKi7bjifWmUpOaTmhBJ3CnD2pvaigl6CseKdGpPampGZA7DogyafHyRnrQ1ZGLkm7IkjU7jkVp2cQYcgVSgjLPntWzZxYTAopx5pBKVkSxRknGOBXQ+EYivifRjj/l7h/9DFZcULmPdg7R3rb8JZHifRwRx9ri/wDQxX0OEj7uh52Id6cvRncfE5QfiHqZI/hi/wDRa1zKrtc9c5rp/ij8vxA1E88iL/0WtYdmimXdKu4elfC5g7Vpvzf5nyOHlamvQYsLbd7A4PSophtUnB/KtgKMEhfl7Cql4GbAI46V5kjspzuZy44LZx3rIvSN5IBxnpWtcjy1NYl0+G69a0o6sUtStJOVOB0I5yKcJMRAVTlJLn0qwBiLPtXa4JWRjKOhk3jZu1yOKfbYwT6Gqk77pz9as2eTnFehKPLBHJW2Hy4zjFXtHwpHXGapTqUcbjU+nyKJQAeKxq3cGZ0ZWaPRPD02yVRniu7snBxz1rzTRpOhHWuz0+6YIPmrzk3c9aMeZHYxSZXFXbYkjJ7dK5eyu3ZtrNkjvXQ20gjhUsevWm5prlOHEUXDQs3TjyWA+9jgVwmo35N8I5UwAe4rqNSkkeMiF8E96xP7D85d88gZ+3tWVayp8q3Z04BU6KcqjLa4kiXYeDTYV+f5qdFbeQAivnirVtGGXJHTvXzmKhyx7MqclFO2xYjGMVIop0a5pC2HCkHBHWvIUJSehwt3HxjDjitCLAxisuZnz8p+uKu2ILLg5r38upez2MasfduaAGRTX71Kgpki19LUg1DmOBPUzLnHmANkKe9WLZF4KnIFFwm5Oe1MsCRIVPSs6eqOtu8NC6BzTiOD60Dqad2Ndajc42yJh61b0YYu3/3D/MVXYVa0gf6W/wDuf1FdWCjbEQ9RXPmD9sb/AJHjQj/1D/8A2o9eMWEuzqa9u/a/jDeNdDJ/58P/AGo1eIW8XYDivoMQ03Zno4eDcU0dLp9+BjntWg94XXg1z1lC27Cg10Nhps0rA7CF968TEckHds9SjSb6FywQyOHbuKu3kZMWQCCO2K2NL0dY4wzc8UupiNEwwx2rxp17zVkevhsvc3qzDs5prdHXL+S38OcAVHd3Upj2wjaD/FU0sqgYxgVQu5DsXGMdK6IPmd2j3aGVwWrK0kF2yb1MpA9Dms67E+f3wPPTIxXYaVqSG3FsrBZh90461JqkBubOVJUUzAfKRVLFShK00EsO4Ts1oeeupzULZxWnLbujEMpGPWqsqelenCpc3ng7Ijjk2RsD1IqPJ96cyY7VGAd3Oa0Vjl9i4vQUnrTM808jPaoyCDTRbi1uLnmnKeaZSpSaLg9SSlAPpSqKeBUtnSoXIj1oNOK80baLi5WNpR704LSke1K4+QYT+VMZuetPfPpVeTrVRVznqO2hNFcMgZAflbqKfGxznI5qsoB61Ig6n0qmr6HJonc17STrmtq0Kuo7VzEDcitixm2rjNdFClqVLVHW2+xbLGRn0zV3wtn/AISjST/09xf+hiuZtpAT1JIrpfCZ/wCKj0f1+1xf+hivaw0eWJxVocsJfM7b4of8lA1AdsRf+i1rOtEUnc3A71ofE44+Iepc/wAMX/otaoQEbVUHrXwuOX7+fq/zPj6PwL0LhA8s7RxWfcEbe9XWJWDHeq8qoU5PNeZXex103ZGHfsDlQwyfWuflOXPNbeoD5yOMDvXPSZ3k54zWmHWht00IEBkuCp6dKtXa+TbnB7UlhHulJ4xS60MQhc9a6+a9RRM5bmDFC0jlhT4pDbF95Hy1bt4yiCsbWpgN65r0aX76XK9jhq7O5LdXczqk7jEROFNEFw0ciMDx1rn3nYxqhdjGDkKTwK1rJhJGntXXOgoxszHDt3sz0Pw7d+YocdQOldLaamA+1hg+tcP4Yk8ubax4Pau1WwS6Tch2tj868GpTSk4o9nDzXU27G9xKCrV1lveQ3VuNp5A5BrgrNEhPzN82MDNX45miYmNiMnoK8mdV0Z7HTOiq3kzpXDSwukLYbsc1Q0q+uLZ2W8Jb6VLpc4KbicnPIrReOGRfurnPpXPUxcaq5E7O5g2qd4SV0yMy+ZIrKTgmtW2RBbFs8jtWc0YULjpnk+laH2q2ESorqx7kVzqLqycnrZfI462qSiWIBu56Zp8h2IAeabbOGOBSynLY7CualTVKPmcbXvFATFbgL1zWxafdz61mtBmVSPxNa9v90CvRwus1qGIkuVWLadBSMMilXpT+1fTxipxszzHoU50zGRVax5kb24q9L904qGGMISR1NcbXK7I6Iy9xosgZpSODTBkE4p55613wszmY1qtaV/x9N/uf1FV2xVnS/wDj6b/c/qK6sJH9/H1Fc+dv2rbbz/F+jEDpY4/8iNXlejaA1yckHb7V7h+0ZaNc+K9I2/8APpj/AMfasfw3pKR26jb83Un1rTMMRL2rhFn02ApL2EZMwND8LW6kMyknHeuki0hUU+nbFdPbWCk/dwAO1FxCI0bivFnTU9Z3Z6dPEJPlicncIYQVHQVzOrnc3BzXW6tgZ29K466Du7EjiuVJKenQ+gwOvvGWq7g2TVadC0ioOma0BGcnI6VMlrlwSK61UUT11UUdTOtLdlnBxjmulS2L8sSTimWthuG8kdelXiDGenasak+bVnJWrc70Ma70+F9wZa5m805Uudi5KetdpMd5461l3kf7w9M1VCtKLtc2oVGtGc4LSKJm3ruHvWbNAu87RxXSy22+QLjk1YbQojHkN81dkcSoayZrL2S+I5JbcFKrTRBTXSf2cUlZecVQu7XaxrphXTe4pUVNcsTD24pyLzVqSLHamkcYro57nMqDi9RqrUgWhVqQVDZ2QgQleaTFWNlATHWlzD9i2yfT7EXRbcxUD0qrPGI5GUHIBxmrKM0f3CRn0qCQZJJqYt8129BOhKLbvoVG6VC4q0VqJk5raLOOrTuRItSpF8ppUXnpViNe2Kbkcjp2Ik4NXoHIwFxVZwA5q1aLuOBXoYd7GTTRsaaCzcmuu8JIf+Em0nB4+1Rf+hiuc023AycfSur8JxkeJNJJGB9pi/8AQhXpU6qOetrTk/JnWfE1f+Lhame2Iv8A0UtZls3zg8DtWj8TXK/ETUx2xF/6KWse3kII4r4rH6Vp27v8z4ijfkRffcWIzx2qnKfWrAcEMSeKoXUhCHHT1rxqibZ1xehjarIVLHjpWMRkdOtaOpOTkmqC/dFdlJWjodHQt6XGAGOB61V1kl3UAVpaeP3ROPeqtxH5jgHmqjK0uZmUtzPRGKDiuQ14lbphXoLxCKIDHauC8VjFzlR7GvTy2fNUZy1l7jMaTGPetXRmyyisP61c0+UxzJyQM17VWHNFnBSlyyPRLMbVDrwRXcaHdbokBPNcHo0vmwjPNa+mXphuvLbOO1fK4iMk21uj18M7ux2F9wwIAzmp7xTHarMhH0qhHOsi85JqjfaibeNgSfLHUHvXmVabqtNI9iLbsjZ0y7YjzEfrxXQ6XdGQEOfmBrgdB1FZiwjBC5zXR2l2qSYB5615uKw7TasFaKd4s7+0eH7MyyY3EjBqPULVREJYgAO4rAsbxXlHPNdHp0m5SGwUPrXNRruk1TktGrfjuePVpyoy5kxdPmGzB6ip3fnIxWdcEwTfIBjNIbhmwAcHua6Zx5HZkOlzPmXU04XBJPersMgxxWXandWhEu3muPD4ibq6bHJWitjRRulSqciq0ZxjNSeZg4r63DYjlV5M4JR7CuKYi9eeKC1IjHd049atPmlcaWhKoqQjimoakPSvRpJWMWRsKs6X/wAfTf7h/mKrt9Kn0v8A4+W/3P6iuvDJKtEnqeZfGay+0+J9MYDJW2x/4+aoaVb+XEARXT/E2ISa/YkjpB/7MayLaMrwRwRWGOX+0SPo8NVth4xLlvGAeKS5st6sSOMVYsoSoO4EelXGjJjI7VySV0Z+3cJ6M841q1YBlUE471zEsXylCK9VvLcAPkCuHv7MLK2B3rzq1Jp3R9Tl+MUlZnMiz3PnHFaENp8g4rUttPd2B24Hqa07ay2nBAJxWsKV1qd1XGJaXMG3tzztGamltWK/dNb1rZ7JSQKuLB82MVXsU0cksXZ6HCfY2VjkEVTurTc24Cu11C1JY5FZ32UL97vWKpO97nXTxd9TmRYFiMDpzT5LZwuBk1uXkXljIHeq6TqEII5NJx6XN1XlJXRmfZMJkgdPSsPUbAbmYDPtXXwDzXwBk1W1LTpVUsU69KLypNS6M0pYjllZs82vbco3Iqls+autvLMvuG3msC5tzExGDXq0aykrHrwcanqUttKBg1IRSY5ra5ryWHxDJIzipTHyO4NRxYzzWhGFO0E89qznKw27FCRSOowRSIhfoKuX0ZHI6d6dYWzFlbjBpc/u3FzLluVDZFhnOM/pVe4tvKHWupNoQg3AYzVK+t1bC4rOGIuzinJSObAp4zitGW0CtwOaW1tDI2NuQK6Paq1zklbczwpaQZxzxWnptudzfXiiWzVGyR9BWxpkICYxzXRDFJR0MakE46Ghp8BwM9K6nwvHjxBpf/XzH/6EKyLVAFwB0rb8Nn/ioNM/6+Y//QhV0cXdnHWjanJeTND4qPj4jaoPaH/0UlZCEmIetaPxVIHxL1b6Q/8AopKxkfIUAdfevIxyviJ+r/M+FofCi35rBDkVUupP3Z9KlaTAx271Sv5gsZyOK87luzrgZN+fl5/CoIhkKKLh9wOfwpbXBA5GQfWupRtHQ3vZGmnyQdOSKrR8z5PpUsjlFHAbH5UyH5pAfas7e7clK428fEWTmuF16MzznaCc+leh3FuXjHFavgHwrb6nqEjTgEIehrqwuIVDVK7eiMMTKMKbbPHofDWpSxrIYCF7U5fD2ooeIDxX0udBsobgQJHEVY8tI2MY9K308P6S0Ko0UJ4+8DXowx9WS1SPHjUp81pJnzHpT3VoRG8LZ6VqyJePMkscPK9s17de+ENNmnXyniDemRUd54JtU+aORMgZ5PeuSpWcpNqK8ztp4mEJaM8wttUlhXbNCRgc+1ZGsa3HLujRck8V6XdeGHSN58xM2OzCuH13QLWO48zDBQctxwawpQpxd5r7j0aOYqT91akvgwJJGWZSO3Wrer3UllMWjPyd6oPremWIij02JxGF+ckYOaa17Ffp5hIKn17VwVKMnV9rKPuv+vvO+nWc5c01v0Oh0zWolKHeSzevauu0rWt2FB5PevJ47c7i+flU8YNb+i3YVl5PBxXFi8HTa5oGtSNOSsetSzrcWytgbxVGMk49ay9Pvd+AMEGty0hBYSHivKr12oqPU4JQVFWZqWMeMEir6n5wMd6qwsMZAwBU6PyPWuehKMHv1PIqXbuaKjpTXGOaWNhx7Cklb0719V7rhc4luNUbgRT4Ux71GrcdOM1ZjIx0row6ugk7DlGKf2pAfanE16tNKJgyN6saZ/x8t/uf1FV3NWNM/wCPhv8Ad/qK6MK/38RWOO+JDbdbsj/0x/8AZjVbS0D4LAGpviaCdZswP+eP/sxqvop2qN3as8frXkj1kr4ZNbm0UVgOOlM9VqdCrAEHrS+TtYtnIriVoo4aUmtJGNfRZVv6Vgx2AeQlwCM9K6q7hyfY1UjtwPTNS4ps9rD4hwhoyklnGkIGwcVnXiCI7kHNb0o2jmsq6TzGwDkUmtdDqw9Rt3ZBZfOMsOTUyRETVcsbUbMYqw9vgj1q2rMc665mkYmoQjaTiseWDdhh610t7GCpDVQjtwQax5bs7KNa0bmJcQK8ZBrHl08FjtzXW3VmMHZms9rZl61Dinud1HEWWjMiytWt8svJqS7uJXgaJwu36VsrEAvaqF/bgodo5rOvB8tuhaqqc7yOTmiG81j6jYiU9gT3rop4ishUjHNUL5Pk/nXNTm4tHsUajTVjh760a3kwSD9Kqmuj1CJXjY47VzrDBINezRnzx1PapT546ixfeGelacEW64jJ+6T2rLU4NatjIu0c85oq3toFS6WhpXNmjOrYz7VPbWqqcjGKSJ92Aeas7WVa8+UpJWZ58pSSsPMYK4FUZ7bc/NWstjrRyxqItxM1dFL7ArnPOelWYdPEQJ71ftogpzVrYCKideWxhOWpzl3a5f2q1YwgL71emt97VJFbkDOKp13y2uDmrEsA+XFbXhlT/wAJBpv/AF8x/wDoQrKijIrY8NgjX9NH/TzH/wChCnQxMlNRv1RxYh/u5ejF+LbbfiXqp/2Yf/RSVgwSAwhuhPUVr/GB8fErVxn/AJ4/+iUrnYZBt6969DHR/fz9X+Z8HQ1gi1LLgHmqOoyhrZtpp8xIXcRwayLi6DFkGQB61xwhzNSO6C0BnyOtR2bBZm96SIE8GmL+7vlVjhT3rqS0cUW3ozTuZWCLhuKt2HzFTn3rJ1CRVjPUjoMVqaK3mIjKcjFYVU+S4UzdjRWQbu9OCTw5a1nmhYc5jbGafbr04/A1pRRDnFcUZamyp3OR1XXtUhQ/aGeUL0Y5Jrn5PG96Dj7VMuO2a9Bu7FWJ3Luz2IrjPEHhq1uW8yErDJjGOmTXo4bEUeZQrR+ZjUwel4JXMgeL7wyB/tsq4PHzVej8dX7Dm9d/Zm61yWo6Bc2+7lWA7is6O3kjYFlPFe1HD4aquZHDOhVWsoHox8ZXjsrPOUhX+FahvfHUt0ssCwIYpCPvr0+lcQGYnANW4Y5N4kcEknqah4SjHVoqFOKd7HT2m25QKVy5q5cac1vBtj6H+dY+lXy294PO4U8fQ10V5erKkSxjPPWvGxHtIVLLY9igvfTRnSRXVvbBvM6EDANaOl3BUoGPzNVeYmTbEo+XOc0y3iYXcagjrmspWnG0jaXw6nc6TcusiZbAPau5spsqgJ6iuAjhaMRnBGOa7DTSXjRj2FfMY2CeqFiYc1NSZ1dseMe1XY0+b2rMs5MgY+lakTgjGea5MFGLdpdD5ysmmW05p5HBpsQzillOxCa+qowbVzg62I4jnIz3qzH0rOtJfMycY5q4jZ711UGkiqkWnYn7nmnHgZqFTxxUh6V2xkc7QhNWdL/4+W/3P6iqjGrWknN0/wDuH+YrfBv/AGiHqKx598Tb0ReNbK2d12tZBwh6k72Gf0p+nupA2kcjtXn/AO0bqh0n4p+G5/k2mx2tuOAAZGya6rR7gSW8bQurAgEFTnNdGY0+Wrfuerg0qlNx6o7K2GVANXGz5RyaxoLolEByGB5rSQs45JIrz7M56lFqV2MZd6fSqjqyv7VdHytjtSFQxOBSZtCXK/IyrpSVwKzrWF/O5BNdE1vntVfyTEdwFJbnbSxCUXFD7eLagprDMlS7iYs96htSxYk81TTMlfWTKd/avITtBNU4LSRchga6aLIPI470s0fy5ArLVMuOMcVyHOSWxzUbWAcHIrckj745qox2npVKzRvDESexhPZFSRVSaAbSCK6JyCelUrmIMCAKiUWdlPEO+px9/aKy5Haub1KLCFa7e+hMZYY4rntThVgflANcVWnb3ke7hK2xw94hCkEGuamGJW+td7dQgjBGRXKavAqPlQBXVhKqeh9Hhaqehkip7RyJVA7moSKfFw4xXopczsdzV0dbYQ7sE1rC0ZsAVQ8PASKO9dvpunNOVCLk12f2Qq9RKTsfPYuv7KTucu+nvsJFVEgZZfmHSvTv+Effytxi3Ae1cvrdh5LH5NpqczyOnhcO6tOWxyUMxhVfKncxRwOKTcalKgKQajVeDmvkbmtSoo6sfEMkZ61fSEMPaqiLjkCr1ucAelY1H2OGpikJ5eOlaPh6Fhr2nEA/8fMf/oQqK2VWb5uma6PR5ra21DT87QWnjUfUsKzp1WqsElfVHHicYoQa3ujz34vXi/8AC4fEVsX+Zfs7Aen+jx1kwyDPHSs/48332H4+64xbbGwtlfjt9njpdPmHlrzmvs80w/LU5u58nhJ3VjXf50PJxXOXjeXKQe54roFb5Ohwa5/Wf9YDg4HNedhld2PUpu+hNZvmQDORmrd7bh1DjJccis+xliEg+U89vSt6EqygdqVVuE7ktmNK4kh2tkPjpV7w5PsLI3b9ai1G12yF0z7ik0pCtxuP5UVOWVFl09zubNxhc961YCNvesSwkBVQOa2IpVRDXlKJ6dJXQy5lUAknGK5/UlDkEc1qzSq5IJBrOmdd5UUr2d0d0KCktTmpIHLP5oBPsKzpdPMivtjyAeDiupuWWM7ymcdqiZgIvMRcB+ldtPEzjsTVpun8Oxw8lpscZXBzzT9zJEqDBXOTxzW5qcZZQAnzeuKqWKLFcKZEDBOcH1r1VW5oXep4+MSS5kh/9lXUtrFdyW0iQE48wrgVtQSW66QIoI1kuGf73cD0ropfEV9PoQtJY4jbH+EoBgVxUbRyakDbKYgOSoPQ1x1LVI8yb0+44sLUk9ZF+3t5jI3ykEdcipLSMf2hHn1roM77eJyo3kYYgVj3P7m6VhwQa8xVXNtHpxk5x1O0uFXbD9K1dIuF2eWx5HQ+tYtvJ9ogQ+gq9ZAbVK9RmvEqRurM6pwTp8rOvsSM1o28n71lNZelN+5BNaMPLg1nSoOEb33Pnq61aNuBhsGabc8pRF0H0p0pGw19NQl+7szydpFC2winHc1bhHJNU8nzPbNXoTxWkDarfclGOacTxTF4zSseK6E7HKxHarWjnN2/+4f5iqUh4NSaLcodXMAb5zAz49gyj+tdOBd8TD1C2h82/thtt8baGf8AqH/+1Hq/8Kdfh1LRYIw6pPbgIU9vWsz9sg/8Vtof/YP/APaj15T4J8QSaNfoSf3DnD4r3sfQdWF1ujrwNRQqLmdkfWsEpZl6dO1b1lKNoGfwrz/QNQE9nFLG29WAIOc112lT+YQCDmvm07nqYqh7t1sbnliQZHBqBZNsjL6VcgTC1XeA/aC3Y0ctteh5NOoruLHI3IBpXRTyelEsJ4Kc1JDbs6YPWqS5tEPniveuVmi+U45BqOCMA4rRFsyJhhVUQOJenFU04PlehcKyaauWI0X8aVwNvNOWMjFJKDtzWbRz813uVbpRs4rPaFmNaRAc7TS/ZvSmo2R1QrezVjnponVuOlFvA00gQdTWpcwEfeXj1qCzjb7UpXjBrSmk3aR2qveDaKWq6I/klsqfX2rjb+wYMy9a9fMfmpyAaoXeiQTDPlr+Fc2JwVZpunFyROCzl09Kh4Vf2rIWJ6VxuuRkuNvrX0DrPhqEow27cjrivF/ENj5F/NHwdhxXk4Gu1UdOatJdGfcZRmVPEv3ehxrQt1p0URDZIrYjtlfjbxUc1tiRdvGD+de/h8WqdRSa2PolXT0N7wunCkjHNe5eFdPhjtY5XXcSK8V0FlULn5TXr3hDVYmhFs8nzjpmvax2LdSnGthZbbo+J4l9pKm3D5ncLs8vAAx6VynjDRIbm2eWNQsg5rqbbDIDmq+phfJYNjBFc2ZVKjwbqN20PhMHiJ0KylFnz/qCNBO6k9KqxzqWrb8YxLHcybSM5PSuOEpV8V8fh17WCkfoVXEKdNNbnRxHfjFWwCg544qjpZV1yx5FXbmRTjB6CsJr3uU+dqYt+05RFmKE1mya4lt4n0G2LBpZtQgULnoPMWk1G9hsrV553Cooya8z0fW21n4neH5iAsY1G3CeuPMWvYyfAe3rKpJe6vzM8Xi+WDit2aX7TJx8b/EBHUC2I/8AAeOqvhi/+12MbE/OvDVY/aZK/wDC89fEpIjxbZ29cfZ464Tw7qz2FxhiTbscYPavssdh/bU9N0eJQqck9T2RtQjuLC1tljCyQltz/wB7NZGppuwTVawuw7BlIZWAxWjOnmxcV8x/DnbY9yjaJlwDy5gMDk4z6VuQ71TaGBU1jywFdw2mpbeVwgVmOQc06iU9UXUj1RtyAuMEZqIQusi4IC9xjrUkd2Jgo8qNQB94VdtxDI4E7MFxwVGTXG7rQyUnFXJbWVowBWktwWQiscYSXIJKds9atrKoUBfXmuedNQk0z1cLV2JuS+B3q/BHYtaeXMsguyeHHTFVreF5W+RGbPoM1FeXP2Q4dWyPbpWUeZPmieyn7S0YvUr3sXlqQ1UIvnUDb+Na93byX+kNdWe6VIyBIccqabp9uGiXjOOtVZwgp20YTmnFrqZ0tvuTGMd+lbOgeEYp4jd3E3XkRgdfxqK5gd32gferS0c6haN9nVMQsfvelX7fltrp1PnsbSnKDUWM1pLaGGOzjgUMf489K46Swltb9+nK8EV0viWxmg1L91J5wZQc9QKdows47W4XUoXe4IPlsOxrqlUhzKHMkmeVhYTp6pXRm2lzIkJST5v0qhduZJQxrTn2QjL4OeOKyrpoxFlWJfPSuSlBOV0e5TbfQ6DRLiUAK75Hpiuggn8rCgZz3rntDHmuGxgYrfPlrIu4ZNeZWsqjO1SUlZnQ2Ny5wN3y46YrorIkgE1yVrIGkURda7DTwxjXdyazVp6Hh45KKua8BGRn0pZUBIqE8FTnFK0hI617NJcsbM8KzvdEMybXyKs2v3eapSnoc9D0qxbvlRzxThLU0mnyF1fSiT7tMDe9JK/Ga7U1Y5LMinYKpJ9K4rwB4tXXPi7qWm2wxbWWmyZPdm82Ln9azfjB47XwxpnkWjqdQuFIjAP3R61wf7K15NffE/WJ7mQyTSaZIzse586KvTyrDtz9rJadCpaKx0f7S/w38V+NfFGlXnhrTBeW8Fn5Ujm4ij2tvY4w7AngivJYfgR8R1PPh9cf9f1v/wDF19yUV9E1chOx83/CvwD450RZLTWtJ8u2+9G/2qF9vtgOa9ZtdC1BCC9uAR/tr/jXb0Vw1Muo1JczudEcXUUeTocydMvMqRFgj/bH+NTnT7phzFz/ALw/xrfoqHldJqzb/D/Ixc2zCFhdDH7v/wAeFPSyuV6R/wDjwraopxyylF3Tf9fIh6mSLa5Iw0X/AI8KYLCfOSn/AI8K2aK2ng4VLc7bt/XYSVjMFpJjGz9RVeWxuDkLHkf7wrbop1sHSqpJq1uw1pqc8mm3O/Jix77h/jVuK0mXGY+fqK1qKVHBU6T5l+I5SctzJmsXkQgxA/iKzpNHuAQY4v8Ax4f4109FFXBU6k+fZ+RUJyhszIgtrgRgNDtI/wBof40/7NP/AM8z+Yr5H/aX8Z+KNG+LWo2Wj+ItYsbNIYCsFteSRopMakkKpA5NeXL8R/HBP/I4eIf/AAYzf/FV0qNla5m43PvzUrC7mhKxQbj/ALyj+teRa98PvE95qE80Gmqyu2QfPjH/ALNXzInxF8b9/F/iH/wYzf8AxVaNj488bu4z4u8QEe+oS/8AxVeLicmw9Ws8TUlK7VulvyPWy3H1sE37JLXvf/NHu0fww8VjJOmKD/18Rf8AxVPX4Y+KQf8AkFr/AOBEX/xVeQReNvGJCj/hKddJ/wCv+X/4qtrT/GXizaBJ4j1kk/3r2Q/1rjq4HCwV25fev8j3P7exz6R+5/5np8Xw38Tpg/2ao/7eI/8A4qtS08EeJocZ0/kdD58f/wAVXlkHi7xTvO/xDq+3/r8k/wAad/wlPih5t58R6wsY7fbJB/WuVUcJCV05r5r/ACIlmWMraS5fuf8AmfRmh2Wtx2iR31gyuBjIlQ/+zU7XtN1ea0K2dqXkPTMiD+Zr5ufxz4hMgjTxFqpPf/TJP8avxeKvE7sqx67qzZ/6e5P8a7MRisPVoewqRfK/NHk/2TU9p7XRffY7vV/AXiq8JK6cCc5/4+Iv/iqwn+F/i8sSNKX/AMCYv/iqZZa94jYDfreqE+90/wDjWtFrOvMvOr6l/wCBD/414yrYCguVKX3r/I7L4iK5br8f8yrB8N/F8YGNLAPr9pi/+Kqyfh54sI500Z/6+Iv/AIqrCatrxwP7W1En/r4f/Gt/TY9fuEDzatfRx+puG/xqFiMFVlywhNvya/yOKtzw96bS+88p8cfCr4gaokcFhom+EDLk3kC5P4vWD4Q+CPxC0/xfol9eaEsdrbXsMsr/AG2A7UVwScB8ngdq+gpbh7IbrjX7xsdV+0sSfwzXO6x4h1OeYtZahqEUY6fv2Gf1r2aWa0cFT5HTat3au/uOWNKdd3W3ex598d/hB438VfFPWNY0LRludOuBAI5Tdwpu2wop4ZwRyp7Vwo+AXxK7+H1/8Drf/wCOV7DJr2vAn/icaiP+3h/8aryeItfB/wCQ1qX/AIEv/jWq4lov7DK+ozXU4zw78HPiHaReXd6GFC9P9NgP8nrq7b4XeMVUCTSVH/bzF/8AFVBc+KfEKZ/4nmpj/t6f/Gsi+8ZeJFQldf1QfS7f/GsJ4zDYmXM4tX80dNOnWguVNHRTfC3xc2dulLz/ANPMX/xVVX+E3jA5/wCJUv8A4Exf/FVwd3478VqzbfEusge17J/jWa/j/wAXD/madb/8Dpf/AIquunh6DWnN96/yN7V0t1+J6dB8K/GcSkDSFx/19Q//ABVXrT4a+Mon+fShj/r5i/8Aiq8d/wCE/wDGG0n/AISrXP8AwPl/+KqCT4h+Mc/8jVro+l/L/wDFVo8DQl3/AA/yImq3W34/5nuzfDfxSwBOmKD/ANfEX/xVIPhv4rH/ADDBj/r4i/8Aiq8DPxE8Z/8AQ2a7/wCB8v8A8VTX+IvjP/obNe/8D5f/AIqh5Zh5Kzv+H+RMalens1+J9K6N4T8X6TcpNFpKy7R903EXP/j1L4o8CeIb+UXFppgMko3SR+fGNh9stXzN/wALE8aHGPFmvf8Agwl/+Kp8vj/xqig/8Jfrxz6ahL/8VSp5Thqd0r6+a+/Y0WYYinNVEo3+f+Z9AWHgLxzYRSJb2SCKYFXQXEeV/wDHq0rLwF4lhj2tp4yev7+P/wCKr5hm+IvjQMNni7xD751GX/4qoX+I/jft4v8AEI/7iM3/AMVTlkmHqJR5pW9V/kOpneJvdxj9z/zPq2HwHr4bL2Q46fvo/wD4qteHwlrSqVaz4PX96n+NfG//AAsnxvnnxh4h/wDBjN/8VXoHwC8ceK9W+Lfh+y1PxLrN5ZyySCSCe9kkRwI2PKk4PIFKPD2GWvNL71/kclTNq1TdL8f8z3i+8D64ykQWIbPbzkH9ay5vAPiVjxpoI/67x/8AxVe80Unw7hW73l96/wAjOOZVYu9l+P8AmfOt58N/Fci/u9MHrj7RF/8AFVRf4X+LnQZ0oBu/+kxf/FV9MUVtDJMPDZv71/kbLOK6Vkl+P+Z4PpXw/wDEttGofTwpA/57xn/2atZvBeusBmxBOP8Ansn+NexUVyy4ZwsnzOUvvX+Qo5xXi7pL8f8AM8q0zwlrUUu6a0Cj/rqh/rXU2ukX0aANBgj/AG1/xrrKKI8M4SLupS+9f5HPXx9Sv8SRy8+l3rIAIMn/AH1/xqMaZqGP+Pfn/fX/ABrrKK6nklBqzb/D/IwVeSVrHHHSNR7W/U/31/xqzBpl6oAaHH/Ax/jXUUVKyLDp35pfev8AIcsRKStY58afdgf6r/x4f41Dc2N+ImMduZGAyFDqM+3JrpqKv+xqHd/ev8jPnZ8keOvhf8RfEmv3V/8A2DhGYiNWvYMhc8D79dd+zn8N/Ffg/wAa39/4j0wWlpLp7wJILiKTLmSNgMKxPRTzX0TRXp06UaaUY7IgKKKK0AKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPhX9q4f8AF5tT558i3/8ARS15EoxXrv7Vo/4vRqf/AFwt/wD0UteRgdMUNlIns0Z5MAcV1Wn2+1BxzWTocBfr3rr7C1XADZx7V5mLqpXR6OHhZXJLGLOBjity3twSCB0pllZqu3Gcmt22tggAxXgYmtrozr06EAQHAwKkubfMRCjqPSrSWJY+YOPar1ogebYyggV5U6yWq6HfRp21OJGkut0GYYX1ruvDlmGQfKOnJrbh0e3ukUNHz7Ctax0ZbZR5ece9cuKx7qwsdFWspxsyjDZKO1aCW+AABV9bZYyM1cihU84rw6ldnHKSWpS061zcJkd81a1yeaVhFG7JGvG1TjNaNnCFcMoHpUV7bAzMQK0w+KnGnPk3dvuOVyhKspNbHJtbHdnGfXNI0ZHUVuT24UZFZs5wTgdKOeTdmdd1JXMq6t8gkVj3KFDg1vzy9cjmsTUnXJNdlBtuxi+xzmpyAEg1z2oyfu8E8GtbU33Oc9BzXI6rf7nZV5UHrX0eDpOVrGsYlG8bG7JNZMj8e9WriXdnBqjK3X2r6ClGysErIYzHGc8GomPSnq52ttOOMH6VC3UHNdMVYwkxjnio3NSsc1G4+taIyeo3HQ0oyRSYpQrY4NUZOJFKARkcGqrA1bkBz7VWkXBrSDOSpEiIBHJAr0f9m7/ktPhr/rpJ/wCinrzk4xXo/wCzh/yWrw0ATgSScf8AbJ62RySR9/UUUUyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4Z/aqGfjNqf/AFwt/wD0UteSRp8wr179qcD/AIXNqWc48i3/APRS15VGEM5EZyueM9azlKxtBXOg0KEAKcHFdjYQZxxxXPaAmVBrtNMA2nPXFfP4yo+Zo9OmrIvafbk7QR3roxZEsmFOMdqz9MQGZBiu2sbQyAH0FeFVak2my+azMOS0lt4smEspqW0sGKmZV4HWumlgbyDgVUslSNjHIpJY8Edq8/EKyVnoepQneN7ak+jQuBlhW5boC5VhTbK3UYx2rRWMZyBzXzmIrSTcTjxFZOWhUe17jmpEjCjFSTvsHXAqOKdGb72a5k5SMk5NXLluvyCnzqCvTmltSCgOaW5cKvWvToU1yXRyNvnMe5jKn1BrH1EpFEzkdBWvcTHcRiuV8TXght2XfgkURp89VRTO5XSOC1rWrp71jC4SMHjHeqcmsyumJFy3rUN2hk3N3zmsouQSGzkV9bSoU3FJR2MHJ3JNUvHljKRgAnvXJXsUi5yK3bubAFZly3APevUw0XTVkjaFWVrMwncrw2fyqs7jkV0trBHezJEyDc5xkdazPE+lNpF55RJwRkfSvQp1oufs3uKVR9TI37cgfnTc8jFM3ZOaepHBFddrEJ3FA4560OCx4pV5PNWET5gcVLlYtQuV44WY9KVhtOAOa1ooBIAQwX3qvdLFFwvze9Zqtd2K9noZcqEnpVWRCWI9BV6RyTwOKrSLzXTBnNVplQjA716N+ziP+L0+Gj/00k/9FPXn3CsMqDjsa9D/AGdMf8Lq8N/9dZP/AEU9dEWebUjY++6KKKswCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPh/9qYf8Xi1I/wDTCD/0WteV2ahnFer/ALUwH/C39S/64Qf+i1ryqxUhxn1rmqvRndRjojtvDsXyjNdbYx4bPr0rmfDo+QV2ukxwsf8ASH2L/exXy+LqPnaO9OyNXTQqyoc16NpUe+IYPavMozh/kOQO/rXQ6Vq89rtG4lfQ141WTjK9hypOVrHe+UPKIIrn5l2agQBxWjYa4p5kiDDuKl1BYbxkuLePyxjGK4sTNTpuzOrDuVOVpLR9SaxuQowa1EcMMiudBMQBqSK/IJCt065rwK0HVfMhVcNz6xNi7iWSM+tZEavFIeDir9tdfaF6ilZ1YkYxisoNw91kU3KneLEilKr941JJJlc561AUGODQzBV+Y4ArenVlHRCcU3dFeT5UZifeuI1aCTUrpkUEjPUDpXV6rdbbdgp5x2rG0bXXtFltzaRyFujn+tevlWH9rU3S9TLEOcY3icBfWz29w8ZBIBxnFM/saS7i3W8LPjkkCvbrPwzpkmneZcxh5HXcWNcLc+ILjQr42mkQxNGWxtZM5r3XGqmtku7OOnWVRO3Q8svtNKXixSAgd8irM2k2/wBjO5eccGvWbXRre+uX1DxVCtvJKoCbBtB98etXtN8FaHemQxzSSxZwBkV03rTgpw1XdbP0FPExj3PnnT4vI1WIIej1u/Ejw5IdMj1IybjtHHtXo3ir4T/Zo5b3SZGk2fMEPWvKfFM91Pp/2eeaTEZwUJ4rr5ajrwntbe6Lp11VT5TzM53GpI8huTTJ12u2c8Glg5YZHWvomtAhUs7F2JQx5zV2GEkiq0TDaFFatqAEzXFVk0j0aWquQPESMDgVUePk5rXdMjjrVaWPnGOvtWUKh0qNzIdMHpUUi56de9aU0WDxVJlVW+YZFdUJ3Mp07ooyxnaSAcDqcV6D+zooHxn8Nc/8tZP/AEU9cKSwVlBO09R61337PCFfjN4aJHWWT/0U9ddOR5OKp2TPvSiiitzzAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD4n/AGn493xg1HH/ADwg/wDRa15lbwEOvFeqftMqT8XtSOP+WEH/AKLWvO59SeaytrP7JDGITnzlHzP9a8+s25NI9CDajFo2dBk8slGPIrudOYeWpGD6ivObCYxzI3GD1rvtHYbA/HzV87jo2ldnouOiZqRNiT/ZNaqAbAc1AksBskhMIEgOTJnrQk4xtBUKOrHsK8irHmtdlwu+htWcuFwGwa3dOuWWHaxzzXDi7QZ2PuX1FXLDV47eIq8pbnPNeZWw0mtDthBy0sdpdTr5ZYnArMhuI5JGKZH1rIbXoZFALYB60lvqMDz4Rxg9q544WUU7o6qdLljZnW2rgLjOQatG4Xdj0rJtJFdRtOatkc8gg+9cU4K+pzTgr6lvzCcEGoLp5GGMnFLGRgA0zVZTb2pZhtQ9yKmEfeSMdEzA1m8SKMruLNXGz38iy5ZWX0Oav6jep9pBkYbAcnPpVTxB4i0F4ljjkXzQOdor6PB0JwtyRb810FOCloWF1nU1tBH/AGjOIP7m7j6VkrfumoJP94odwzWWdYtJpFjgl3c+lT6jJHBIMOMbQa9SXtZNRqXfqcXJH4Uj1pfGOg6joBm1zERiHzL1OfauG034jWenapIdNSVrTdwJAQSK801iczyDazeX3A6GqqzRKDkjcOwr1aVCCipWfN/XQ53hqadnsfUWkfEfRNRthukaNyOVZa8M+I0FtJqtxPatiGUlueBTPCGi6tqJWWytZXiByzdqseOtMmitlFwjRk/3hRWx/PUjSbMqVClTk+R6njeoAJcOoOeagjkwan1KMrcv9aqouXGM5r3Y6xIbszRtmy4ratnwBU1l4VvT4ebVXjZYAcBscGs8MYxjJzXFOUat1F7HoYWrGS0NQlSOKhdgcnv0qos544oaUdCOaw9m0ejBpiy8niqM6kNzVxXAbjr71Xum3MSa2hdOxrZWKTDFeg/s+Zb4xeGueBLJ/wCinrz96779nr/ksnhzHTzZP/RT12U90eZjILkZ94UUUV2HzwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8bftKc/Fq/GODDB/6LWrelfD6wPhS21u8l3x4DvGBztpP2jkVvipqG4gEQw4/79iuSsfGWqx6DPoyOptdpxnqB6V49dRnNqd7a7Ox3TpzdODgyLxF/Y0d9J/YzTeRxsDjnPerOj3vkKDxz6muZgInddw71vWlmjELv2f73Oa83EwilyyPWpNcqT2NqXW2CnYvQd6zLjUpbl0B+7noDUeo25t4FaOQSFjjArOhV/NCtkH3rCnShbmR6FHkSvE9M0WGWSy3wxNIFXLYGcCsTWJlJBQ4cnoKpWevXunuLeyuCqyDaw7Y71M7wxOFH74nGWPauFUPZy5nu/wAgpKSm2TWccspyoYjFWRDcedn5lNdDoVrFJEvHJ64rXm0uAoThg3rmuCrjVGbVhyxig7NFr4czxjUhDfuq54TceCa9MvNESeQyRvjPbFeHXUE9s2UYOg59xTR4q1fSwZYNUmC/3HO4frXXglhJxcK8L3d7rf0ODE0J1pe1ozs9rHpHiSGXRAk3yle2elcj478bW+o6Zb21ohSZeZBjAFcb4i+IGqa0iQ3br5a9No6+9clqEzLKTcSsAwyMetdlPAUsPOUaPwy7q7Kp0Xyqdf4kJrmovcMysSB9awDLlz3xWj5Ec9sTlxLn8KzHt8FljYMR1Ir1KMYRXKgqTvsju/B8dmbBridEDj86Z411DTpHhGm53bfn+tV/B4It1Qjdn1pfEmmpKFSGBluSeSB1FedCnH625Sv9+h5k8T7ORmSXFsNOVFCtI35g1mxKvnocDqKl1HRL/TIUmureRImHDkcVStLpUnG5c54FelCEXFum7o1p16UoaH1V8LLmJ/DVukcYVh94461y/wAftR02HRVtJFzeudyEDpXNeAfE9xbWbxqcIo4NeYePNcutV1iaS4l8zDELzVYCsmnRlFaHC8E6cvaX0MhdLF7HNL5igr2JqzpHhK8vNKuNStlDxW7Ycf1rmp5XRjtdhnsDXceEvHk2g+G77TkjSRrnoWGcV01YV1H93Ld9jXlUnZI9T8B36al8NdT0t1R5LeFmVT1PFeEXDHJDLgg4I9KbZ69qenTTPY3LRecpVwOhBqvDcOWk3/MXHJPrXQ42iu4Yai6U21sx4kKgkUxpCD3JogXe2OuKZOhR2HpWdlex7ESxHuLjHOep9Ktapai3RDvUkjkCqcLArsIx3z0zTZJGI+Yk49aOTUfO7kDkYPFd/wDs9/8AJZPDf/XWT/0U9efHNehfs9j/AIvH4b/66yf+inrenujnxWtOT8j7uooorsPnQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5D/AGlrYn4lXcn96CIj/vgCvLNN06fUJjHbozv7V6x+0WHf4oXuOVEEQx/wAVxXhnWdO0Rba7QtLOJAZYyMYH9a8LFVJxlJU1d3PTdRwoR0uZ9xot7ol2IdQiaKUjIBFa9nsKqZFDDIzn0rq/iF4n0fxGNMmgjfzGXBlYHgemO9cxd/YjdCLSrh549o3MybcHuK4sQufVdgwmIlJLmVi7c/2bAk7hHIK5hHUBveseVxNKHKAOR271YjuUkj8pkHpnNMuIw0irFnaByc9K5Ka5dGexQ90js7TB81sDnitGO0Z1LsrFaggYMwXoo7+tdlpmq6G2iNZ3ri0uN3MhTfuHse1J885WRtUrypK6VzU+HaaWfOXUb4W5QZVWOK0b3V4opJY2KGH+BwfvCvO/EcukeXEuj3Ut1IDlyYyuB7VStnUwBpJJp3/wCefI4+tYVsFBwtONpPr19OxwySqSdRt69GdVrGv2saEKwJx2rzm+1Ga5ncqWwTwtaGoxSODJbWkgUerZrmZbqa3n8wx8qc4IrtwOEhST5NWV7ZU46Fu4aWG2ZmZlfPSqEM0tzN+/mdwPWpr/VVvrYAW3lyA/M27OfwqhbLI0UropwCMkdq9KEGo3loyFXjKSa2NZpR5e1apxXE0JIhOGJ5NXfDtk2qXnkrgKqlmLNjoM1RMipcvHFHkbsA5zUwik3GxFfExlomel/D/TWufKYpuGRmve7DwzpFxHC8lpGZUAOSOa8s+F9sUt4zn5QAa9n05v3auteFQqwlim6sbq54uKXNI4b44PHb+EGtodPSUSELuCcR4718uyWsiXAJjYAH0r7O1+7tpYTaXsKvG4wwNcxF4e8LbZGuYUwefmHFeviszjGahQhdP5ffcdChVtex5FZWAtPCR1C2m+cKdy15gy/a5y85xuOTivcfHGmaNb2skmn3UoiIIMfRfyrxPUJYUdlt1O0eprPLnJ8107vv/md8Yzivf2Of1BVW4dY8lQcA0xHYsNxJOAKmdd5Jx1pI1G5favdTsrDpwbdxFQluatQQgygFc0kS7pBV+2CrcqX6ZGaxnUaPTpUdL2KkSGG6II5Han3kWW3Y61d1ERm8dovuk9abJ80JGc46Viql7SOhU/IzAAjdTj2pHB3AY+9UzLzkAVG56eordSuRKFiOaPYRivQf2fP+SweGxjjzZD/5CeuGdw8QH613f7PoH/C4fDntLJ/6KetKbd0cldfupeh900UUV3HzgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8k/tExO3xQvmyRH5MOT/wAAFeRPBtlIGSuePevYf2iufiTeqDnMMPH/AAAV5jHAA+SOK8GtUcakvVnr0Y81NXL+pazHc6VpVpBbeTPaAh5P72TVVLqaJJFbG1uc0pjTClV5xzVYxs0ny5Oa524z6bGtOjCCsh0MsgidsfcGSauWVyWj5bLHtVQaTcTMSAQPTNWLezlhcb0P1qJ+za3HPEcnwmlbQTynKocVoR6XK6HegJ9a6Xw3FZnSg8zqJx/BVuZgMLGB+VeNVxU4yskSsZKWxgafpHkruZihYYOO4rYjhtIYfKitjJKf4jUsURdl3/Kvqe1aA8Qafo0TJZ2ou7wjAZxwprGMamIl5fgc9Wvrrqzl9Qm+z7t42Y7YriNemiuc+Wiq3r612WsveavIzzIA7Hoq4ArIbw5NIx2Jz716GHlSoSu5C9qnG1jhHTbGTjnPSn6Zqslmlzb7V8mcYOR0PrXY2nhW9eC6lPkpHE2H3kZrhtftBZ3hjV1f/dPFexRrUsS3Tvc11pRU4sg8+VFMayEA9x3rR0tU4OM1gxlxjPQ9K6vwrYyXZ+Vc8+tdGKap023sYJo91+HcTrpkRVeSBXq1qRbWQMhAwMmuS8ARWlpoturxsbnHIIrT8Qajti8rG0nsK+ZjSsvacyuzlinUqWtoZ2sXiy3QwcjNYuuXirZlABg9arSXaiQs5+UVynirWo0t5FjYlzwK82cKleryra57VJKKscv4u1VdjRJJuPpXm925dya6S3gXUL5klcrkEjvk1g3cISV19GIr7DBU40Y8i3Mqj5pcvYpAfLzR5ZB9DUypzViG1aeVVjViT2rslNLVnbRpWV2MtU+cGrYjPUDvXQJ4eEGl/aZQwf0qjb24aRR2yK4frMZ3cXsd9Llkroy5YmOCRUTZRsH0r6E034f2E/hyOdkUzMm7G2vJPE+gG1vJvLy204IPUVhh8whVlytWMKOLp1W4rochJg44waiYZNWJIyknI6djULDnpXppm843QQxmQASPtjXqfT8K9E+Bqwp8Y/DCxIUbfIWyc/8ALJ8ZrzeQfNXonwCuHf4weHFYIMySZYKMn90/U10U3qjzMVFqEvQ+5KKKK7j5sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+Qv2ip1i+KuoDGW8mH/ANFrXm8Mks5xj8q9Z+PemfafilfSgA5ihH/kMVxtporIRXz2LrQjUl3udEcS7ct9jGt7Rjw5PHp3rZsdPGVxGOe9blroDnBC7s1t2Ph+dx8q4xXkVa8pr3R/Wopaso6Zp1rHtkuT8uOanvora4QpbwYA6HFdHp/hC9u8DG2M92rqNP8AAaRqDPKGPtXFGnOctncTxEd07nJ+FfCov7csVKso4x3q43h27jujDDASO7N2r1HSdOisYVjTkAVcmVQc4Arujl044f20nZ3MPatyt0PNrXwK9xta7mKf7IrUi8CaVCpZgWb1NdZcTJAhZ2AHvXGeIfFEYikjiUjHfNck6UUtXc2pwnPY0joWkww5aFOPzrCuLezaQrDAiAHGSKydM8VWImVb0yAZwTjIFWvF2v2rW/lWMasCP9YGrFUYN66W7mqp1L8tjx34sI8GutHbTuIZBuZUPBNebXULDBbOO2a7zXtRUaiTJD5jIfutWD4o1O01IwLaWhgZBhyT1r6fBykoxjy6dzaVNpWZzUKsWwv3e9elfDiJElDzEKucZNc34bsEu7S9baMxLurd0bVISlskKsGQfP7mpx03WjKmltuYat2R9Kw2Rt9OWZW3AJkEelcB4m1OVLlw8hz2GavaV8Rra30qNL+I4C7dy85/CuG8SX1nqV/NNaTjym5UE8/SvBlS5bRd7HRhKTbd1Yz9Y1qYDbExAHfNcrcXbT3KGZ2ZSfmrorbRrjVC2CIolH3j3rl9Qtvsss0edxQ9fWvQwqpq8Y7no25dGTamLWxCyWkuZiM49K5khpWdmO5mOSafI8jNyeDWtoNtbNIXumAAHC+tekv3ELt3Lp01J3SL3hLwnc61JlEIhHVq9IOj6J4Wsd06CW7YfKp5P1NYcHi57DTls9LiEXGGk9a5+6kudQmJyzuepLV5s71/erPTt/mbRw1WpL947R7E/iDWXvk8oYSIHhVPFYTvsX3qw+nTxqC4qu9u+0kitqahFWi9D0qdOMI2jsXofFOu2tukEd/MLcD5VDEcUia7LM5F2u4t1fOTWXIjHAPaoGzuNbuEaitJGfsIXuoo29T02Gez+0QHLe3euUlQq2DXS6JqACPZy/xH5Ce1ZeqQiKZw445x9aMO5Qk6cvkJQcW0zIdflru/2fv+SxeHP+usn/op64qdBwVGFI4rt/2fxj4w+Hf+usn/AKKevTpfEjixkf3Un5M+56KKK9E+SCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPGfiL4al1Lxrc3KxlkZIwD9FFZ9l4Mk80ZQAV6nqqA6q5PoP5UiIoPQV5NTK5VZyk5WTPPlJuTVzkbLwuka7CvT2rYstFhgcFUGfetjOM5qOSX04rGtgMNh481RtlQhd6DBCkfYCobi7gtlzI6j8aivLyGBD5jjp6157ruvJPeGFGBXpnNeNiMbyX9nGyR7GEwDq6y2Okn8WwRXgQbWj7kNyKlvvEkTQl1lVFxwSea8s1uAWux1Y5c5rK1TUGYIgJIA5yetebTxFWeifus9eGXU+ZNI7XWfFMZJLTA49TXE6vr9tLuKyLvJzXM6nO0rg8gfWsG8bgjmu6jg/aW55Hc8Ioq5tX+tqQwQjP1qjZ6zOJkSa42wnqTzgVgux6VJHE2Ae5r0/qtKMeWxlCjzOxp6n9nN7LJFMZ4icBz3rIlsjdXJFrGzseijk1ZkhIUHHTtUumSS2l0s9s2yZTkGnGTpxvF3Zq8Mpe7YteHbC7066mhvY2gWeNgu7jPBrIsZDa3Q3ZAV8Gukl1PUtc1JJb9xI0YwNqgACsTU4fLvJge5zRCpzScZbtK5531WUJWluemXejaSfC41BdbgEpTIiz+leVidVvAQ3yhs5B61qwacbnS9qQjcOd+8/wAqwDCyXAVuxxToKnZxiL2FSkkm7nsvwrZfEepy20hxDEgyfWtP4heAdMsLaW8W58osCFUnqa474aanL4fv5buOESwsoDjPIq94h1O88R6k91cErAvypGTwB9K437GkpWdvmEcvxMsRzP4Tzu608o2Bz9Kfb2bhQShx9K7/AEzQluXDupz2BFbw0COFMMq/lXLVzWMPdPciuV6I8tjtJnGUDH2xWlp6m2cNKMexr0mwhtrQ/PCvH+zWD4mgSZh5SKCeeBWMcf7V8ttDdOUnyuOhmxtBJCxLL09axryAHcUqwLc/cH3s+tWp0REVe9aRfI9GNQ5Xoc29qSDxVK+sxFhlbLHr7V1UkKqCeKyL1AwJ9a7KVZtm0NTndrBwVOCO9Xb8Ca0SXOWHXvUTxjzD6CrmnRpJHPG54xkV2Sla0uwqsbanPSD2rvP2fwP+Fu+H9wY/vJNuD38tq4y8iClsduhrtfgMc/GDw70/1knT/rk9ehRd5JnmY7WjP0Z9wUUUV6h8YFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc/qYzqb/QfyqEuQcLVfxHfx2upyCQ4+Ufyrl7zxTHGzBEzjvXl4zMOS8Ke63OWnQlUm7dzori5WPJkf8KwNY8SxWsbBSC3auJ1vxc8krLGOelcnqGrvOSz/AM6+YrVZSd92fRYPARVro3tY166upced8noKxlOZ9xOec1npdCX7gy3pWpbRAgM3Brz6ra1Z9Lh8I0i3qJN1bxZ5ZKoPZq68gE1fxkbVFM+dJMMvFc8JOKsjtjhlcyG0eA5BTjrxXP69pSRkmFSBXdOBt+vSsbW7ctbnaOa68NiZKauzaFFfCjgk0ppYmlRlwh5BPJq3p1lHLKBO20Y7etPuYTHIFXOTWzYGJikk0aLsGOO/1r1ateXLe5y1qKp6RLCaVb2+kFpoB5j8qzdSK5eeD/SlKRjHoK66/u5L0Iz4CIMKo7CsC/uHs3WWBQXzxmsMPOV33ZzwhLqQaNIbLWS0igxkcoelT3YtrjUGnljGCc7e1UhcXE9wZ5trSN6DGK29H0lrwl3Ocdq1rNQfPJ20sNUEleQ9Gili2xIIwRjC8cVj3ujxeexi3Y68+tdLHYNE+Any+tb1jp6TKokQEVwvFqhrFl/V1FXscXo+k3LY8uRlTvg12+haLH5iGXc+OeehrYtdMRXAUfu/pXQ6fYAEbQQK8rF5jKonYwqVVTja4yDTokUbIgD24p09lxyufrXQ2toAAcc0+eAFSpFeFOrOLu9jyfrj5jg7+yAU4GDWBc2oJORmu91CzySPSuZ1K28twB3r0cNiL9T2cLXU1Y5W40wL+8Xr6VmXtvwSM7hXWvEXG3FVXsBu5FerTxNtzsUUcRP5kZw4IBqjImVODXXavYfIcCuZnhaPINepQqqaui4xsjCurfADZ61UXcso2sR9K2LmMFT61QWA+cjbSUzyRXp053QTWmpl3ec88jrXZfAP/kr3h7n/AJayf+inrm9XhRH+QYHpXTfAMY+L3h7/AK6Sf+i3r0MLLmaZ5GPX7iTXZn3BRRRXsHxIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4f8AFjXBZeLLi3LYCxocfVQa8x1HxIzf6onBrW/aAv8AyPiLfRf9Mov/AEAV5xA73IO0gkdq+axdJupKUtrs9bBULpOxpTapJKXIOKjtp5J2w2Saz0RvMKng1vaPZbpBjmuCu4QVz6zC4ZLdGrp1mysjFTyO9dZY6NPcRh0Hy9/aqWmWu5lXbXrfhFbaOz8pkQOex7140I/Wqqg5W8wzHGvB07wV2cHDoux87ug6Ur2YE24xjjjkV293YRJeSBBx1Bqlc2SOOgz61ssNyNx3t1POjmLnZs4y4sPMD7UAxyDWFqNo6owJDCu4vYHiB2qT9K5XUZQVZCpB71FSmoa2PXwlaU3psee6nbstwoAySeKsXukXFpCkkrrhhuwpzVzWYxgkA56isyOfdFs2Y/GuyE5Simj0qtDnXOiza3EZttrNiX+EetJqP+leXELQRMg5J/iqmLadmXyUY+4FbFrbTth5w24etKfLB8yZxSw2vMVbHR5Nilk967PQdPWGFi6hSemKi02Dcirjk10lvZOU+7x3xXk4vFSl7rMKtoKzZlRWRY7UXPNben6cFUfKQaW2gImAA710drBg7WAJribdRPU4cVinFWRBBpTPENgzWlaWJg5btWjaQhIwBUzR5rN4WUlc+fq4uUm09iBAAMYpZFB7ZqTZgUbeOap03y8rRy82tzKvLcNGc1yer26qxJFd1Mm5CDXJ65CQDWNOj7JXR62X1XzWOWhVWl4zUrxjninWyAStmpWX5jXQ5an0EpamNe2wYEkZrmL+1B3bUBNdndY2H6VzN+21jxXfhajOuj76scdd27oWLLgVkO5SUbSQScHFdPqzgoSO1c0+HmGBzkV9Fhptq7NZR913ItUQ4BZTjHWuj+A4P/C3/D3HHmSf+i3qnf6fJOmIwOFzya0PgahT4weHlPUSyf8Aop69LAVFNpHgY+SdCSXZn2zRRRXvnxQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8i/tF4/4Wjf8Ar5MP/osV55ZkhlKnBr0L9okE/FTUOf8AljD/AOixXnkHY14mL+KR9Xl1nGL8ka9tGZZc12ug2uFG4DNc1oKI0g3Yr0LQ7cFgMcV8rj6j+BH0rlyQudBolmFZWYDkeldbbwIUHQe9ZmnQAqgUc9q6D7N5ar6H+dKhTt0PlsbX5p6siWJ9pwCT9aqNHL5o3AgelbcEkcAHmEc+tNv9jtujAAxXaoe7e+p50a7UrWOZvxtzxzXGazCql3OOTXbavL5Yyo3VxWss0gZcYzWNWKUW2fRZa3ozk7mEyvyAVpYrAFf3cCMfpXU6dpEM0O6TKt6YqxbabHGSck47Vwc02vdPanjYL3V0MOxtjHFjywCParUNiJp0Ujk9a6OK1DwYVQMnir1lpRLjKAN61lKlJ63OCpjlG72K+maTEhAChj610lpp6hSMdqLaxMDr3Ga3IowBwMVDo+/ax83jMbKWzOeg08LM3y96viAhgQtaRg+bNTCIVEMJO5xzxjk7sjhT5RxUxQY6U9EqQrxXsUMG+S7RwyqalR1A6UzaO4qyy9ahccVzVaCjK7RUZNlS5G1CVrl9aGYmPeupmyRiua1tcQNXm1FFJ2PUwEnzo45m2y57VOW3D6VTu22vTraXPy1k46XPqnFtXI7twFb6VzGoqX3YFdNejCkDvWBdpgnnqa68M7anXhnY5m8hLgjHPpWJPb+VOpA5B712EsQ3Ef3qyb+2G4tXtUK1tDWrU0sZ+p3ckkSglUBGDs4rT+CagfGDw9j/AJ6yf+inqgmlXN8jvEMqnJJ6VrfBUg/Fvw/uA3CWQf8AkN69fL3FTUYnzuPcfZTjHoj7Nooor6U+MCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPkH9ovd/wALWv8Abz+5hz/37FeeQfKQDXqnxp0q41j4x6pb2a+ZKsMB2Drjy1rz7U9KlsZCkilXU4ZWGCDXgYuovaOJ9blThKmknqjX8PFC+G5Fd9oM/kv+8fCds15hos4ik5OK7zR7iO5j2hh6V8zj4NSufRfHCzPUNPnUKm0jdjIra/tXKqkse3/azmuE0O4MZ8uQ5x0rpA/mKMdaMNV5kfOYrCxU/eNeYmbnPy9qQt5cO05NZ6Xh27HGCOlWbe4jWVHlIMfeuyMrxOGVKUVsUL5g0XzAgn1rnp9Mnu5v3bbQDXbeI5rOW1ie2aN33YIU9BXP+dhsjg+1Z4uHL7rd15Hfg68uTmirPzIYLRrdVUnPrRLacFg2Ce1XYT5pGOta0NnH5R3x/N2Nea2tgqYp03dlXRbASwjzM8V0MVskajCiqNhOkWI2GMmtbcNvbFaQg2lc8XF1pynrsQsg3DNSpx2qtcHps5PtVqAZA3DBqowvNJHLN+7cnC8ZxRjmpCBt4pAvNep7HSyObmJoFBGT2qR1BU9M1HEQgqQuMcV9FhvZew5ZWuYt6lSRagdatvVd6+cxtKN7G8JWKMg65rA1uB5VOwZFdFIoJ+lNltkkiYNxmvnZUJ1JOMeh6FGuqTUjybUbR0k56VPp2ny3HEKMzEdBXQa3YAFsHpV3wO8CXEsZI83HGT1rTB4b29WNGTtc+jq49xwzqRV7HP6r4fvYLPzmgO1Rk1xV8h3Hivd/Ek6Q6NcF2VcrgZrxK9IZ2PHJr0sxwNPA1FGnK9zXJcbUxMHKa2ZjiPLc1q2vhHUNVsJriCMBEGQWON30qkSAx44rpdK8ZRafo1zZTBhLsPlnsTTwUadSpaq7Kx05lUrqF6Cuzym7vrvSjPAhYLkhl9DVv4Iyl/i94dJHWaTP/fp6x9elaVnf+J2JNX/gc5Hxn8Nx9MSSZH/bJ6+jy6CumeVmU1GjLTVn2/RRRXvHyQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8rfEvxGvh79onUJZpkhge3gDuy5/5ZLiotZRvE1tPex4kmQ5faOoriv2pm2fGfUiOogtyP+/a0fCjxwdGukW6XzbSQ7ZVb+deJmWG/5ex+Z6GAqOjJzgveM518i6ZSMHNdL4buSlwBnCnrWh8VtJsrS7tdS0hQLS8XcMdAa5vRpSZBzzXkYqmpU9HdH2eCxca8OaPU9W0ybDKc5zXV2k6ggGvO9LuSqLk8V1FrcMEBzubtmvCw65ZtMnFUefVHUTGNl461XYfJis6C7LJucbW9KmjuWlkEYAya9FS7Hm+xlAf5ewgp+NTwWrSEsRxXRaHoyyJunwQecVuDS7ZFISMCuunl9avD2kVoefWzOEHyrVnHWMbJPtIGO1dTDGCvI7U3+z4UfcqjNWkTA6V50sO+fVHn4nEqq04lV7ZCc7Bn1pzpxjHFTt2ppwTgio5OV6HPzN7leOLDDjirSpxQq81IBW+Ho63ZnOVxQOKcBSHpSg8V6MXbczsKPag+1ApCa39o1Emw1jULgkVLmh1O2uSpF1CloU2WoLh2CkZ/Grbjiqs4+WvErqUL2OmFm9TndUBdSOtc3eIYQXRmRx0ZTgiurvlIBJXiuZ1ABgQa85z5NVufR4KeiXQ5nUb++uWUXlzJLGg+VWPFZoYuSWq/qIGTjFUEHbiuxTdT3pbn0MXGMNFYjmXapI5rC1L7ucdK1rucAFRWDqkuIzzXZhou6OSpN3MK7lAMhkAK7e9P+AMpl+Nnh9zjJlk6f9cnrmdfvmi3Ip5bNb37O5/4vN4c/wCukn/op6+zy6jyR5n1Pms2rKUuRPY+9KKKK9Q8MKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+GP2rCT8ZdSGOkEH/opa8v069a2kHBKHqK+yPil8BE8e+MbnXm8RNYGZI08gWXmY2qFzu8wdcelcmP2VIx08YN/4Lf/ALbUTipKzLhNwd0eO23ieW60UaZeFnhB3RN/d9qLC98mUE5BFe3Wn7MKQcHxa7gf9Q7H/tWrf/DN0e4EeKX/APAD/wC2V5c8uSuoLRntYTMYUtW7HmGm69tKl8Fa7DTNbiuFGG2kdQa6eL9ncJj/AIqdj/24f/bK0bf4FCEAf8JExx/05Y/9qV5NfJKktYR19Ue3HOcE42lL8H/kc4t6JMBD1rsfCdkHInlXIP3c1btPhL9nCg62Xx62uP8A2euv07wwtlarCLosR/F5eP61hRyjFqXvx/Ff5nn4/M8POnyUZXv5Mls9qjA4q0XUDk1DHoskSMI7zBJzkx5x+tOTSZ8/Pehh6eVj+tfQ0Pb0KXs1Tu15r/M+ZlBN35vzGMys3HfvUohGOtO/so5/1/8A45/9erKWhUcyZ/4DU4fDSnJvEQ39P8yJK2xnTxbRntVfgHNbMlnvXHmY/CoDpef+W3/jv/164MdlU3UvQjdfIqL7mcpyalH0q7HpgU583P8AwH/69TCzAGN/6UYbKav/AC8dhSfYziDtyaQGtM2nGN/6VF/Z3ORL/wCO/wD163rZbNW9nqJXKgRjyBURJBOa1Vs8DG/9Kik0/ec+Zj/gNVXy18idPV9hK5nIcsKkuHyMZ6VdTTgp5kz/AMBpr6ZubImx/wAB/wDr1ksFiIUXGK1fmO2plgbge1RSoM4rXXSsf8t//Hf/AK9NbSNzZ8//AMc/+vXDPKa8o/Br6r/MtOxgX0KtbNkDpXnmrTrGXGRivW7vQnnhaMXezIxny8/1rmLv4ai53Z1Yrn/p3z/7NXnYrIsXUkvZ09PVf5nsZZiqNG/tpfgzyC6lDMxPSqLS4BAr1x/hEH/5jZ/8Bf8A7Oq7/BpWz/xPSP8At0/+zq4ZHjFo4fiv8z3J5xg2rKf4P/I8ZuJRuO6uZ8S3yW8BYn8PWvoOX4IK+f8AioGB/wCvP/7OsLWP2cf7SAB8VtGoOcf2fn/2pXp4TKa0Zp1FZeqOGvmlHlbhK76aM+Ub64e5mLuDz0HpXd/s6qf+FzeHDg8Syc/9snr10/srxn/mb3/8F3/22uh+Hn7PaeDvGOm68PErXhs2ZvINj5e/KlfveYcdfSvpox5VZHzk6nO229T3eiiirMgooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoclip hemostasis of a bleeding duodenal ulcer after epinephrine injection. This patient began to bleed while an inpatient and required six units of packed RBC transfusion for resuscitation. After the combination hemostasis (epinephrine and hemoclips) he was treated with 72 hours with high dose proton pump inhibitor (PPI) (pantoprazole 80 mg IV bolus and 8 mg/hr IV drip, followed by twice daily oral PPI. He did not rebleed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M. Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30612=[""].join("\n");
var outline_f29_57_30612=null;
var title_f29_57_30613="Pediculosis ciliaris";
var content_f29_57_30613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculosis ciliaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 36-year-old woman developed itching in the pubic area and eye lids. Nits are visible on the eyelashes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Samuel Freire da Silva, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30613=[""].join("\n");
var outline_f29_57_30613=null;
var title_f29_57_30614="Hypersensitivity vasculitis in adults";
var content_f29_57_30614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypersensitivity vasculitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30614/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30614/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30614/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30614/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30614/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/57/30614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nomenclature of hypersensitivity vasculitis is diverse and often confusing. Names often used interchangeably but inappropriately have included drug-induced vasculitis, leukocytoclastic vasculitis, cutaneous vasculitis, serum sickness, serum sickness-like reactions, and allergic vasculitis.",
"   </p>",
"   <p>",
"    Serum sickness and serum sickness-like reactions may, but in many cases do not, have a vasculitic component. Classically, it is the result of exposure to foreign proteins, but it is sometimes the result of reactions to infectious diseases and drugs. Serum sickness and serum sickness-like reactions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term &ldquo;hypersensitivity vasculitis&rdquo; has also been used to include Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and mixed cryoglobulinemia, which are discussed separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given this diversity and the varying definitions of this syndrome, the American College of Rheumatology in 1990 proposed the following five criteria for the classification of hypersensitivity vasculitis in a patient with vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;16 years",
"     </li>",
"     <li>",
"      Use of a possible offending drug in temporal relation to the symptoms",
"     </li>",
"     <li>",
"      Palpable purpura",
"     </li>",
"     <li>",
"      Maculopapular rash",
"     </li>",
"     <li>",
"      Biopsy of a skin lesion showing neutrophils around an arteriole or venule",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of three or more of these criteria had a sensitivity and specificity for the diagnosis of hypersensitivity vasculitis of 71 and 84 percent, respectively. These criteria do not distinguish hypersensitivity vasculitis from Henoch-Sch&ouml;nlein purpura (IgA vasculitis); the latter is characterized by the deposition of immunoglobulin A (IgA) in the skin lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cutaneous vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative classification has been proposed which takes into account the presence or absence of internal organ involvement and which does not include the term hypersensitivity vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/4\">",
"     4",
"    </a>",
"    ]. According to this nomenclature, patients with isolated skin purpura are considered to have cutaneous leukocytoclastic vasculitis, while those who also have systemic disease that is associated with few or no immune deposits in the vessels are considered to have microscopic polyarteritis or microscopic polyangiitis. The pauci-immune nature of these lesions distinguishes microscopic polyarteritis from Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and from mixed cryoglobulinemia (ie, type II or type II cryoglobulinemia), in which immunoglobulins are deposited in vascular walls. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drug-induced hypersensitivity vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypersensitivity vasculitis may be idiopathic, may be directly caused by a drug, or may occur in association with a known disorder, such as infection (eg, cryoglobulinemia with hepatitis C infection). (See below.) Although drugs are the most common cause, drug-induced vasculitis is a poorly defined disorder since proving causality is frequently difficult. There are virtually no reliable findings that prove vasculitis results directly from a particular exposure.",
"   </p>",
"   <p>",
"    We favor a classification of all suspected cases of drug-induced vasculitis by the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The precipitating agent",
"     </li>",
"     <li>",
"      The involved organs (eg, isolated to the skin, gastrointestinal tract)",
"     </li>",
"     <li>",
"      The pathologic description",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A related issue is drug-induced antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of skin vasculitis with palpable petechiae or purpura is typically a major finding in hypersensitivity vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"     picture 1",
"    </a>",
"    ). Biopsy of these lesions reveals inflammation of the small blood vessels, called a leukocytoclastic vasculitis, that is most prominent in the postcapillary venules (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"mobipreview.htm?7/58/8106\">",
"     picture 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H16171991#H16171991\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two predominant histologic patterns have been described, both of which may be necrotizing or non-necrotizing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mononuclear cell predominant",
"     </li>",
"     <li>",
"      Polymorphonuclear cell predominant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of cutaneous pathology and immunopathology is highly sensitive to the timing of the biopsy and to the age of the lesion. Lesions that are less than 24 hours old are more likely to reveal leukocytoclastic changes and are polymorphonuclear predominant, while older lesions show enhanced numbers of mononuclear cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/6\">",
"     6",
"    </a>",
"    ]. Little correlation exists between the clinical manifestations and the specific histologic pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity vasculitis is thought to represent an immune complex process. Evidence for circulating immune complex formation includes the detection of soluble complexes, hypocomplementemia in many patients (but not Henoch-Sch&ouml;nlein purpura [IgA vasculitis]), and the deposition of immune reactants in vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Immune complexes are detected more frequently in early, rather than late, lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity vasculitis was, in the past, induced primarily by the administration of heterologous antisera (hence the name serum sickness). This disorder is typically caused by drugs that probably act as haptens to stimulate an immune response. Many medications can cause hypersensitivity vasculitis, but the penicillins, cephalosporins, sulfonamides (including most loop and thiazide-type diuretics),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    have been most often implicated (",
"    <a class=\"graphic graphic_table graphicRef81148 \" href=\"mobipreview.htm?2/22/2414\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/1,7,10,11\">",
"     1,7,10,11",
"    </a>",
"    ]. Certain infections, such as hepatitis due to hepatitis B or C virus, chronic bacteremias (eg, endocarditis, infected shunts), and human immunodeficiency virus (HIV), may also be associated with this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical findings, in addition to the skin lesions, palpable purpura,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    petechiae (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62546 \" href=\"mobipreview.htm?29/6/29794\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60323 \" href=\"mobipreview.htm?36/50/37677\">",
"     picture 4",
"    </a>",
"    ), include fever, urticaria, arthralgias, lymphadenopathy, low serum complement levels, and an elevated erythrocyte sedimentation rate. In most patients, these symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    findings begin 7 to 10 days after antigen exposure, the time required to produce a sufficient quantity of antibody to produce antigen-antibody complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. However, the latent period may be as short as two to seven days with a secondary antigen exposure or may be longer than two weeks with a long-acting drug such as benzathine penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the disorder is usually acute and abates once the antigen has been cleared, chronic disease has been observed in some patients with chronic hepatitis B or C virus infection and occasionally among those with idiopathic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visceral target organ involvement is rarely observed but may be severe. It is difficult to ascertain the frequency of noncutaneous organ involvement. Reasons include the frequent absence of detailed examination for internal organ involvement and a bias for reporting isolated cases with serious end organ damage. Glomerulonephritis, interstitial nephritis, and varying degrees of hepatocellular injury have all been described; involvement of the lung, heart, and central nervous system has rarely been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal involvement that is usually mild may be seen in some patients, being manifested by hematuria, proteinuria, and cellular casts. Acute renal failure is rare but can occur with heavy or prolonged antigen exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/18\">",
"     18",
"    </a>",
"    ]. Renal biopsy, if performed, generally reveals a proliferative glomerulonephritis with immunoglobulin (primarily IgG) and complement deposition along the glomerular capillary wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SERUM SICKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sickness and serum sickness-like reaction are terms that are often used inconsistently. Historically, they have been applied to a clinical pathologic syndrome occurring 8 to 12 days after exposure to a therapeutic administration of foreign proteins. Consensus opinion would apply the diagnostic term &ldquo;serum sickness&rdquo; to the development of a rash (generally urticarial, morbilliform, or even angioedema), arthralgia, arthritis, and fever occurring 5 to 14 days after foreign protein, protein-based therapeutic biologic, or other drug exposure. Serum sickness and serum sickness-like reactions are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypersensitivity vasculitis is usually suggested by the clinical findings and by the history of an offending drug or infection. Skin biopsy, as noted above, shows a leukocytoclastic vasculitis which, if associated with IgA deposition, is considered to represent Henoch-Sch&ouml;nlein purpura (IgA vasculitis). There are also clinical criteria that can be used to distinguish between the two disorders. One report, for example, suggested that hypersensitivity vasculitis rather than Henoch-Sch&ouml;nlein purpura (IgA vasculitis) is present with 74 percent accuracy if no more than two of the following criteria are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpable purpura",
"     </li>",
"     <li>",
"      Bowel angina",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Age at onset &le;20 years",
"     </li>",
"     <li>",
"      No recent use of medications with potential to cause vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Affected patients should be tested for serum complement levels, erythrocyte sedimentation rate, and cryoglobulins; the presence of this last finding often means the patient has mixed cryoglobulinemia which is usually due to chronic hepatitis C virus infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity vasculitis may be difficult to distinguish from other forms of vasculitis, particularly when confined to the skin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpable purpura may, at times, be the presentation of paraneoplastic or malignancy-associated forms of vasculitis frequently due to a lymphoproliferative disease. These tend to be chronic and to be associated with signs or symptoms of cancer, but they may be clinically occult.",
"     </li>",
"     <li>",
"      Systemic vasculitides such as granulomatosis with polyangiitis (Wegener&rsquo;s), polyarteritis nodosa (including that due to hepatitis B), and microscopic polyarteritis may occasionally present with predominantly cutaneous involvement, such as palpable purpura. The presence of systemic signs and symptoms, evidence of internal visceral target organ involvement, and ANCA positivity in combination with the lack of evidence of immune deposits may be helpful in identifying these syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/4,11\">",
"       4,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of the inciting drug or antigen should lead to resolution of the signs and diagnosis within a period of days to a few weeks. In one report of 95 patients, for example, 54 required no therapy, 26 required only a nonsteroidal antiinflammatory drug, and 14 were given glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/11\">",
"     11",
"    </a>",
"    ]. At a mean follow-up of 16 months, 93 had completely recovered while two had slight renal dysfunction.",
"   </p>",
"   <p>",
"    The recognition of hypersensitivity vasculitis due to an ongoing infection is extremely important since the administration of antiinflammatory medications may be harmful. Treatment should be aimed at the underlying infection, such as the administration of interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    to those with hepatitis C virus and cryoglobulinemia.",
"   </p>",
"   <p>",
"    In patients with more severe or persistent cutaneous disease not due to infection, drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , antihistamines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/12,20,21\">",
"     12,20,21",
"    </a>",
"    ]. Occasionally, combinations of these drugs (eg, dapsone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    ) are more effective than single therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with complicated or systemic disease in whom more toxic therapies are required should be referred to a rheumatologist for consultation. Immunosuppressive therapy with glucocorticoids or cytotoxic agents should be reserved for the infrequent patient with fulminant or progressive disease, some of whom may have microscopic polyarteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report described the successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    of two patients with severe, progressive, cutaneous, small-vessel vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30614/abstract/22\">",
"     22",
"    </a>",
"    ]. Further investigation of this treatment in well-defined patient groups is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86082342\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hypersensitivity vasculitis commonly exhibit at least three of the following: age &gt;16 years, use of a possible offending drug in temporal relation to the symptoms, palpable purpura, maculopapular rash, and biopsy of a skin lesion showing neutrophils around an arteriole or venule. We classify suspected cases of drug-induced vasculitis by the following characteristics: the precipitating agent, the involved organs (eg, isolated to the skin, gastrointestinal tract), and the pathologic description. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Cutaneous vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Drug-induced hypersensitivity vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of skin vasculitis with palpable petechiae or purpura is typically a major finding in hypersensitivity vasculitis. Biopsy of these lesions reveals inflammation of the small blood vessels (a leukocytoclastic vasculitis), which is most prominent in the postcapillary venules, which may exhibit a necrotizing or non-necrotizing histologic pattern, and which can be either mononuclear or polymorphonuclear cell predominant. The pattern of cutaneous pathology and immunopathology is highly sensitive to the timing of the biopsy and to the age of the lesion. Hypersensitivity vasculitis is thought to represent an immune complex process. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypersensitivity vasculitis may be idiopathic, may be directly caused by a drug that probably acts as a hapten to stimulate an immune response, or may occur in association with a known disorder, such as infection. The penicillins, cephalosporins, sulfonamides (including many diuretics),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      have been most often implicated (",
"      <a class=\"graphic graphic_table graphicRef81148 \" href=\"mobipreview.htm?2/22/2414\">",
"       table 1",
"      </a>",
"      ). Infections associated with hypersensitivity vasculitis include certain viral infections, such as hepatitis B, hepatitis C, and HIV, as well as chronic bacteremias. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical findings, in addition to palpable purpura or petechiae, include fever, urticaria, arthralgias, lymphadenopathy, low serum complement levels, and an elevated erythrocyte sedimentation rate. In most patients, these symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      findings begin 7 to 10 days after antigen exposure. The disorder is usually acute and abates once the antigen has been cleared, but chronic disease can occur. Visceral target organ involvement is rare but may be severe; it can affect the kidney, liver, lung, heart, and central nervous system. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hypersensitivity vasculitis is usually suggested by the clinical findings and by the history of an offending drug or infection. Skin biopsy, as noted above, shows a leukocytoclastic vasculitis which, if associated with IgA deposition, is considered to represent Henoch-Sch&ouml;nlein purpura (IgA vasculitis). There are also clinical criteria that can be used to distinguish between the two disorders. Affected patients should be tested for serum complement levels, erythrocyte sedimentation rate, and cryoglobulins. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypersensitivity vasculitis may be difficult to distinguish from other forms of vasculitis, particularly when confined to the skin. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation of the inciting drug or antigen should lead to resolution of the signs and diagnosis within a period of days to a few weeks. Treatment should be aimed at any underlying infection, if present. In patients with more severe or persistent cutaneous disease not due to infection, drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , antihistamines, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      may be helpful. Immunosuppressive therapy with glucocorticoids or cytotoxic agents should be reserved for the infrequent patient with fulminant or progressive disease, some of whom may have microscopic polyarteritis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/1\">",
"      Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol 1996; 8:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/2\">",
"      Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/3\">",
"      Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/4\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/5\">",
"      Soter NA, Mihm MC Jr, Gigli I, et al. Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol 1976; 66:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/6\">",
"      Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis. Serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol 1990; 126:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/7\">",
"      Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr. Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 1979; 10:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/8\">",
"      Tosca N, Stratigos JD. Possible pathogenetic mechanisms in allergic cutaneous vasculitis. Int J Dermatol 1988; 27:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/9\">",
"      van Rossum AP, Pas HH, Fazzini F, et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006; 54:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/10\">",
"      Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/11\">",
"      Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/12\">",
"      Sais G, Vidaller A, Jucgl&agrave; A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995; 131:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/13\">",
"      Blanco R, Mart&iacute;nez-Taboada VM, Rodr&iacute;guez-Valverde V, Garc&iacute;a-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 1998; 77:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/14\">",
"      Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 1986; 81:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/15\">",
"      Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/16\">",
"      Dubost JJ, Souteyrand P, Sauvezie B. Drug-induced vasculitides. Baillieres Clin Rheumatol 1991; 5:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/17\">",
"      Jain KK. Drug-induced cutaneous vasculitis. Adverse Drug React Toxicol Rev 1993; 12:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/18\">",
"      de La Pava, Nigogosyan G, Pickren JW. Fatal glomerulonephritis after receiving horse anti-human-cancer serum. Report of three cases. Arch Intern Med 1962; 109:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/19\">",
"      Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Sch&ouml;nlein purpura: a comparison between the 2 disorders. J Rheumatol 1992; 19:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/20\">",
"      Winkelmann RK, Wilson-Jones E, Smith NP, et al. Neutrophilic urticaria. Acta Derm Venereol 1988; 68:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/21\">",
"      N&uuml;rnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol 1995; 75:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30614/abstract/22\">",
"      Chung L, Funke AA, Chakravarty EF, et al. Successful use of rituximab for cutaneous vasculitis. Arch Dermatol 2006; 142:1407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8241 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30614=[""].join("\n");
var outline_f29_57_30614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86082342\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cutaneous vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drug-induced hypersensitivity vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SERUM SICKNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86082342\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8241|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/36/9794\" title=\"picture 1\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/20/43333\" title=\"picture 2A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/37/23126\" title=\"picture 2B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/6/29794\" title=\"picture 3\">",
"      Petechiae in Henoch Schonlein purpura IgA vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/50/37677\" title=\"picture 4\">",
"      Drug induced skin vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/22/2414\" title=\"table 1\">",
"      Drugs cutaneous vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_57_30615="Talc pleurodesis";
var content_f29_57_30615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Talc pleurodesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30615/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30615/contributors\">",
"     Marc Noppen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30615/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30615/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/57/30615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleurodesis is a procedure performed to obliterate the pleural space to prevent recurrent pleural effusion or pneumothorax or to a treat persistent pneumothorax. Pleurodesis is commonly accomplished by draining the pleural fluid, when present, followed by either a mechanical procedure (ie, abrasion, or (partial) pleurectomy) or instillation of a chemical irritant into the pleural space, which causes inflammation and fibrosis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     Talc pleurodesis",
"    </a>",
"    is a specific form of chemical pleurodesis.",
"   </p>",
"   <p>",
"    This topic will review the indications, contraindications, patient selection, procedure, and outcomes of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    . Discussions of the management of malignant and refractory nonmalignant pleural effusions and an overview of chemical pleurodesis are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHAT IS TALC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talc is predominantly hydrated magnesium silicate (Mg3Si4O10(OH)2), and was first used for pleurodesis in 1935 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/1\">",
"     1",
"    </a>",
"    ]. Varying amounts of calcium, aluminum, and iron may be present, according to the origin of the formulation. Talc may also contain several mineral contaminants (eg, magnesite, dolomite, kaolinite, calcite, chlorite, serpentine, and quartz); medicinal talc is asbestos free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Particle size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talc preparations with a high proportion of particles &lt;5 micron in diameter are associated with more severe local and systemic inflammatory responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, formal standards for talc production for pleurodesis are lacking, and there is a wide variation in composition and particle size in the various talc preparations used worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the USA, talc approved by the Food and Drug Administration is provided in two forms: sterile talc powder and as a talc aerosol canister with two delivery tubes (4 gm of talc per tube) that use dichlorofluoromethane (CFC-12) as a propellant. The particle size distribution for the FDA approved talc has not been disclosed by the manufacturer. (See",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       \"Talc (sterile): Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In Europe, commercial talc for pleurodesis is manufactured by Novatech (La Ciotat, France), and comes in four forms: Steritalc&reg; F2 (2 grams of sterile talc powder in a glass vial), Steritalc&reg; F4 (4 grams of sterile talc powder in a glass vial), Steritalc&reg; Spray (3 grams in a spray canister with propellant gas), and Steritalc&reg; PF4 spray (4 grams in a",
"      <span class=\"nowrap\">",
"       hand/air-driven",
"      </span>",
"      pump). The French Novatech talc (not approved for use in the USA) is size-calibrated with a median particle diameter of 31.3 microns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talc instillation (by insufflation or slurry) causes an intense intrapleural inflammatory response characterized by the production of cytokines, adhesion molecules, and other mediators of inflammation, such as interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-beta) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/5\">",
"     5",
"    </a>",
"    ]. Among other effects, IL-8 causes neutrophil chemotaxis involved in the acute inflammatory response; VEGF causes increased capillary permeability and angio- and lymphogenesis; and TGF-beta contributes profibrotic and immunomodulatory properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDICATIONS AND EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     Talc pleurodesis",
"    </a>",
"    is used to manage recurrent malignant pleural effusions, refractory non-malignant pleural effusions, and recurrent and persistent primary and secondary spontaneous pneumothoraces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recurrent malignant effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis by catheter or thoracoscopy, rather than repeat therapeutic thoracentesis, is recommended for most patients whose malignant pleural effusion reaccumulates sufficiently rapidly to make multiple repeat thoracenteses burdensome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Refractory non-malignant effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     Talc pleurodesis",
"    </a>",
"    is sometimes used to treat refractory non-malignant effusions, including those caused by chronic ambulatory peritoneal dialysis, yellow nail syndrome, chylothorax, nephrotic syndrome, lupus, hepatic hydrothorax, and heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A controversial aspect of using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    for the treatment of refractory non-malignant pleural effusions is concern about exposure of patients with non-malignant disease to rare, but potentially severe adverse effects associated with talc pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Complications and safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recurrent and persistent spontaneous pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary spontaneous pneumothorax and secondary spontaneous pneumothorax both occur in the absence of a precipitating event. However, the former occurs in the absence of lung disease, while the latter occurs in the presence of lung disease. Pleurodesis is indicated for prevention after a recurrent primary spontaneous pneumothorax or a first secondary spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. The choice of chemical or mechanical pleurodesis in these settings is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful pleurodesis requires physical contact between the visceral and parietal pleura. In cases of incomplete expansion of the lung (eg, lung entrapment or insufficient drainage), pleurodesis with talc (or any other agent) will fail. In patients with severe underlying lung disease, the use of non-size calibrated talc should be weighed against the small risk of deterioration in pulmonary function should severe post talc inflammation occur. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Complications and safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION AND OUTCOME PREDICTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patient and pleural fluid characteristics are associated with greater and lesser degrees of success with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    . These features are discussed separately. None of these findings, however, has sufficient predictive power to exclude patients from a talc pleurodesis attempt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success of chemical pleurodesis is largely dependent on achieving apposition of the visceral and parietal pleural surfaces. To achieve proper apposition, the pleural space needs to be emptied of air or pleural fluid either by chest tube drainage prior to the procedure or at the time of thoracoscopy. Pleural drainage by tube thoracostomy in preparation for pleurodesis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Concomitant medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoid therapy may decrease the success of pleurodesis due to its potent antiinflammatory effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This is supported by experimental studies in animals that found that talc-induced pleural adhesions were markedly reduced by concomitant administration of systemic glucocorticoids. Data regarding the use of nonsteroidal antiinflammatory agents are conflicting; in animal models,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    was shown to decrease the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/16\">",
"     16",
"    </a>",
"    ], whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/17\">",
"     17",
"    </a>",
"    ]. Whenever possible, glucocorticoids and NSAIDs should be discontinued several days prior to pleurodesis.",
"   </p>",
"   <p>",
"    Systemic anticoagulation is generally reversed for video-assisted thoracoscopy and for placement of a chest tube. It is not necessary to hold anticoagulation for instillation of talc slurry once the chest tube is in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TALC INSUFFLATION OR TALC SLURRY?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between talc insufflation (thoracoscopic) or talc slurry (via chest tube) usually depends more on the medical circumstances requiring pleurodesis than the relative efficacy of the two procedures. When pleural malignancy is identified during a diagnostic thoracoscopy, it is reasonable to proceed with talc insufflation during the procedure. In patients with a low Karnofsky index (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ), talc slurry is often preferred because it is less invasive.",
"   </p>",
"   <p>",
"    Talc insufflation is at least equally effective, and in some studies, including a randomized trial, significantly more effective than talc slurry; slurry has never been shown to be superior to insufflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]. In a randomized trial that assigned 482 patients with malignant pleural effusions to receive talc insufflation or slurry, there was a trend toward greater success at 30 days among the patients who received talc insufflation (78 versus 71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/22\">",
"     22",
"    </a>",
"    ]. In the subgroup of patients with primary lung or breast cancer, talc insufflation was significantly more successful at 30 days (82 versus 67 percent). Respiratory failure developed in 19 patients (8 percent) who received talc insufflation and 10 patients (4 percent) who received talc slurry. Both groups had a mortality of approximately 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trials comparing talc slurry versus insufflation in refractory nonmalignant effusion and spontaneous pneumothorax have not been reported; however, it seems likely that results would be similar.",
"   </p>",
"   <p>",
"    Patient and clinician preferences also have a role in deciding between insufflation and slurry. The principal issues include duration of procedure, degree of invasiveness, and discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PLEURODESIS PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talc is delivered to the pleural space for pleurodesis via one of two procedures: thoracoscopy for talc insufflation and closed tube thoracostomy for talc slurry. The choice between these procedures is discussed above. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Talc insufflation or talc slurry?'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Talc insufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talc insufflation (also called thoracoscopic talc poudrage) is only performed during a thoracoscopic procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sedation and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate sedation and analgesia must be assured. One of three types of sedation may be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local analgesia, conscious sedation, and spontaneous ventilation",
"     </li>",
"     <li>",
"      Total intravenous anaesthesia with spontaneous breathing",
"     </li>",
"     <li>",
"      Total intravenous anaesthesia and mechanical ventilation (using a single or double lumen endotracheal tube). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41414?source=see_link&amp;anchor=H8#H8\">",
"       \"An overview of medical thoracoscopy\", section on 'Techniques'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with a spontaneous pneumothorax, talc insufflation is particularly painful; intravenous injection of an opiate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrapleural administration of 25 mL (250 mg) of 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    via spray is necessary to control pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases of pleurodesis for benign or malignant pleural disease, talc insufflation is typically less painful than when performed for pneumothorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Insufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After aspiration of all pleural fluid (there is no risk for reexpansion edema because of pressure equilibrium in the pleural space), and careful lysis of adhesions when indicated (in order to maximize the pleural surfaces that can be reached), 3 to 5 grams of talc are insufflated into the pleural space. For pneumothorax pleurodesis, 3 grams of talc are sufficient.",
"   </p>",
"   <p>",
"    Talc powder can be administered (usually blind) from pressurized canisters via a delivery tube with one end attached to the canister and the other end inserted through a pleural trocar into the pleural space. The aerosol is administered by pressing the button on the canister. The distal end of the delivery tube should be pointed in several different directions while short bursts are administered, in order to distribute the talc powder equally and extensively on the visceral and parietal pleural surfaces. Sudden decompression of the propellant gasses can cause pain in conscious patients because of important temperature drops. Alternatively, talc can be insufflated (usually under direct vision) by hand-driven air pumping of talc powder from a glass or plastic vial.",
"   </p>",
"   <p>",
"    After talc insufflation, a chest tube (16 to 24 Fr) is left in place, and negative pressure is applied (5 to 20 cmH2O). We typically remove the chest tube after 24 hours, although traditional practice has been to remove the chest tube when pleural fluid drainage is less than 150 mL per day. Data from talc slurry pleurodesis suggest that the tube can be removed within 24 hours after talc insufflation, regardless of daily fluid production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Talc slurry'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Talc slurry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of talc slurry via a chest tube is performed after complete drainage of the pleural space (ie, when drainage is less than 150 mL per day",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when complete lung expansion is documented).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Slurry preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talc slurry is a nondissolving suspension of talc powder in saline, and must be prepared. A volume of 50 mL of sodium chloride 0.9 percent should be injected into the talc powder bottle using a 16-gauge needle attached to a 60 mL LuerLock syringe. The bottle should be swirled continuously. The contents of the bottle can then be aspirated back into a 60 mL syringe, or divided (25 mL each) in two 60 mL syringes, and additionally diluted with 25 mL of sodium chloride in each syringe. The slurry should be injected within 12 hours of preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Sedation and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once full expansion of the lung has been documented with a radiograph and the talc slurry prepared, administer an intravenous analgesic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , piritramide) and an",
"    <span class=\"nowrap\">",
"     anxiolytic/amnestic",
"    </span>",
"    (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ). Additionally, some clinicians spray 25 mL (250 mg) of 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    intrapleurally a few minutes before talc slurry administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Slurry instillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syringe(s) containing the talc slurry should be continuously agitated to suspend the talc. After clamping the chest tube, the slurry is injected intrapleurally (usually 5 grams). Talc slurry distributes quite poorly over the pleural surfaces, and tends to collect at the caudal sinuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/19\">",
"     19",
"    </a>",
"    ]. Rotation of the patient, however, with the purpose to spread the slurry more evenly, does not increase the likelihood of successful pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chest tube should stay clamped for one hour; thereafter active suction (5 to 20 cmH2O) is warranted. We typically remove the chest tube after 24 hours, although traditional practice has been to remove the chest tube when pleural fluid drainage is less than 150 mL per day. The rationale was that leaving the chest tube in position maintained apposition of the pleural surfaces and pleurodesis could be repeated if pleural fluid drainage did not decrease. However, there is no empiric evidence that this strategy is superior to removing the tube within 24 hours regardless of the amount of fluid drainage. In a trial that randomly assigned 41 patients with a malignant pleural effusion to have their chest tube removed either 24 hours or 72 hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    , there was no difference in the success rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=see_link&amp;anchor=H15#H15\">",
"     \"Chemical pleurodesis\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse events occurring after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    are fever (10 to 17 percent), pain, and gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Less common side effects include arrhythmia, dyspnea, respiratory failure, systemic inflammatory responses, empyema, and talc dissemination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with malignant pleural effusions,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       talc pleurodesis",
"      </a>",
"      does not increase mortality compared with chest tube drainage alone or chemical pleurodesis with other agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When used to treat nonmalignant effusions, talc slurry is associated with mild complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. As an example, in a study that used talc slurry for nonmalignant effusions in 22 patients; all patients had mild pain, four had a low grade fever, and one patient developed an empyema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complications among patients administered talc insufflation for pneumothorax were also mild. For example, among 41 patients who had talc insufflation for secondary pneumothorax due to COPD, the following symptoms were noted: pain in 13, fever in 5, subcutaneous emphysema in 27, and prolonged air leak in 7 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/34\">",
"       34",
"      </a>",
"      ]. Postoperative chest tube drainage and hospital stay were 4 and 5 days, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to side effects related to talc, other complications may occur related to chest tube placement and thoracoscopy. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H16#H16\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41414?source=see_link&amp;anchor=H11#H11\">",
"     \"An overview of medical thoracoscopy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Insufflation versus slurry",
"    </span>",
"    &nbsp;&mdash;&nbsp;One question is whether patients experience any difference in side effects with talc given by insufflation compared to slurry. A few trials have reported the relative risk of complications with insufflation versus slurry for recurrent malignant effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As an example, a randomized trial of 482 patients reported treatment-related death after insufflation (9 patients) and slurry (7 patients), a difference that was not statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/22\">",
"     22",
"    </a>",
"    ]. As size-calibrated talc was not used in this study, the risk of these severe side effects may be overestimated.",
"   </p>",
"   <p>",
"    In the same study, chest pain (5 to 10 percent), fever (30 to 35 percent), and dyspnea (16 percent) were common, but not significantly different between the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/22\">",
"     22",
"    </a>",
"    ]. A trend towards an increase in deep venous thrombosis, red cell transfusions, and pneumonia was noted in the insufflation group. Other smaller trials have not found differences in duration of chest tube drainage, hospital stay, parenteral narcotic requirements, chest pain, or fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Systemic inflammation and respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic inflammation after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    appears to be linked to the systemic absorption of talc particles. Systemic absorption is increased when talc particles are small, when a large total dose of talc is used, and when an access route that facilitates systemic absorption (eg, pleural abrasion or multiple parietal pleura biopsies) is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Small particle size talc\" (greater than 10 to 50 percent of particles smaller than 5 to 10 microns) has been shown in experimental animal studies to be systemically absorbed, and in a human study to cause a more intense pleural, lung, and systemic inflammation characterized by fever and increased serum C reactive protein levels, without increasing the likelihood of successful pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/2,3,5,35,36\">",
"     2,3,5,35,36",
"    </a>",
"    ]. The extent, degree and type of intrapleural inflammation may also contribute to this \"leaking\" of talc particles into the systemic circulation.",
"   </p>",
"   <p>",
"    Respiratory failure and ARDS are rare when less than 5 grams of a size-calibrated talc preparation are used. As an example, a prospective series found no instances of ARDS among 558 patients who underwent talc insufflation for malignant pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, using less than 5 grams of talc is not completely protective when non-sized calibrated talc is used. Among 138 patients who underwent thoracoscopic talc insufflation using non-size-calibrated sterile talc (Sclerosol, available in the United States), talc-related lung injury developed in four, and the dose of talc was less than 5 grams in two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/38\">",
"     38",
"    </a>",
"    ]. Talc may have contributed to respiratory deterioration in an additional four patients, one of whom received less than 5 grams of talc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Long-term adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term adverse effects related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    appear minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/3,39,40\">",
"     3,39,40",
"    </a>",
"    ]. Specifically, in patients administered talc for pneumothorax, no significant impairment in lung function, development of fibrosis, or increased likelihood of cancer has been documented. In addition, talc pleurodesis does not preclude subsequent ipsilateral lung surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/11,40\">",
"     11,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Measures to improve safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to improve the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30615/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use size-calibrated talc with less than 10 percent small particles (eg, 5 to 10 microns)",
"     </li>",
"     <li>",
"      Use no more than 5 grams of talc",
"     </li>",
"     <li>",
"      Avoid simultaneous bilateral pleurodesis to minimize the total dose of talc",
"     </li>",
"     <li>",
"      Avoid talc administration following extensive pleural abrasion or multiple biopsies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Talc (hydrated magnesium silicate) is an effective choice for chemical pleurodesis. It may be administered by insufflation at the time of thoracoscopy or by slurry through a chest tube. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       Talc pleurodesis",
"      </a>",
"      may be used to manage a recurrent malignant pleural effusion, a refractory non-malignant pleural effusion, and also a recurrent primary spontaneous pneumothorax and secondary spontaneous pneumothorax. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications and efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Talc insufflation and slurry appear to be equally effective for achieving pleurodesis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Talc insufflation or talc slurry?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with malignant effusion who are undergoing thoracoscopy for diagnosis, we suggest talc insufflation at the time of the procedure rather than subsequent talc slurry (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with recurrent malignant pleural effusion who are too ill or prefer not to undergo thoracoscopy, pleural drainage by chest tube followed by talc slurry is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Talc insufflation or talc slurry?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that glucocorticoid and NSAID therapy be reduced or discontinued prior to chemical pleurodesis, whenever possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Patient preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       talc pleurodesis",
"      </a>",
"      , we recommend NOT using more than 5 grams of talc, NOT performing bilateral pleurodesis, and NOT performing pleurodesis after pleural abrasion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). A size-calibrated formulation of talc that contains LESS than 10 percent of small particles (5 to 10 microns) is preferred, when available, as centers using these formulations have rarely observed respiratory failure following talc pleurodesis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications and safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After either talc insufflation or slurry, we suggest leaving the chest tube in place until fluid drainage is less than 150 mL per day rather than removal in the first 24 hours (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/1\">",
"      Bethune, N. Pleural poudrage: new technique for the deliberate production of pleural adhesion as preliminary to lobectomy. J Thorac Surg 1935; 4:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/2\">",
"      Ferrer J, Villarino MA, Tura JM, et al. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001; 119:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/3\">",
"      Noppen M. Who's (still) afraid of talc? Eur Respir J 2007; 29:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/4\">",
"      Rossi VF, Vargas FS, Marchi E, et al. Acute inflammatory response secondary to intrapleural administration of two types of talc. Eur Respir J 2010; 35:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/5\">",
"      Genofre EH, Marchi E, Vargas FS. Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics (Sao Paulo) 2007; 62:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/6\">",
"      Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/7\">",
"      Ghio AJ, Roggli V, Light RW. Talc should not be used for pleurodesis in patients with nonmalignant pleural effusions. Am J Respir Crit Care Med 2001; 164:1741; author reply 1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/8\">",
"      Noppen M, De Keukeleire T. Pneumothorax. Respiration 2008; 76:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/9\">",
"      Tschopp JM, Boutin C, Astoul P, et al. Talcage by medical thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study. Eur Respir J 2002; 20:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/10\">",
"      Noppen M, Meysman M, d'Haese J, et al. Comparison of video-assisted thoracoscopic talcage for recurrent primary versus persistent secondary spontaneous pneumothorax. Eur Respir J 1997; 10:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/11\">",
"      Doddoli C, Barl&eacute;si F, Fraticelli A, et al. Video-assisted thoracoscopic management of recurrent primary spontaneous pneumothorax after prior talc pleurodesis: a feasible, safe and efficient treatment option. Eur J Cardiothorac Surg 2004; 26:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/12\">",
"      Steger V, Mika U, Toomes H, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 2007; 83:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/13\">",
"      Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997; 10:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/14\">",
"      Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/15\">",
"      Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998; 157:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/16\">",
"      Teixeira LR, Vargas FS, Acencio MM, et al. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. Chest 2005; 128:4041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/17\">",
"      Liao H, Guo Y, Jun Na M, et al. The short-term administration of Ketoprofen does not decrease the effect of Pleurodesis induced by talc or Doxycycline in rabbits. Respir Med 2007; 101:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/18\">",
"      Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: talc slurry versus thoracoscopic talc insufflation in a porcine model. Ann Thorac Surg 1996; 62:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/19\">",
"      Colt HG, Russack V, Chiu Y, et al. A comparison of thoracoscopic talc insufflation, slurry, and mechanical abrasion pleurodesis. Chest 1997; 111:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/20\">",
"      Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/21\">",
"      Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg 2006; 30:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/22\">",
"      Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/23\">",
"      Debeljak A, Kecelj P, Triller N, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON 2006; 11:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/24\">",
"      Terra RM, Junqueira JJ, Teixeira LR, et al. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest 2009; 136:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/25\">",
"      Lee P, Colt HG. A spray catheter technique for pleural anesthesia: a novel method for pain control before talc poudrage. Anesth Analg 2007; 104:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/26\">",
"      Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions. Chest 2003; 123:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/27\">",
"      Goodman A, Davies CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. Lung Cancer 2006; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/28\">",
"      Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/29\">",
"      Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; :CD002916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/30\">",
"      Laisaar T, Palmiste V, Vooder T, Umbleja T. Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesis. Interact Cardiovasc Thorac Surg 2006; 5:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/31\">",
"      Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996; 110:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/32\">",
"      Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/33\">",
"      Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/34\">",
"      Lee P, Yap WS, Pek WY, Ng AW. An Audit of medical thoracoscopy and talc poudrage for pneumothorax prevention in advanced COPD. Chest 2004; 125:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/35\">",
"      Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/36\">",
"      Ferrer J, Montes JF, Villarino MA, et al. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002; 122:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/37\">",
"      Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/38\">",
"      Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 2010; 137:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/39\">",
"      Hunt I, Barber B, Southon R, Treasure T. Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax? Interact Cardiovasc Thorac Surg 2007; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30615/abstract/40\">",
"      Gy&ouml;rik S, Erni S, Studler U, et al. Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007; 29:757.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6690 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30615=[""].join("\n");
var outline_f29_57_30615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHAT IS TALC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Particle size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDICATIONS AND EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recurrent malignant effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Refractory non-malignant effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recurrent and persistent spontaneous pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT SELECTION AND OUTCOME PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Concomitant medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TALC INSUFFLATION OR TALC SLURRY?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PLEURODESIS PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Talc insufflation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sedation and analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Insufflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Talc slurry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Slurry preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Sedation and analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Slurry instillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS AND SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Insufflation versus slurry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Systemic inflammation and respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Long-term adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Measures to improve safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=related_link\">",
"      Talc (sterile): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_57_30616="Management of chronic constipation in adults";
var content_f29_57_30616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of chronic constipation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30616/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30616/contributors\">",
"     Arnold Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30616/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30616/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/57/30616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/57/30616/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/57/30616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30890925\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is a common complaint that may be due to a variety of causes. Appropriate management requires an evaluation for secondary etiologies, such as systemic disorders and drugs (",
"    <a class=\"graphic graphic_table graphicRef70425 graphicRef62307 \" href=\"mobipreview.htm?8/7/8317\">",
"     table 1A-B",
"    </a>",
"    ). Once secondary causes have been eliminated, idiopathic constipation may be associated with normal or slow colonic transit, defecatory dysfunction (pelvic floor dysfunction), or both.",
"   </p>",
"   <p>",
"    This topic review will discuss the management of idiopathic chronic constipation. The etiology and evaluation of chronic constipation, as well as the management of constipation related to chronic opiates, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link\">",
"     \"Etiology and evaluation of chronic constipation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188292857\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a patient with chronic constipation will depend on whether studies indicate normal or slowed colonic transit and whether there is a defecatory dysfunction (",
"    <a class=\"graphic graphic_algorithm graphicRef88130 \" href=\"mobipreview.htm?19/57/20382\">",
"     algorithm 1",
"    </a>",
"    ). The specific choice of agents and order of their introduction varies with the etiology of the condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of normal and slow transit chronic constipation includes patient education, behavior modification, dietary changes, and laxative therapy. Severe, intractable, slow transit constipation is rare and may be treated with surgery, but with extreme caution; patients should be referred to specialized centers for a full evaluation prior to surgery. Treatment for normal or slow transit constipation is shown in an algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef88131 \" href=\"mobipreview.htm?9/5/9311\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Management of defecatory dysfunction involves suppositories, biofeedback, botulinum toxin injections into the puborectalis muscle, or relaxation exercises (",
"      <a class=\"graphic graphic_algorithm graphicRef88134 \" href=\"mobipreview.htm?35/26/36270\">",
"       algorithm 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with both slow transit and defecatory dysfunction should be reevaluated after treatment of the defecatory dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890932\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of idiopathic chronic constipation includes patient education, dietary changes, bulk forming laxatives,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of non-bulk forming laxatives or enemas. Efficacy, safety, convenience, costs, and clinical response all weigh into the choice of the initial treatment selected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890939\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education involves efforts to reduce dependency on laxatives and to increase fluid and fiber intake. Patients who are dependent on laxatives should be advised to try to taper their use, as they introduce new measures to improve bowel function. Patients should be advised to try to defecate after meals, thereby taking advantage of normal postprandial increases in colonic motility. This is particularly important in the morning when colonic motor activity is highest. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/10/34977?source=see_link\">",
"     \"Patient information: Constipation in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890946\">",
"    <span class=\"h2\">",
"     Dietary changes and bulk forming laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary fiber and bulk forming laxatives such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    are the most physiologic and effective approach to therapy. Taken together with adequate fluids, this can improve bowel habits in many patients with constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Prunes were also shown to be effective in one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/5\">",
"     5",
"    </a>",
"    ]. The cross-over trial included 40 patients with chronic constipation who were assigned to receive either prunes or psyllium daily for three weeks followed by a one week wash-out period prior to switching to the other treatment. Patients reported more complete spontaneous bowel movements while receiving prunes compared with psyllium (mean 3.5 versus 2.8 per week). In addition, patients reported improved stool consistency with prunes. There were no differences in straining and global constipation symptoms. Both treatments were well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890953\">",
"    <span class=\"h3\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiber supplementation can improve symptoms in patients with normal transit constipation. Fiber is available in a large variety of supplements and natural foods (",
"    <a class=\"graphic graphic_table graphicRef82094 \" href=\"mobipreview.htm?17/1/17438\">",
"     table 2",
"    </a>",
"    ). Because fiber supplements are low cost, are easy to use and safe, they are frequently used first in the management of normal transit constipation. Cereal fibers generally possess cell walls that resist digestion and retain water within their cellular structures. Fiber found in citrus fruits and legumes stimulates the growth of colonic flora, thereby increasing fecal mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/6\">",
"     6",
"    </a>",
"    ]. Wheat bran is one of the more effective fiber laxatives but may aggravate bloating and abdominal pain in irritable bowel syndrome.",
"   </p>",
"   <p>",
"    There is a dose response between fiber intake, water intake, and fecal output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Larger particle size of the fiber source, such as the large particle size of cereal products, enhances fecal bulking effects. In addition to fiber, sugar components (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    and fructose) of foods such as apples, peaches, pears, cherries, raisins, grapes, and nuts are also beneficial.",
"   </p>",
"   <p>",
"    The recommended amount of dietary fiber is 20 to 35",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In addition to consuming foods with high fiber, patients may add raw bran (two to six tablespoons with each meal) followed by a glass of water or another beverage to achieve the fiber intake goal.",
"   </p>",
"   <p>",
"    For some patients (and especially almost all those with slow transit constipation), fiber increases bloating and distention, leading to poor compliance (estimated to be as low as 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients should be warned that consuming large amounts of fiber can cause abdominal bloating or flatulence; this can be modulated by starting with small amounts and slowly increasing fiber intake according to tolerance and efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890960\">",
"    <span class=\"h3\">",
"     Bulk forming laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulk forming laxatives include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    seed (eg, Metamucil),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    (eg, Citrucel), calcium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29651?source=see_link\">",
"     polycarbophil",
"    </a>",
"    (eg, FiberCon), and wheat",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    (eg, Benefiber) (",
"    <a class=\"graphic graphic_table graphicRef59746 \" href=\"mobipreview.htm?29/62/30701\">",
"     table 3",
"    </a>",
"    ). They are natural or synthetic polysaccharides or cellulose derivatives that primarily exert their laxative effect by absorbing water and increasing fecal mass. These laxatives are effective in increasing the frequency and softening the consistency of stool with a minimum of adverse effects. They may be used alone or in combination with an increase in dietary fiber.",
"   </p>",
"   <p>",
"    Despite substantial anecdotal clinical experience indicating benefit for bulk forming laxatives, objective evidence regarding the effectiveness is inconsistent. A systematic review found evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    increases stool frequency in patients with chronic constipation but found insufficient evidence for other forms of fiber including calcium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29651?source=see_link\">",
"     polycarbophil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    , and bran [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"     10",
"    </a>",
"    ]. Another review found evidence supporting the efficacy and safety of calcium polycarbophil, but poor evidence supporting the use of psyllium and methylcellulose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890967\">",
"    <span class=\"h2\">",
"     Other laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who respond poorly to fiber, or who do not tolerate it, may require laxatives other than bulk forming agents (",
"    <a class=\"graphic graphic_table graphicRef59746 \" href=\"mobipreview.htm?29/62/30701\">",
"     table 3",
"    </a>",
"    ). There are few data comparing various non-bulk forming laxative options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"     10",
"    </a>",
"    ].The risk of side effects from these agents is minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. Thus, the choice among them is based upon costs, ease of use, patient preference, and results of response to empiric treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1802253998\">",
"    <span class=\"h3\">",
"     Surfactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to support the use of surfactant agents in chronic constipation. Stool softeners such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    sodium (eg, Colace) are intended to lower the surface tension of stool, thereby allowing water to more easily enter the stool. Although these agents have few side effects, they are less effective than other laxatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"     10",
"    </a>",
"    ]. A systematic review concluded that stool softeners may be inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    for improvement in stool frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6451384\">",
"    <span class=\"h3\">",
"     Osmotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyethylene glycol (PEG), poorly absorbed or nonabsorbable sugars, and saline laxatives cause intestinal water secretion and thereby increase stool frequency. Excessive use of these agents may result in electrolyte and volume overload in patients with renal and cardiac dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PEG &ndash; PEG electrolyte solutions (eg, GoLYTELY) and powdered preparations (eg, MiraLAX) that do not contain electrolytes are available for the treatment of chronic constipation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. A systematic review found evidence that polyethylene glycol is effective in improving stool frequency and consistency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"       10",
"      </a>",
"      ]. A reasonable approach is to start with 17 g of powder dissolved in 8 oz of water once daily and titrate up or down (to a maximum of 34 g daily) to effect. There is no need to use PEG more than once daily. If patients do not respond, one can decrease PEG to 17 g daily and add a stimulant laxative every other to every third day as needed.",
"     </li>",
"     <li>",
"      Synthetic disaccharide &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"       Lactulose",
"      </a>",
"      (eg, Enulose) is a synthetic disaccharide. It is not metabolized by intestinal enzymes; thus, water and electrolytes remain within the intestinal lumen due to the osmotic effect of the undigested sugar. Lactulose requires some time (24 to 48 hours) to achieve its effect.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"       Sorbitol",
"      </a>",
"      is an equally effective and a less expensive alternative. A systematic review found evidence that lactulose is effective in improving stool frequency and consistency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"       10",
"      </a>",
"      ]. Both lactulose and sorbitol may cause abdominal bloating and flatulence. PEG, however, is superior to lactulose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Saline &ndash; Saline laxatives such as milk of magnesia and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      are poorly absorbed agents that act as hyperosmolar solutions. Hypermagnesemia, seen primarily in patients with renal failure, is the major complication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6451393\">",
"    <span class=\"h3\">",
"     Stimulant laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulant laxatives such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    (eg, some forms of Dulcolax),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    (eg, Senokot), and sodium picosulfate (eg, Dulcolax drops) primarily exert their effects via alteration of electrolyte transport by the intestinal mucosa. They also increase intestinal motor activity. A randomized four-week trial of sodium picosulfate (10 mg daily) in 45 patients with chronic constipation demonstrated improved bowel function for those receiving medication compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second randomized trial looked at the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were assigned to receive either bisacodyl (10 mg daily; n = 247) or placebo (n = 121) for four weeks. At baseline, patients in both groups reported having a mean of 1.1 complete spontaneous bowel movements per week. At the end of treatment, patients in the bisacodyl group had significantly more complete spontaneous bowel movements per week compared with the placebo group (5.2 versus 1.9). Bisacodyl was also superior to placebo with regard to quality of life scores. Overall, bisacodyl was well-tolerated, although diarrhea and abdominal pain were more common in the bisacodyl group compared with the placebo group (53 versus 2 percent and 25 versus 3 percent, respectively).",
"   </p>",
"   <p>",
"    Continuous daily ingestion of these agents may be associated with hypokalemia, protein-losing enteropathy, and salt overload. Thus, these drugs should be used with caution if taken chronically.",
"   </p>",
"   <p>",
"    There is no convincing evidence that chronic use of stimulant laxatives causes structural or functional impairment of the colon, nor does it increase the risk for colorectal cancer or other tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890974\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SEVERE CONSTIPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe constipation have generally failed the above measures and require a different approach to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968261206\">",
"    <span class=\"h2\">",
"     Suppositories",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of defecatory dysfunction, we favor an initial trial of suppositories (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    ), since suppositories can be effective in liquifying stool and thereby overcoming obstructive defecation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890981\">",
"    <span class=\"h2\">",
"     Disimpaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a fecal impaction (a solid immobile bulk of stool in the rectum) should initially be disimpacted starting with manual fragmentation if necessary. After this is accomplished, an enema with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    will help to soften the stool and provide lubrication.",
"   </p>",
"   <p>",
"    If disimpaction is unsuccessful or only partially successful, we order a water soluble contrast enema (Gastrografin or Hypaque) administered under fluoroscopy to assure absence of any obstruction and to eliminate more proximal impactions. Occasionally, fractionation of impacted stool beyond the reach of the finger must be accomplished using flexible or rigid sigmoidoscopy with instrumentation. The colon must then be thoroughly evacuated. This can be accomplished with daily warm water enemas for up to three days, or by drinking a balanced electrolyte solution containing polyethylene glycol (PEG) until cleansing is complete. We prefer warm water enemas (three to six ounces) in older adults because of the potential dangers of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    enemas in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This was demonstrated in a retrospective series in which the use of sodium phosphate enemas in older adults (mean age 80 years, all but one of age 70 years or older) was associated with complications including hypotension and volume depletion, hyperphosphatemia, hypo- or hyperkalemia, metabolic acidosis, severe hypocalcemia, renal failure, and EKG changes (prolonged QT interval) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/19\">",
"     19",
"    </a>",
"    ]. We suggest that sodium phosphate enemas be avoided in older adults.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     Sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    , or electrolyte-free PEG-containing solution may be given after bowel cleansing to produce one stool at least every other day. The patient is instructed to use the bathroom after meals to take advantage of meal-stimulated increases in colonic motility.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     Bisacodyl",
"    </a>",
"    or glycerine suppository is administered if there is no defecation after two days to prevent recurrence of fecal impaction. Alternatively, enemas may be administered. These approaches have achieved success rates of up to 78 percent of patients with idiopathic constipation, although relapses are not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/21\">",
"     21",
"    </a>",
"    ]. Treatment failures have been attributed to patient and family noncompliance; underlying disturbances of bowel function may also have a role.",
"   </p>",
"   <p>",
"    A modified program may be used in demented or bedridden patients with fecal impaction. After disimpaction and bowel cleansing with enemas or PEG-containing solutions, a fiber restricted diet together with cleansing enemas once or twice per week will assist nursing management by decreasing the buildup of stool and recurrence of fecal impaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890988\">",
"    <span class=\"h2\">",
"     Behavioral approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Habit training has been used successfully in children with severe constipation. A modified program may also be helpful in adults with neurogenic constipation, dementia, or those with physical impairments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30890995\">",
"    <span class=\"h3\">",
"     Biofeedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback is a behavioral approach that can be used to correct inappropriate contraction of the pelvic floor muscles and external anal sphincter during defecation in patients with defecatory dysfunction such as dyssynergic defecation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various instruments, including anal plugs and anorectal manometers, have been used to monitor external anal sphincter pressures during attempted expulsion of the apparatus. The patient watches the recordings of EMG activity or sphincter pressure responses and is asked to modify inappropriate responses through trial and error.",
"   </p>",
"   <p>",
"    Clinical improvement has been reported in adults who have received EMG biofeedback for defecatory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. Two controlled trials in such patients found that biofeedback was more effective than laxatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Approximately two-thirds of patients with dyssynergic defecation have co-existing slow transit constipation. In this group of patients, biofeedback improves bowel function, dyssynergia, and colonic transit by improving outlet dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/22\">",
"     22",
"    </a>",
"    ]. However, biofeedback does not appear to benefit patients with slow transit constipation without dyssynergic defecation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biofeedback is not widely available, has not been well standardized, and results may vary at different centers. However, where available, it is an attractive alternative for patients with pelvic floor dysfunction and severe constipation as it provides the potential for treatment without laxatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891002\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1747782838\">",
"    <span class=\"h3\">",
"     Linaclotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/17/20755?source=see_link\">",
"     Linaclotide",
"    </a>",
"    is a minimally absorbed peptide agonist of the guanylate cyclase-C receptor that stimulates intestinal fluid secretion and transit. Linaclotide has been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation at a dose of 145 micrograms daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the role of linaclotide in treating chronic constipation and the long-term risks and benefits remain to be determined. In two large phase 3 trials of patients with chronic constipation, the linaclotide treated groups (both 145 microgram and 290 microgram) had significantly higher rates of three or more complete spontaneous bowel movements (CSBM) per week and an increase in one or more CSBMs from baseline during at least 9 out of 12 weeks as compared to placebo (145 micrograms: 21 and 16 percent; 290 micrograms: 19 and 21 percent; versus placebo: 3 and 6 percent). The most common and dose-related adverse event was diarrhea that led to discontinuation of treatment in 4 percent of patients in both linaclotide treated groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891009\">",
"    <span class=\"h3\">",
"     Lubiprostone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"     Lubiprostone",
"    </a>",
"    is a locally acting chloride channel activator that enhances chloride-rich intestinal fluid secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/31\">",
"     31",
"    </a>",
"    ]. Its approval was based upon two placebo-controlled trials that included a total of 479 patients with chronic idiopathic constipation who were randomly assigned to active treatment (either 24 or 48 mcg daily) or placebo for four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/32\">",
"     32",
"    </a>",
"    ]. Significantly more patients receiving active treatment achieved the primary endpoint (an increase in spontaneous bowel movements to at least three per week) during each week of observation. Corresponding improvement was observed for abdominal bloating, discomfort, stool frequency and straining.",
"   </p>",
"   <p>",
"    Three subsequent open-label trials involving a total of 871 patients showed persistent improvement compared with baseline in abdominal bloating, discomfort, and constipation for 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/32\">",
"     32",
"    </a>",
"    ]. The most common side effect was nausea, which occurred in approximately 30 percent of patients (compared with 5 percent in placebo). The incidence of nausea was dose-dependent and was lower with the 24 mcg dose (17 percent). In addition, diarrhea was reported in 13 percent of patients (compared with 1 percent for placebo). The approved dose is 24 mcg taken twice daily with food.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"     lubiprostone",
"    </a>",
"    in the treatment of chronic constipation remains to be determined. There have been no comparisons with other options for treatment of severe constipation and its long-term safety is not yet established. Until further data are available (and because it is expensive compared with other options and induces nausea), it is best reserved for patients with severe constipation in whom other approaches have been unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891016\">",
"    <span class=\"h3\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is a prostaglandin analog which has been used successfully to treat some patients with severe constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Anecdotal experience suggests that misoprostol (200 mcg every other day and increased by 200 mcg every other day at weekly intervals as tolerated to efficacy) can be effective when used with PEG (without electrolytes) in doses ranging from 17 to 34 g daily. Misoprostol should not be used in women who could become pregnant since it induces labor and can lead to loss of the fetus. It can also increase menstrual bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2057146038\">",
"    <span class=\"h3\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    may be effective for the treatment of chronic constipation. A randomized trial found that patients treated with one milligram daily, compared with those treated with placebo, had improved scores for symptoms of constipation at the end of the two-month trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/35\">",
"     35",
"    </a>",
"    ]. Others have reported effectiveness for doses of 0.6 mg three times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/34\">",
"     34",
"    </a>",
"    ]. Colchicine should not be used in patients with renal insufficiency. The drug can induce a myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14393093\">",
"    <span class=\"h3\">",
"     Prucalopride",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available in Europe and Canada, but not in the United States, this 5HT4 prokinetic agent in a dose of 1 to 4 mg once daily has been shown to be superior to placebo in 4 to 12-week trials, and safe and well tolerated in patients age 65 or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Patients from three of the trials were followed in open-label studies for up to 24 months. The improvement in quality of life scores seen at the end of the 12-week trials was maintained for up to 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891030\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pelvic floor dysfunction have been treated successfully with injection of botulinum toxin into the puborectalis muscle but experience is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/39\">",
"     39",
"    </a>",
"    ]. An open label trial reported that injections of 60 to 100 units of type A botulinum toxin into both sides of the puborectalis muscle under ultrasound guidance was effective in treating patients with defecatory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/39\">",
"     39",
"    </a>",
"    ]. Repeat injections may be necessary to maintain benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891037\">",
"    <span class=\"h2\">",
"     Colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtotal colectomy with ileorectal anastomosis can dramatically ameliorate incapacitating constipation in carefully selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. At least five criteria should be met prior to consideration of surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has chronic, severe, and disabling symptoms from constipation that are unresponsive to medical therapy.",
"     </li>",
"     <li>",
"      The patient has slow colonic transit of the inertia pattern. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link\">",
"       \"Etiology and evaluation of chronic constipation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient does",
"      <strong>",
"       not",
"      </strong>",
"      have intestinal pseudoobstruction, as demonstrated by radiologic or manometric studies.",
"     </li>",
"     <li>",
"      The patient does",
"      <strong>",
"       not",
"      </strong>",
"      have pelvic floor dysfunction based on anorectal manometry.",
"     </li>",
"     <li>",
"      The patient does",
"      <strong>",
"       not",
"      </strong>",
"      have abdominal pain as a prominent symptom.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcome of surgical treatment was illustrated in a study that included 74 patients with severe, refractory slow transit constipation who underwent colectomy and ileorectostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/41\">",
"     41",
"    </a>",
"    ]. Postoperative complications included small bowel obstruction (9 percent) and prolonged ileus (12 percent). Most patients were satisfied with the results of surgery (97 percent) and reported a good or improved quality of life (90 percent) during a mean follow-up period of 56 months. Similar complication rates have been found by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/42\">",
"     42",
"    </a>",
"    ]. A review of 13 studies of 362 patients who underwent colectomy and who were followed for a mean of 106 months reported a high degree of patient satisfaction (88 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/57/30616/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891044\">",
"    <span class=\"h2\">",
"     Other surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients complaining of constipation may present with rectoceles and rectal intussusceptions. However, surgical repair of these problems may not alleviate symptoms of difficult defecation. Thus, caution must be used when attributing defecatory difficulties to these entities. Improved rectal evacuation when pressure is placed on the posterior wall of the vagina during defecation should be demonstrated before considering a rectocele repair.",
"    <strong>",
"    </strong>",
"    In addition, tests to exclude pelvic floor dysfunction should be done prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=see_link\">",
"     \"Laparoscopic surgery for repair of pelvic floor defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is the treatment of choice for Hirschsprung disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=see_link\">",
"       \"Patient information: Constipation in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/51/35634?source=see_link\">",
"       \"Patient information: High-fiber diet (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/10/34977?source=see_link\">",
"       \"Patient information: Constipation in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=see_link\">",
"       \"Patient information: High-fiber diet (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30891058\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is a common complaint and often responds to dietary changes and various laxatives.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic constipation may be associated with normal or slow colonic transit, defecatory dysfunction , or both (",
"      <a class=\"graphic graphic_algorithm graphicRef88130 \" href=\"mobipreview.htm?19/57/20382\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H188292857\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of normal and slow transit chronic constipation includes patient education, behavior modification, dietary change, bulk forming laxatives, and the use of non-bulk forming laxatives or enemas (",
"      <a class=\"graphic graphic_algorithm graphicRef88131 \" href=\"mobipreview.htm?9/5/9311\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H188292857\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients over the age of 70 years, we suggest that warm water enemas rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      enemas be used for the treatment of constipation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The use of sodium phosphate enemas in older adults has been associated with complications including hypotension and volume depletion, hyperphosphatemia, hypo- or hyperkalemia, metabolic acidosis, severe hypocalcemia, renal failure, and EKG changes (prolonged QT interval). (See",
"      <a class=\"local\" href=\"#H30890981\">",
"       'Disimpaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of defecatory dysfunction often involves suppositories, biofeedback, botulinum toxin injections into the puborectalis muscle, or relaxation exercises (",
"      <a class=\"graphic graphic_algorithm graphicRef88134 \" href=\"mobipreview.htm?35/26/36270\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H188292857\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As initial management in the treatment of idiopathic constipation, we suggest dietary fiber and bulk forming laxatives such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"       methylcellulose",
"      </a>",
"      , together with adequate fluids",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30890946\">",
"       'Dietary changes and bulk forming laxatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not tolerate bulk forming laxatives or respond poorly to fiber, we suggest an osmotic laxative next if tolerated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other options include stool softeners, stimulant laxatives (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"       bisacodyl",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"       senna",
"      </a>",
"      , and sodium picosulfate), and secretory agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"       lubiprostone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/17/20755?source=see_link\">",
"       linaclotide",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30890967\">",
"       'Other laxatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of severe constipation and defecatory dysfunction may involve suppositories, biofeedback, botulinum toxin injections into the puborectalis muscle, or subtotal colectomy under specific circumstances. (See",
"      <a class=\"local\" href=\"#H30890974\">",
"       'Management of severe constipation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various pharmacologic therapies (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"       lubiprostone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      ) have been used to treat severe constipation with limited success. (See",
"      <a class=\"local\" href=\"#H30891002\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/1\">",
"      Tramonte SM, Brand MB, Mulrow CD, et al. The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med 1997; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/2\">",
"      Badiali D, Corazziari E, Habib FI, et al. Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig Dis Sci 1995; 40:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/3\">",
"      M&uuml;ller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. Br Med J (Clin Res Ed) 1988; 296:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/4\">",
"      Petticrew M, Watt I, Sheldon T. Systematic review of the effectiveness of laxatives in the elderly. Health Technol Assess 1997; 1:i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/5\">",
"      Attaluri A, Donahoe R, Valestin J, et al. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 2011; 33:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/6\">",
"      Floch MH, Wald A. Clinical evaluation and treatment of constipation. Gastroenterologist 1994; 2:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/7\">",
"      Voderholzer WA, Schatke W, M&uuml;hldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997; 92:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/8\">",
"      Anti M, Pignataro G, Armuzzi A, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology 1998; 45:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/9\">",
"      Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/10\">",
"      American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005; 100 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/11\">",
"      Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/12\">",
"      Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000; 46:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/13\">",
"      Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007; 102:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/14\">",
"      Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database Syst Rev 2010; :CD007570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/15\">",
"      Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010; 105:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/16\">",
"      Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 2011; 9:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/17\">",
"      Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol 2003; 36:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/18\">",
"      M&uuml;ller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/19\">",
"      Ori Y, Rozen-Zvi B, Chagnac A, et al. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med 2012; 172:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/20\">",
"      Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther 2007; 26:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/21\">",
"      Levine MD, Bakow H. Children with encopresis: a study of treatment outcome. Pediatrics 1976; 58:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/22\">",
"      Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007; 5:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/23\">",
"      Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007; 50:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/24\">",
"      Bassotti G, Chistolini F, Sietchiping-Nzepa F, et al. Biofeedback for pelvic floor dysfunction in constipation. BMJ 2004; 328:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/25\">",
"      Heymen S, Jones KR, Scarlett Y, Whitehead WE. Biofeedback treatment of constipation: a critical review. Dis Colon Rectum 2003; 46:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/26\">",
"      Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology 2005; 129:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/27\">",
"      Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/28\">",
"      Lee BH, Kim N, Kang SB, et al. The Long-term Clinical Efficacy of Biofeedback Therapy for Patients With Constipation or Fecal Incontinence. J Neurogastroenterol Motil 2010; 16:177.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation. Available at: file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/30\">",
"      Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/31\">",
"      Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/32\">",
"      Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology 2008; 135:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/33\">",
"      Roarty TP, Weber F, Soykan I, McCallum RW. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther 1997; 11:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/34\">",
"      Wald A. Slow Transit Constipation. Curr Treat Options Gastroenterol 2002; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/35\">",
"      Taghavi SA, Shabani S, Mehramiri A, et al. Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial. Int J Colorectal Dis 2010; 25:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/36\">",
"      Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/37\">",
"      M&uuml;ller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010; 22:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/38\">",
"      Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010; 32:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/39\">",
"      Maria G, Cadeddu F, Brandara F, et al. Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol 2006; 101:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/40\">",
"      Wofford SA, Verne GN. Approach to patients with refractory constipation. Curr Gastroenterol Rep 2000; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/41\">",
"      Nyam DC, Pemberton JH, Ilstrup DM, Rath DM. Long-term results of surgery for chronic constipation. Dis Colon Rectum 1997; 40:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/42\">",
"      Knowles CH, Scott M, Lunniss PJ. Outcome of colectomy for slow transit constipation. Ann Surg 1999; 230:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/57/30616/abstract/43\">",
"      Pikarsky AJ, Singh JJ, Weiss EG, et al. Long-term follow-up of patients undergoing colectomy for colonic inertia. Dis Colon Rectum 2001; 44:179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2636 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30616=[""].join("\n");
var outline_f29_57_30616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30891058\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30890925\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188292857\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30890932\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30890939\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30890946\">",
"      Dietary changes and bulk forming laxatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30890953\">",
"      - Fiber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30890960\">",
"      - Bulk forming laxatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30890967\">",
"      Other laxatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1802253998\">",
"      - Surfactants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6451384\">",
"      - Osmotic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6451393\">",
"      - Stimulant laxatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30890974\">",
"      MANAGEMENT OF SEVERE CONSTIPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1968261206\">",
"      Suppositories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30890981\">",
"      Disimpaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30890988\">",
"      Behavioral approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30890995\">",
"      - Biofeedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30891002\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1747782838\">",
"      - Linaclotide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30891009\">",
"      - Lubiprostone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30891016\">",
"      - Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2057146038\">",
"      - Colchicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14393093\">",
"      - Prucalopride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30891030\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30891037\">",
"      Colectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30891044\">",
"      Other surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30891058\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2636|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/57/20382\" title=\"algorithm 1\">",
"      Evaluation algorithm for chronic constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?9/5/9311\" title=\"algorithm 2\">",
"      Treatment algorithm for normal or slow transit constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?35/26/36270\" title=\"algorithm 3\">",
"      Treatment algorithm for defecating disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/58/18348\" title=\"table 1A\">",
"      Causes of constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/11/21691\" title=\"table 1B\">",
"      Drugs causing constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/1/17438\" title=\"table 2\">",
"      Dietary fiber content of frequently consumed foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/62/30701\" title=\"table 3\">",
"      Laxatives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=related_link\">",
"      Laparoscopic surgery for repair of pelvic floor defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/10/34977?source=related_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_57_30617="Etoposide: Drug information";
var content_f29_57_30617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etoposide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/3/43061?source=see_link\">",
"    see \"Etoposide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/17/41240?source=see_link\">",
"    see \"Etoposide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Toposar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14225985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Etoposide Injection USP;",
"     </li>",
"     <li>",
"      Vepesid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Podophyllotoxin Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Topoisomerase II Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer (combination chemotherapy):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 35 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days, up to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Due to poor bioavailability, oral doses should be twice the I.V. dose (and rounded to the nearest 50 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Testicular cancer (combination chemotherapy):",
"     </b>",
"     I.V.: 50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for days 1-5",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 3, and 5 repeated every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Non-Hodgkin lymphoma (in combination with other agents), nonsmall cell lung cancer (alone or in combination), small cell lung cancer (first-line in combination; second-line alone or in combination), testicular cancer (in combination; oral therapy for refractory disease):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V.: 50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral: 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; administer daily doses &gt;200 mg in  2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Adult unlabeled uses and/or dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hematopoietic stem cell transplant conditioning regimen, lymphoid malignancies:",
"     </b>",
"     I.V.: 60 mg/kg over 4 hours as a single dose 3 or 4 days prior to transplantation (Horning, 1994; Snyder, 1993; Weaver, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer:",
"     </b>",
"     I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 2, and 3 every 3 weeks for 4 cycles or every 4 weeks for 3-4 cycles (in combination with cisplatin) (Arriagada, 2004)",
"     <b>",
"      or",
"     </b>",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1-5 and days 29-33 (in combination with cisplatin and radiation therapy) (Albain, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, refractory:",
"     </b>",
"     Oral: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 21 days every 4 weeks until disease progression or unacceptable toxicity (Rose, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer, limited stage (combination chemotherapy):",
"     </b>",
"     I.V.: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, and 3 every 3 weeks for 4 courses (Turrisi, 1999)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, and 3 for induction therapy, followed by consolidation chemotherapy (Saito, 2006)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, and 3 every 3 weeks up to a maximum of 6 cycles (Skarlos, 2001)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day I.V. on day 1, followed by 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"     <b>",
"      orally",
"     </b>",
"     on days 2 through 4 every 3 weeks for a maximum of 5 courses (Sundstrom, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer, extensive stage (combination chemotherapy):",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day I.V. on days 1, 2, and 3 every 3 weeks for 4 cycles (Lara, 2009)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day I.V. on day 1, followed by 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"     <b>",
"      orally",
"     </b>",
"     on days 2 through 4 every 3 weeks for a maximum of 5 courses (Sundstrom, 2002)",
"     <b>",
"      or",
"     </b>",
"     I.V.: 80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, and 3 every 3 weeks up to 8 cycles (Ihede, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Testicular cancer (combination chemotherapy):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Nonseminoma:",
"     </i>",
"     I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1 through 5 every 21 days for 3-4 courses (Saxman, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Nonseminoma, metastatic (high-dose regimens):",
"     </i>",
"     I.V.: 750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day administered 5, 4, and 3 days before peripheral blood stem cell infusion, repeat for a second cycle after recovery of granulocyte and platelet counts (Einhorn, 2007)",
"     <b>",
"      or",
"     </b>",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (beginning on cycle 3) on days 1, 2, and 3, with peripheral blood stem cell support, administered at 14- to 21-day intervals for 3 cycles (Kondagunta, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thymoma, locally advanced or metastatic:",
"     </b>",
"     I.V.: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 2, and 3 every 3 weeks (in combination with cisplatin) for up to 8 cycles (Giaccone, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Unknown primary adenocarcinoma:",
"     </b>",
"     Oral: 50 mg once daily on days 1, 3, 5, 7, and 9 alternating with 100 mg once daily on days 2, 4, 6, 8, and 10 every 3 weeks (in combination with paclitaxel and carboplatin) (Greco, 2000; Hainsworth, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/17/41240?source=see_link\">",
"      see \"Etoposide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      AML induction (unlabeled use; combination chemotherapy)",
"     </b>",
"     (Woods, 1996): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &lt;3 years: 3.3 mg/kg/day continuous infusion for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &ge;3 years: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Central nervous system tumors (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;3 years: 6.5 mg/kg/dose days 3 and 4 of each 28-day &ldquo;B&rdquo; treatment cycle (Duffner, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;3 years: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, and 3 of a 3-week treatment cycle (Taylor, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;6 years: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 3 and 4 of a 3-week treatment course (Kovnar, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hematopoietic stem cell transplantation conditioning regimen:",
"     </b>",
"     I.V.: 60 mg/kg/dose over 4 hours as a single dose 3 or 4 days prior to transplantation (Horning, 1994; Snyder, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma (unlabeled use):",
"     </b>",
"     I.V.: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1, 2, and 3 every 3 weeks (Kelly, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-5 of each cycle (Kaneko, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hematopoietic stem cell transplantation conditioning regimen:",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days beginning 8 or 9 days prior to transplantation (Kaneko, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sarcoma, refractory (unlabeled use):",
"     </b>",
"     I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-5 of cycle; repeat cycle every 21 days (Van Winkle, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. labeling recommends the following adjustments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL minute: Data not available; consider further dose reductions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Peritoneal dialysis: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of dose and reduce for hyperbilirubinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: Administer 50% of dose; supplemental posthemodialysis dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Peritoneal dialysis: Administer 50% of dose; supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Janus, 2010: Hemodialysis: Reduce dose by 50%; not removed by hemodialysis so may be administered before or after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 85% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Administer 75% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F169286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following adjustments have also been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donelli, 1998: Liver dysfunction may reduce the metabolism and increase the toxicity of etoposide. Normal doses of I.V. etoposide should be given to patients with liver dysfunction (dose reductions may result in subtherapeutic concentrations); however, use caution with concomitant liver dysfunction (severe) and renal dysfunction as the decreased metabolic clearance cannot be compensated by increased renal clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Floyd, 2006: Bilirubin 1.5-3 mg/dL or AST &gt;3 times ULN: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     King, 2001; Koren, 1992: Bilirubin 1.5-3 mg/dL or AST &gt;180 units/L: Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F14934910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Infusion (hypersensitivity) reactions: Interrupt infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold treatment until recovery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe adverse reactions (nonhematologic): Reduce dose or discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     WBC 2000-3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets 75,000-100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Canadian labeling (not in U.S. labeling): Reduce dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 20 mg/mL (5 mL, 25 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toposar&reg;: 20 mg/mL (5 mL, 25 mL, 50 mL) [contains dehydrated ethanol 33.2%, polyethylene glycol 300, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Doses &le;200 mg/day as a single once daily dose; doses &gt;200 mg should be given in 2-4 divided doses. If necessary, the injection may be used for oral administration (see Extemporaneously Prepared). Canadian labeling recommends administering capsule on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer standard doses over at least 30-60 minutes to minimize the risk of hypotension. Higher (unlabeled) doses used in transplantation may be infused over longer time periods depending on the protocol. Etoposide injection contains polysorbate 80 which may cause leaching of diethylhexyl phthalate (DEHP), a plasticizer contained in polyvinyl chloride (PVC) tubing. Administration through non-PVC (low sorbing) tubing will minimize patient exposure to DEHP. Tissue irritation and inflammation have occurred following extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Concentrations &gt;0.4 mg/mL are very unstable and may precipitate within a few minutes. For large doses, where dilution to &le;0.4 mg/mL is not feasible, consideration should be given to slow infusion of the undiluted drug through a running normal saline, dextrose or saline/dextrose infusion; or use of etoposide phosphate. Etoposide solutions of 0.1-0.4 mg/mL may be filtered through a 0.22 micron filter without damage to the filter; etoposide solutions of 0.2 mg/mL may be filtered through a 0.22 micron filter without significant loss of drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F169339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,  NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, cladribine, doxorubicin liposomal, fludarabine, gemcitabine, granisetron, melphalan, methotrexate, micafungin, mitoxantrone, ondansetron, paclitaxel, piperacillin/tazobactam, sargramostim, sodium bicarbonate, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, filgrastim, gallium nitrate, idarubicin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of  refractory  testicular tumors (injectable formulation); treatment of small cell lung cancer (SCLC)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Treatment of small cell lung cancer (SCLC; first- and second-line); treatment of nonsmall cell lung cancer (NSCLC); treatment of non-Hodgkin lymphomas (first-line); treatment of testicular cancer (first-line [injectable formulation] and refractory)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2565786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute lymphocytic leukemia (ALL), refractory acute myeloid leukemia (AML), recurrent or metastatic breast cancer, central nervous system tumors, Ewing's sarcoma, gestational trophoblastic disease, Hodgkin lymphoma, merkel cell cancer, refractory multiple myeloma, neuroblastoma, neuroendocrine tumors (adrenal gland and carcinoid tumors), non-Hodgkin lymphomas, nonsmall cell lung cancer (NSCLC), osteosarcoma, ovarian cancer (refractory), prostate cancer, retinoblastoma, metastatic soft tissue sarcoma, thymic malignancies (locally advanced or metastatic), unknown-primary adenocarcinoma, Wilms' tumor; conditioning regimen for hematopoietic cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F169342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Etoposide may be confused with teniposide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Etoposide may be confused with etoposide phosphate (a prodrug of etoposide which is rapidly converted in the plasma to etoposide)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VePesid may be confused with Versed",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The following may occur with higher doses used in stem cell transplantation: Alopecia, ethanol intoxication, hepatitis, hypotension (infusion-related), metabolic acidosis, mucositis, nausea and vomiting (severe), secondary malignancy, skin lesions (resembling Stevens-Johnson syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (8% to 66%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (31% to 43%), anorexia (10% to 13%), diarrhea (1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (60% to 91%; grade 4: 3% to 17%;  nadir: 7-14 days; recovery: by day 20), thrombocytopenia (22% to 41%; grades 3/4: 1% to 20%; nadir 9-16 days; recovery: by day 20), anemia (&le;33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1% to 2%; due to rapid infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis (1% to 6%), abdominal pain (up to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic toxicity (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic-like reaction (I.V. infusion 1% to 2%; oral capsules  &lt;1%; including chills, fever, tachycardia, bronchospasm, dyspnea)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amenorrhea, blindness (transient/cortical), cyanosis, extravasation (induration/necrosis), facial swelling, hypersensitivity, hypersensitivity-associated apnea, interstitial pneumonitis, laryngospasm, maculopapular rash, metabolic acidosis, MI, mucositis, myocardial ischemia, optic neuritis, perivasculitis, pruritus, pulmonary fibrosis, radiation-recall dermatitis, rash, reversible posterior leukoencephalopathy syndrome (RPLS), seizure, Stevens-Johnson syndrome, tongue swelling, toxic epidermal necrolysis, toxic megacolon,  vasospasm",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etoposide or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe dose-limiting and dose-related myelosuppression with resulting infection or bleeding may occur.",
"     </b>",
"     Treatment should be withheld for platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or absolute neutrophil count (ANC) &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reaction: May cause anaphylactic-like reactions manifested by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension. In addition, facial/tongue swelling, coughing, chest tightness, cyanosis, laryngospasm, diaphoresis, hypertension, back pain, loss of consciousness, and flushing have also been reported less commonly. Incidence is primarily associated with intravenous administration (up to 2%) compared to oral administration (&lt;1%). Infusion should be interrupted and medications for the treatment of anaphylaxis should be available for immediate use. High drug concentration and rate of infusion, as well as presence of polysorbate 80 and benzyl alcohol in the etoposide intravenous formulation, have been suggested as contributing factors to the development of hypersensitivity reactions. Etoposide intravenous formulations may contain polysorbate 80 and/or benzyl alcohol, while etoposide phosphate (the water soluble prodrug of etoposide) intravenous formulation does not contain either vehicle. Case reports have suggested that etoposide phosphate has been used successfully in patients with previous hypersensitivity reactions to etoposide (Collier, 2008; Siderov, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Hypotension may occur due to rapid administration; infuse slowly over at least 30-60 minutes. If hypotension occurs, interrupt infusion and administer I.V. hydration and supportive care; decrease infusion upon reinitiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Secondary acute leukemias have been reported with etoposide, either as monotherapy or in combination with other chemotherapy agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage should be adjusted. Canadian labeling contraindicates use in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoalbuminemia: Use with caution in patients with low serum albumin; may increase risk for toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage should be adjusted. Canadian labeling contraindicates use in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; may be more likely to develop severe myelosuppression and/or GI effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: The use of concentrations higher than recommended were associated with higher rates of anaphylactic-like reactions in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcohol content: Injectable formulation may contain benzyl alcohol, which has been associated with \"gasping syndrome\" in neonates. Benzyl alcohol may also play a role in the development of hypersensitivity reactions occurring with intravenous administration. Injectable formulation also contains alcohol (~33% v/v); may contribute to adverse reactions, especially with higher etoposide doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Injectable formulation contains polysorbate 80; do not use in premature infants. Polysorbate 80 may also play a role in the development of hypersensitivity reactions occurring with intravenous administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Must be diluted; do not give I.V. push, infuse over at least 30-60 minutes; hypotension is associated with rapid infusion. Tissue irritation and inflammation have occurred following extravasation. Do not administer I.M. or SubQ.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F169328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: May increase the serum concentration of Etoposide. Management: Separate administration of atovaquone and etoposide by at least 1-2 days. Avoid concomitant administration of atovaquone and etoposide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Etoposide. Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Etoposide may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid concurrent St John's wort; may decrease etoposide levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2565787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and fetal loss. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14934871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue etoposide or to discontinue breast-feeding during treatment should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Etoposide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (20): $1336.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Etoposide Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $9.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Toposar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (25 mL): $45.59",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential; liver function (bilirubin, ALT, AST), albumin, renal function tests; vital signs (blood pressure)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F169265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Celltop (FR);",
"     </li>",
"     <li>",
"      Citodox (AR);",
"     </li>",
"     <li>",
"      Cryosid (MX);",
"     </li>",
"     <li>",
"      Ebeposide (SG);",
"     </li>",
"     <li>",
"      Eposin (CO, MY, TH, TW);",
"     </li>",
"     <li>",
"      Epsidox (CN);",
"     </li>",
"     <li>",
"      Etonco (MX);",
"     </li>",
"     <li>",
"      Etopos (MX);",
"     </li>",
"     <li>",
"      Etoposid (IL);",
"     </li>",
"     <li>",
"      Etoposide (AU, IL, NZ);",
"     </li>",
"     <li>",
"      Etoposide Pierre Fabre (LU);",
"     </li>",
"     <li>",
"      Etoposide Teva (HU);",
"     </li>",
"     <li>",
"      Etoposido (PE);",
"     </li>",
"     <li>",
"      Etopul (ID, PH);",
"     </li>",
"     <li>",
"      Etosid (IN, VE);",
"     </li>",
"     <li>",
"      Lastet (BG, CN, HU, IN, JP, MY, PE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Lastet-S (KP);",
"     </li>",
"     <li>",
"      Nexvep (BR);",
"     </li>",
"     <li>",
"      Sintopozid (HK);",
"     </li>",
"     <li>",
"      Topo (TH);",
"     </li>",
"     <li>",
"      Topresid (PH);",
"     </li>",
"     <li>",
"      Vepesid (AR, AT, BE, CH, CL, CZ, DE, DK, EE, ES, FI, GB, GR, HN, IE, IT, JP, MT, NL, NO, PH, PK, PL, PT, RU, SE, SK, TR, TW, UY, ZA);",
"     </li>",
"     <li>",
"      VePesid (AU, HR, HU, LU);",
"     </li>",
"     <li>",
"      Vepeside (FR);",
"     </li>",
"     <li>",
"      VP-Gen (EC, PY);",
"     </li>",
"     <li>",
"      VP-TEC (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Etoposide has been shown to delay transit of cells through the S phase and arrest cells in late S or early G",
"     <sub>",
"      2",
"     </sub>",
"     phase. The drug may inhibit mitochondrial transport at the NADH dehydrogenase level or inhibit uptake of nucleosides into HeLa cells. It is a topoisomerase II inhibitor and appears to cause DNA strand breaks. Etoposide does not inhibit microtubular assembly.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Significant inter- and intrapatient variation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Average V",
"     <sub>",
"      d",
"     </sub>",
"     : 7-17 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; poor penetration across the blood-brain barrier; CSF concentrations &lt;5% of plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP3A4 and 3A5, to various metabolites; in addition, conversion of etoposide to the O-demethylated metabolites (catechol and quinine) via prostaglandin synthases or myeloperoxidase occurs, as well as glutathione and glucuronide conjugation via GSTT1/GSTP1 and UGT1A1 (Yang, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~50% (range: 25% to 75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: I.V.: 4-11 hours; Children: Normal renal/hepatic function: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: I.V.: Urine (~55% as unchanged drug) in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.V.: Urine (56%; 45% as unchanged drug) within 120 hours; feces (44%) within 120 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albain KS, Swann RS, Rusch VW, et al, &ldquo;Radiotherapy Plus Chemotherapy With or Without Surgical Resection for Stage III Non-Small-Cell Lung Cancer: A Phase III Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9687):379-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/19632716/pubmed\" id=\"19632716\" target=\"_blank\">",
"        19632716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arriagada R, Bergman B, Dunant A, et al, &ldquo;Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(4):351-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/14736927/pubmed\" id=\"14736927\" target=\"_blank\">",
"        14736927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berger M, Grignani G, Ferrari S, et al, &ldquo;Phase 2 Trial of Two Courses of Cyclophosphamide and Etoposide for Relapsed High-Risk Osteosarcoma Patients,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2009, 115(13):2980-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/19452540/pubmed\" id=\"19452540\" target=\"_blank\">",
"        19452540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bishop JF, Matthews JP, Young GA, et al, \"Intensified Induction Chemotherapy With High Dose Cytarabine and Etoposide for Acute Myeloid Leukemia: A Review and Updated Results of the Australian Leukemia Study Group,\"",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 1998, 28(3-4):315-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/9517503/pubmed\" id=\"9517503\" target=\"_blank\">",
"        9517503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleman M, Martin P, Ruan J, et al, &ldquo;Prednisone, Etoposide, Probarbazine, And Cyclophosphamide (PEP-C) Oral Combination Chemotherapy Regimen For Recurring/Refractory Lymphoma: Low-Dose Metronomic, Multidrug Therapy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 112(10):2228-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/18338745/pubmed\" id=\"18338745\" target=\"_blank\">",
"        18338745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Collier K, Schink C, Young AM, et al, &ldquo;Case Report: Successful Treatment With Etoposide Phosphate in Patients With Previous Etoposide Hypersensitivity,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2008, 14(1):51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/18337441/pubmed\" id=\"18337441\" target=\"_blank\">",
"        18337441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos ML, Hamata L, and Vu T, &ldquo;Leaching of Diethylhexyl Phthalate from Polyvinyl Chloride Materials into Etoposide Intravenous Solutions,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2005, 11(4):155-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16595068/pubmed\" id=\"16595068\" target=\"_blank\">",
"        16595068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demor&eacute; B, Vigneron J, Perrin A, et al, &ldquo;Leaching of Diethylhexyl Phthalate from Polyvinyl Chloride Bags into Intravenous Etoposide Solution,&rdquo;",
"      <i>",
"       J Clin Pharm Ther",
"      </i>",
"      , 2002, 27(2):139-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/11975699/pubmed\" id=\"11975699\" target=\"_blank\">",
"        11975699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al, \"Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's disease,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2386-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/12802024/pubmed\" id=\"12802024\" target=\"_blank\">",
"        12802024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donelli MG, Zucchetti M, Munzone E, et al,  &ldquo;Pharmacokinetics of Anticancer Agents in Patients With Impaired Liver Function,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1998, 34(1):33-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/9624235/pubmed\" id=\"9624235\" target=\"_blank\">",
"        9624235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duffner PK, Horowitz ME, Krischer JP, et al &ldquo;Postoperative Chemotherapy and Delayed Radiation in Children Less Than Three Years of Age With Malignant Brain Tumors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(24):1725-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/8388548 /pubmed\" id=\"8388548 \" target=\"_blank\">",
"        8388548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einhorn LH, Williams SD, Chamness A, et al, &ldquo;High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-cell Tumors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(4):340-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/17652649/pubmed\" id=\"17652649\" target=\"_blank\">",
"        17652649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fulton D, Urtasun R, and Forsyth P, &ldquo;Phase II Study of Prolonged Oral Etoposide (VP-16) for Patients With Recurrent Malignant Glioma,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 1996, 27(2):149-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/8699237/pubmed\" id=\"8699237\" target=\"_blank\">",
"        8699237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giaccone G, Ardizzoni A, Kirkpatrick A, et al, &ldquo;Cisplatin and Etoposide Combination Chemotherapy for Locally Advanced or Metastatic Thymoma. A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(3):814-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/8622029/pubmed\" id=\"8622029\" target=\"_blank\">",
"        8622029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Burris HA 3rd, Erland JB, et al, \"Carcinoma of Unknown Primary Site,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2000, 89(12):2655-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/11135228/pubmed\" id=\"11135228\" target=\"_blank\">",
"        11135228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, \"Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hainsworth JD, Spigel DR, Litchy S, et al, &ldquo;Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(22):3548-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16877720/pubmed\" id=\"16877720\" target=\"_blank\">",
"        16877720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Negrin RS, Chao JC, et al, &ldquo;Fractionated Total-Body Irradiation, Etoposide, and Cyclophosphamide and Non-Hodgkin&rsquo;s Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2552-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/7989928/pubmed\" id=\"7989928\" target=\"_blank\">",
"        7989928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ihde DC, Mulshine JL, Kramer BS, et al, &ldquo;Prospective Randomized Comparison of High-Dose and Standard-Dose Etoposide and Cisplatin Chemotherapy in Patients With Extensive-Stage Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(10):2022-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/7931470/pubmed\" id=\"7931470\" target=\"_blank\">",
"        7931470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joel SP, Shah R, Clark PI, et al, &ldquo;Predicting Etoposide Toxicity: Relationship to Organ Function and Protein Binding,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(1):257-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/8558207/pubmed\" id=\"8558207\" target=\"_blank\">",
"        8558207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juergens C, Weston C, Lewis I, et al, &ldquo;Safety Assessment of Intensive Induction With Vincristine, Ifosfamide, Doxorubicin, and Etoposide (VIDE) in the Treatment of Ewing Tumors in the EURO-E.W.I.N.G. 99 Clinical Trial,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 47(1):22-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16572419/pubmed\" id=\"16572419\" target=\"_blank\">",
"        16572419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaneko M, Tsuchida Y, Mugishima H, et al, &ldquo;Intensified Chemotherapy Increases the Survival Rates in Patients With Stage 4 Neuroblastoma With MYCN Amplification,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2002, 24(8):613-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/12439032/pubmed\" id=\"12439032\" target=\"_blank\">",
"        12439032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KM, Hutchinson RJ, Sposto R, et al, \"Feasibility of Upfront Dose-Intensive Chemotherapy in Children With Advanced-Stage Hodgkin's Lymphoma: Preliminary Results From the Children's Cancer Group Study CCG-59704,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(Suppl 1):107-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/12078889/pubmed\" id=\"12078889\" target=\"_blank\">",
"        12078889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondagunta GV, Bacik J, Donadio A, et al, &ldquo;Combination of Paclitaxel, Ifosfamide, and Cisplatin is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(27):6549-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16170162/pubmed\" id=\"16170162\" target=\"_blank\">",
"        16170162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondagunta GV, Bacik J, Sheinfeld J, et al, &ldquo;Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(1):85-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/17194908/pubmed\" id=\"17194908\" target=\"_blank\">",
"        17194908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992,  26(3):363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/1554959/pubmed\" id=\"1554959\" target=\"_blank\">",
"        1554959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovnar EH, Kellie SJ, Horowitz ME, et al, &ldquo;Preirradiation Cisplatin and Etoposide in the Treatment of High-Risk Medulloblastoma and Other Malignant Embryonal Tumors of the Central Nervous System: A Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1990, 8(2):330-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/2153766 /pubmed\" id=\"2153766 \" target=\"_blank\">",
"        2153766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lara PN Jr, Natale R, Crowley J, et al, &ldquo;Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results from SWOG S0124,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15):2530-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/19349543/pubmed\" id=\"19349543\" target=\"_blank\">",
"        19349543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le Deley MC, Guinebreti&egrave;re JM, Gentet JC, et al, &ldquo;SFOP OS94: a Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2007, 43(4):752-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/17267204/pubmed\" id=\"17267204\" target=\"_blank\">",
"        17267204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLeod HL and Relling MV, &ldquo;Stability of Etoposide Solution for Oral Use,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(11):2784-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/1471649/pubmed\" id=\"1471649\" target=\"_blank\">",
"        1471649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milligan DW, Wheatley K, Littlewood T, et al, &ldquo;Fludarabine and Cytosine are Less Effective than Standard ADE Chemotherapy in High-Risk Acute Myeloid Leukemia, and Addition of G-CSF and ATRA are not Beneficial: Results of the MRC AML-HR Randomized Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(12):4614-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/16484584/pubmed\" id=\"16484584\" target=\"_blank\">",
"        16484584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose PG, Blessing JA, Mayer AR, et al, &ldquo;Prolonged Oral Etoposide as Second-Line Therapy for Platinum-Resistant and Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(2):405-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/9469322/pubmed\" id=\"9469322\" target=\"_blank\">",
"        9469322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saito H, Takada Y, Ichinose Y, et al, &ldquo;Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(33):5247-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/17114657/pubmed\" id=\"17114657\" target=\"_blank\">",
"        17114657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saxman SB, Finch D, Gonin R, et al, &ldquo;Long-Term Follow-Up of a Phase III Study of Three Versus Four Cycles of Bleomycin, Etoposide, and Cisplatin in Favorable-Prognosis Germ-Cell Tumors: The Indian University Experience,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(2):702-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/9469360/pubmed\" id=\"9469360\" target=\"_blank\">",
"        9469360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siderov J, Prasad P, De Boer R, et al, &ldquo;Safe Administration of Etoposide Phosphate After Hypersensitivity Reaction to Intravenous Etoposide,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 86(1):12-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/11857004/pubmed\" id=\"11857004\" target=\"_blank\">",
"        11857004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skarlos DV, Samantas E, Briassoulis E, et al, &ldquo;Randomized Comparison of Early Versus Late Hyperfractionated Thoracic Irradiation Concurrently With Chemotherapy in Limited Disease Small-Cell Lung Cancer: A Randomized Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2001, 12(9):1231-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/11697833/pubmed\" id=\"11697833\" target=\"_blank\">",
"        11697833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snyder DS, Chao NJ, Amylon MD, et al, &ldquo;Fractionated Total Body Irradiation and High-Dose Etoposide as a Preparatory Regimen for Bone Marrow Transplantation for 99 Patients With Acute Leukemia in First Complete Remission,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1993, 82(9):2920-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/8219241/pubmed\" id=\"8219241\" target=\"_blank\">",
"        8219241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sundstrom S, Bremnes RM, Kaasa S, et al, &ldquo;Cisplatin and Etoposide Regimen is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years&rsquo; Follow-up,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(24):4665-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/12488411/pubmed\" id=\"12488411\" target=\"_blank\">",
"        12488411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor RE, Bailey CC, Robinson K, et al, &ldquo;Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(8):1581-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/12697884/pubmed\" id=\"12697884\" target=\"_blank\">",
"        12697884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turrisi AT, Kim K, Blum R, et al, &ldquo;Twice-daily Compared With Once-daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(4):265-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/9920950/pubmed\" id=\"9920950\" target=\"_blank\">",
"        9920950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Winkle P, Angiolillo A, Krailo M, et al, &ldquo;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children&rsquo;s Cancer Group (CCG) Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(4):338-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/15503297/pubmed\" id=\"15503297\" target=\"_blank\">",
"        15503297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weaver CH, Petersen FB, Appelbaum FR, et al, &ldquo;High-dose Fractionated Total-Body Irradiation, Etoposde, and Cyclophosphamide Followed by Autologous Stem-Cell Support in Patients With Malignant Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2559-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/7989929/pubmed\" id=\"7989929\" target=\"_blank\">",
"        7989929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson WH, Grossbard ML, Pittaluga S, et al, &ldquo;Dose-Adjusted EPOCH Chemotherapy for Untreated Large B-Cell Lymphomas: A Pharmacodynamic Approach With High Efficacy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(8):2685-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/11929754/pubmed\" id=\"11929754\" target=\"_blank\">",
"        11929754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woods WG, Kobrinsky N, Buckley JD, et al, &ldquo;Timed-Sequential Induction Therapy Improves Postremission Outcome in Acute Myeloid Leukemia: A Report From the Children's Cancer Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1996, 87(12):4979-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/8652810/pubmed\" id=\"8652810\" target=\"_blank\">",
"        8652810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang J, Bogni A, Schuetz EG, &ldquo;Etoposide Pathway,&rdquo;",
"      <i>",
"       Pharmacogenet Genomics",
"      </i>",
"      , 2009, 19(7):552-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/57/30617/abstract-text/19512958/pubmed\" id=\"19512958\" target=\"_blank\">",
"        19512958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8430 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30617=[""].join("\n");
var outline_f29_57_30617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708769\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169278\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225985\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169333\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169283\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169311\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169284\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169285\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169286\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14934910\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169256\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169241\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169259\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169339\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169257\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2565786\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169342\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169331\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169262\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169245\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169328\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169250\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169275\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169252\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2565787\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169296\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14934871\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323139\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169254\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169265\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169244\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169261\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/3/43061?source=related_link\">",
"      Etoposide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/17/41240?source=related_link\">",
"      Etoposide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_57_30618="Erythema multiforme target";
var content_f29_57_30618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68640%7EDERM%2F79955%7EDERM%2F62370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68640%7EDERM%2F79955%7EDERM%2F62370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical target lesion of erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plaque from a patient with erythema multiforme shows a central erosion on an erythematous base, surrounded by a pale edematous rim and a peripheral erythematous halo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Target lesions of erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Target lesions with central bullae are present on the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple acrally distributed target lesions and mucosal erosions are present in this patient with erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30618=[""].join("\n");
var outline_f29_57_30618=null;
var title_f29_57_30619="Graded prognostic assessment for brain metastases from melanoma";
var content_f29_57_30619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Graded prognostic assessment for brain metastases from melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle3\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Karnofsky performance score",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td>",
"        70-80",
"       </td>",
"       <td>",
"        90-100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number of brain metastases",
"       </td>",
"       <td>",
"        &gt;3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" colspan=\"4\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Median survival (months) by score: 0-1.0 = 3.4; 1.5-2.0 = 4.7; 2.5-3.0 = 8.8; 3.5-4.0 = 13.2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30619=[""].join("\n");
var outline_f29_57_30619=null;
var title_f29_57_30620="Alopecia combination chemo";
var content_f29_57_30620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate incidence of complete alopecia from selected combination chemotherapy regimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reported incidence of alopecia (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AC",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AC-T",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CAF/FAC",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMF",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEC",
"        <sub>",
"         50",
"        </sub>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEC",
"        <sub>",
"         100",
"        </sub>",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TAC",
"       </td>",
"       <td>",
"        98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Gastrointestinal malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FOLFIRI",
"       </td>",
"       <td>",
"        25 to 42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FOLFOX",
"       </td>",
"       <td>",
"        9 to 19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carboplatin/etoposide",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cisplatin/etoposide",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paclitaxel/carboplatin",
"       </td>",
"       <td>",
"        50 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ABVD",
"       </td>",
"       <td>",
"        24 to 31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BEACOPP",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        R-CHOP",
"       </td>",
"       <td>",
"        45 to 90",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: doxorubicin, cyclophosphamide; AC-T: doxorubicin, cyclophosphamide, paclitaxel; ABVD: doxorubicin, bleomycin, vincristine, dactinomycin; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CAF/FAC: cyclophosphamide, doxorubicin, fluorouracil; CMF: cyclophosphamide, methotrexate, fluorouracil; FEC: fluorouracil, epirubicin, cyclophosphamide; FOLFIRI: fluorouracil, leucovorin, irinotecan; FOLFOX: fluorouracil, leucovorin, oxaliplatin; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; TAC: docetaxel, doxorubicin, cyclophosphamide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30620=[""].join("\n");
var outline_f29_57_30620=null;
var title_f29_57_30621="Depression cardiovasc events";
var content_f29_57_30621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival free of a cardiovascular event is lower in recently depressed elderly men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 237px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In men over 70 years of age, the recent onset of depression, but not chronic depression, was associated with an increased risk of a cardiovascular disease event and all cause mortality. This association was not seen in women over 70 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Penninx, BWJH, Guralnik, J, Mendes de Leon, CF, et al, Am J Cardiol 1998; 81:988.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30621=[""].join("\n");
var outline_f29_57_30621=null;
var title_f29_57_30622="Predicted survival of PD pts according to KtV";
var content_f29_57_30622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Graph showing predicted probability of survival among CAPD patients according to weekly Kt/V",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Predicted probability of survival in patients treated with continuous peritoneal dialysis according to the weekly Kt/V. A progressive decline in two-year survival is noted at lower values for Kt/V. The values were 81 percent at a Kt/V of 2.3 versus only 66 percent at a Kt/V of 1.5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from CANADA-USA (CANUSA) Peritoneal Dialysis Study Group, J Am Soc Nephrol 1996; 7:198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30622=[""].join("\n");
var outline_f29_57_30622=null;
var title_f29_57_30623="Ulcerated basal cell carcinoma";
var content_f29_57_30623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 186px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large basal cell tumors may develop vascular compromise, leading to central ulceration. This appearance has been historically referred to as a \"rodent ulcer.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_57_30623=[""].join("\n");
var outline_f29_57_30623=null;
